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Abstract 
The first line of defence against viral infection is the interferon (IFN) response, 
which must be overcome by a virus for successful replication.  Pattern 
recognition receptors detect virus which triggers induction of IFNβ.  Secreted 
IFNβ stimulates the JAK/STAT signal transduction pathway and the 
upregulation of IFN stimulated genes (ISGs) culminating with expression of 
hundreds of antiviral proteins.  Bunyamwera virus (BUNV) is the prototype virus 
for the genus Orthobunyavirus and the family Bunyaviridae.  BUNV is a 
trisegmented single stranded negative sense RNA virus whose genome 
comprises the Large (L), Medium (M) and Small (S) RNA segments.  The L 
segment encodes the RNA polymerase, the M segment the two glycoproteins 
Gn and Gc and a non-structural protein NSm, and the S segment the 
nucleoprotein and a non-structural protein NSs in overlapping reading frames.  
The NSs protein interferes with RNA polymerase II mediated transcription 
thereby inhibiting cellular mRNA production, including IFN mRNA, and hence it 
is the primary IFN antagonist.  A recombinant virus, rBUNdelNSs, that is unable 
to express the NSs protein, does not inhibit cellular transcription and is thus a 
strong IFN inducer.  The aim of this thesis was to understand how IFN inhibits 
BUNV replication.  Cells stimulated into the antiviral state by IFN treatment were 
protected against BUNV infection but addition of IFN 6 hours (or later) post 
infection had little effect on the replication cycle.  However, addition of IFN 
immediately following infection conferred restriction on BUNV replication by 
initially increasing viral protein synthesis and then by blocking translation of 
positive sense viral RNA.  To identify ISGs with anti-BUNV activity, I screened a 
panel of 26 cell lines that inducibly express individual ISGs.  To aid screening, 
recombinant BUNV that expressed green fluorescent protein (GFP) were 
employed, including an NSs deletion virus with GFP fused to the Gc, 
rBUNGceGFPdelNSs, that I created and characterised.  By a combination of 
virus yield assays, Western blotting and fluorescence techniques, three cell 
lines that inducibly express PKR, viperin or MTAP44 were shown to restrict 
BUNV replication.  More detailed studies revealed PKR to restrict BUNV RNA 
and protein synthesis, but when PKR was knocked-down in IFN competent 
A549 cells viral replication was not blocked in cells pre-treated with IFN.  Viperin 
inhibited viral protein synthesis and virally-induced host cell protein synthesis 
shut-off.  Additionally, viral RNA synthesis was restricted by viperin and this was 
dependent on the CX3CX2C motif 1 of viperin.  Taken together, these data show 
that the restriction of BUNV replication mediated by IFN is an accumulated 
effect of several different ISGs acting on different stages of the viral life cycle. 
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1 Introduction 
The immune response 
The mammalian immune system is categorised into the innate (non-specific) 
and the adaptive (specific) immune systems, both of which are able to 
distinguish between self and non-self.  The adaptive immune response is highly 
specialised and responds only to specific antigens originating from pathogens.  
It can take several days for this response to get established, and it is not able to 
prevent or stop the initial infection.  However, the adaptive response does 
provide long-term protection against the same antigens because of the 
immunological memory provided by memory B and T cells of the adaptive 
immune response.  Furthermore, repeated exposure to the same 
pathogen/antigen results in a significantly increased and rapid adaptive immune 
response.  This response is mediated by specialised cells called lymphocytes 
(Braciale, 2007). 
The innate immune system is non-specific and comprises various defence 
mechanisms; physical barriers (such as the skin), physiological barriers (such 
as the low pH of the stomach), cellular components and proteins which are 
released by the cells (such as cytokines).  This response occurs at the time of 
exposure to foreign agents and is mediated by phagocytic cells, which ingest 
and destroy foreign agents, and natural killer cells (NK) which destroy infected 
cells.  All of these cells secrete cytokines, which are small proteins involved in 
the regulation of the innate immune response.  When secreted, the cytokines 
are able to initiate signalling pathways in neighbouring cells, and to keep the 
response to the correct magnitude required to clear the infection as efficiently 
and rapidly as possible, by affecting the growth, differentiation and production of 
cells in the body (Biron, 2007). 
Of considerable importance to the host cell is the counteraction of a viral 
infection.  This begins with the innate response, which must be successful 
enough to quash the infection, or at the very least suppress it for long enough 
that the adaptive response has time to be established.  Immediately, viruses 
can be targeted for phagocytosis by the complement cascade system, coating 
the virions in complement components (Lachmann & Davies, 1997), and 
circulating neutralising antibodies are highly effective at preventing virus 
dissemination to vital organs and their subsequent adsorption and entry into 
cells (Ochsenbein et al., 1999).  Viruses that manage to attach and enter cells 
then have the extremely powerful interferon response to contend with.  This 
response rapidly attempts to stop the viral infection at all levels from replication 
to egress, and also subsequent entry into surrounding cells, and can even 
stimulate apoptosis to limit the spread of the virus (Randall & Goodbourn, 
2008). 
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Virus detection by the host cell 
Pattern recognition receptors 
Pattern recognition receptors (PRRs) are now known to be the main receptors 
involved in detecting an invading pathogen.  They have evolved to detect highly 
conserved specific pathogen associated molecular patterns (PAMPs) which are 
located within or on the surface of pathogens.  PRRs are able to detect both 
extracellular and intracellular viruses, and the most intensely studied detect 
different classes of nucleic acids and include Toll-like receptors (TLRs), and the 
RNA helicases retinoic acid inducible gene I (RIG-I) (Yoneyama et al., 2004) 
and melanoma differentiation-associated gene 5 (MDA5) (Andrejeva et al., 
2004). 
The Toll-like receptors 
The Toll-like receptors are type I transmembrane glycoproteins that consist of 
an intracellular Toll/interleukin-1 resistance (TIR) domain for signal transduction 
and an extracellular domain of leucine-rich repeats (LRR) for PAMP recognition 
and binding (Kawai et al., 2005; Takeda & Akira, 2005).  Binding of PAMPs to 
the LRR initiates receptor dimerisation and conformational changes in the 
receptor, which in turn trigger recruitment of cytosolic adaptor proteins to the 
TIR domain of the receptor and thereby activate intracellular signal transduction 
pathways. 
TLR3 detects endosomal and extracellular RNA 
In 2001, it was determined that TLR3 was the receptor molecule responsible for 
responses to exogenous dsRNA, leading to the activation of nuclear factor 
kappa B (NF-κB) and induction of interferon (IFN) expression (Alexopoulou et 
al., 2001).  TLR3 is expressed on a wide variety of cell types, most notably 
myeloid dendritic cells (mDCs) (Matsumoto et al., 2003).  Specifically, TLR3 
relocates from the endoplasmic reticulum to the cell surface and the endosome 
of fibroblasts (Matsumoto et al., 2002; Matsumoto et al., 2003);   to the 
lysosome of bone marrow derived macrophages (de Bouteiller et al., 2005); and 
to the endosome of mDCs (Johnsen et al., 2006).  Thus, the specific location of 
TLR3 enables it to detect extracellular and intracellular (through endosomal 
uncoating of the viral protein coat) viral dsRNA irrespective of viral replication or 
not.  It has been shown previously that dsRNA from DNA and positive-stranded 
RNA viruses is an extremely potent inducer of IFN (Marcus, 1983; Weber et al., 
2006), now known to be through TLR3.  Knockout mice deficient in TLR3 
receptors are resistant to infection by vesicular stomatitis virus (VSV), reovirus 
and lymphocytic choriomeningitis virus (LCMV) (Edelmann et al., 2004) 
because these viruses are detected by different PRRs. 
Binding of dsRNA to TLR3 initiates receptor dimerisation and the subsequent 
phosphorylation of its intracellular tyrosine residues, initiating signal 
transduction within the cell (Fig 1.1 (Sarkar et al., 2004)).  This recruits the TIR 
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domain-containing adaptor inducing IFN-β (TRIF) adaptor protein and a 
member of the family of proteins known as TRAFs (TNF receptor-associated 
factor) leading to either interferon regulatory factor (IRF) 3 or NF-κB activation 
(Hacker et al., 2006; Hoebe et al., 2003; Jiang et al., 2004; Yamamoto et al., 
2002; Yamamoto et al., 2003). 
For NF-κB activation, TRIF enlists the E3 ubiquitin ligase TRAF6 and the 
receptor interacting protein 1 (RIP1) (Cusson-Hermance et al., 2005; Meylan et 
al., 2004; Sato et al., 2003).  This recruitment leads to the oligomerisation and 
auto-ubiquitination of TRAF6 and the K63-linked poly-ubiquitination of RIP1 
(Chen, 2005; Deng et al., 2000).  The transforming growth factor β-associated  
kinase 1 (TAK1), as well as TAK1-binding proteins 2 and 3 (TAB2 and TAB3), 
interact with TRAF6 and RIP1 via recognition of, and binding to, the 
polyubiquitin chains (Kanayama et al., 2004).  The inhibitor of NF-κB (IκB) 
kinase, IKK, is subsequently recruited to this protein complex (Ea et al., 2006; Li 
et al., 2006a; Wang et al., 2001; Wu et al., 2006).  The subunits IKKα, IKKβ, 
and the regulatory subunit IKKγ (also known as NF-κB essential modifier 
(NEMO)) together make up the heterotrimeric IKK complex recruited by 
polyubiquitinated RIP1 and other members of the aforementioned complex 
(DiDonato et al., 1997; Mercurio et al., 1997; Rothwarf et al., 1998; Zandi et al., 
1998).  Now the IKKβ subunit is adjacent to, and thus directly phosphorylated 
by, TAK1 (Wang et al., 2001).  The activated IKK complex then phosphorylates 
IκB, which is then polyubiquitinated with K48-linked chains and is subsequently 
degraded.  This results in the release of NF-κB from IκB, which allows activated 
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NF-κB to translocate to the nucleus.  This process is regulated by the enzyme 
A20, which removes ubiquitin from TRAF6 (Boone et al., 2004). 
The activation of IRF3 by TLR3 is less well understood than the activation of 
NF-κB.  TRAF3 has been shown to be essential for TLR-stimulated IFN 
induction (Hacker et al., 2006).  For IRF3 activation, TRAF3 is recruited by 
TRIF, thereby enabling TRAF3 to directly interact with TRAF associated NF-κB 
activator (TANK) (Li et al., 2002) and TANK can then directly associate with 
TANK binding kinase 1 (TBK1) (Fitzgerald et al., 2003; Hemmi et al., 2004; 
Sharma et al., 2003).  Together with the related IKKε, TBK1 phosphorylates 
IRF3, which is then able to translocate to the nucleus.  Both IKKε and TBK1 
have been shown to activate IRF7 as well (Sharma et al., 2003).  TANK has 
also been shown to interact with IKKγ indicating a possible dual role in both NF-
κB and IRF3 activation via TLR3 stimulation (Chariot et al., 2002). 
TLR7 and TLR9 detect endosomal ssRNA and DNA 
TLR3 is not expressed on plasmacytoid dendritic cells (pDCs) (Kadowaki et al., 
2001), however pDCs are one of the few cell types to express TLR7 (and also 
constitutively express IRF7) and they secrete large amounts of IFN during viral 
infection (Colonna et al., 2004).  TLR7 is only expressed in the endosomal 
compartment of the cells (Diebold et al., 2004; Jarrossay et al., 2001; Kadowaki 
et al., 2001) and it has been shown that only TLR7 responds to single stranded 
RNA (ssRNA) in a non-sequence-specific manner (Diebold et al., 2004; Heil et 
al., 2004).  However, this is not always enough to prevent host DNA and RNA 
from activating the TLR-mediated response (Diebold et al., 2004; Kariko et al., 
2005), thus identification of self and non self DNA and RNA is thought to be due 
to modifications of the nucleosides and their subcellular location (Crozat & 
Beutler, 2004; Ishii & Akira, 2005; Kariko et al., 2005).  It is important to note 
that the ability to detect self DNA by TLR7 has been linked to auto-immune 
disorders, such as lupus.  Thus, the endosomal localisation and non-sequence 
specific PAMP are not sufficient to prevent auto-immune activation.  
Additionally, virus internalisation is required for TLR7 and TLR9 activation (Lund 
et al., 2003; Lund et al., 2004).  It has more recently been observed that TLR7 
can also respond to viruses that replicate in the cytoplasm because the 
cytosolic viral replication intermediates are transported to the lysosome by 
autophagy and presented internally to the endosomal TLR7 (Fig 1.2 (Iwasaki, 
2007; Lee et al., 2007)).  Following ligand binding to TLR7 the adaptor protein 
myeloid differentiation factor 88 (MyD88) is recruited to the cytosolic domain of 
the receptor (Lund et al., 2004).  MyD88 then recruits the interleukin-1 receptor-
associated kinase 4 (IRAK4), IRAK1 and the TRAF6 complex which also 
involves TRAF3 (Hacker et al., 2006).  Once TRAF6 is recruited, the activation 
of the IKK complex by TAB2/3 and TAK1 and the subsequent activation of NF-
κB occurs, as described above for the TLR3 signalling pathway.  However, IRF7 
is constitutively expressed in pDCs to quite high levels and therefore is the 
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predominant IRF that is activated in these cells.  As such, TRAF6 is able to 
directly conjugate K63-linked polyubiquitin chains onto IRF7 (Kawai et al., 2004) 
following formation of the MyD88-IRAK1-IRAK4-TRAF6 complex (Honda et al., 
2004; Uematsu et al., 2005), which is also dependent on polyubiquitinated RIP1 
(Huye et al., 2007; Uematsu et al., 2005).  IRAK1 then phosphorylates IRF7 
which can then translocate to the nucleus and alter gene expression (Uematsu 
et al., 2005). 
A role for TLR9 in detection of viral nucleic acids has also been described.  
TLR9 knockout mice demonstrated a higher susceptibility to murine 
cytomegalovirus (MCMV) infection which correlated with decreased levels of 
IFN in the knockout compared to the wild-type mice (Fig 1.2 (Krug et al., 2004; 
Tabeta et al., 2004)).  TLR9 is present in the endosomal compartment of both 
mDCs and pDCs and it detects unmethylated CpG motifs in the lumen of the 
endosome as foreign viral DNA (Abe et al., 2005; Hemmi et al., 2000; Rutz et 
al., 2004).  However, the signalling pathways are different for each cell type.  
The mDCs use TLR9 stimulation by the IRF-1-activated MyD88 bound with the 
IRAK kinases complex to activate the NF-κB pathway (Schmitz et al., 2007), 
whereas in the pDCs, IFN induction is MyD88-dependent and the CpG ligand 
must be retained in the endosomal vesicle (Honda et al., 2005). The signalling 
pathway leading to NF-κB and IRF7 activation is the same as that for TLR7 
(Randall & Goodbourn, 2008). 
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The transcription factor IRF5 has both negative and positive effects on IFN 
induction depending on which IRF-interacting partner it has (Yanai et al., 2007).  
TLR7 and TLR9 stimulation can also trigger IFN induction and subsequent 
secretion into the serum via IRF5 (Barnes et al., 2004; Yasuda et al., 2007), and 
this is also MyD88-dependent as it is for IRF7.  IRF5 deficient mice were shown 
to be more susceptible to viral infection and to have lower levels of IFN in their 
sera (Yanai et al., 2007). 
The RNA helicases RIG-I and MDA5 detect cytoplasmic RNA 
Intracellular RNA from replicating viruses can be detected independently of the 
TLRs (Edelmann et al., 2004) by a class of cytosolic PRRs known as the RIG-I-
like receptors (RLRs).  The RLRs comprise three proteins, RIG-I, MDA5 and 
LGP2 (laboratory of genetics and physiology 2).  RIG-I was identified as a 
receptor for dsRNA produced or released into the cytosol during viral infection, 
as well as being able to detect the dsRNA analogue poly I:C (Yoneyama et al., 
2004).  MDA5 was originally found to bind to the IFN antagonistic V protein of 
parainfluenza virus 5 (PIV5) (Andrejeva et al., 2004) and shows similar 
characteristics to RIG-I (Yoneyama et al., 2005).  LGP2 was first identified as a 
negative regulator of RIG-I and MDA5 (Rothenfusser et al., 2005) but more 
recently has been shown to facilitate the recognition of viral RNA by MDA5 and 
RIG-I (Satoh et al., 2010).  RIG-I and MDA5 are helicases that have two critical 
functional domains, one comprising two N-terminal caspase recruitment 
domains (CARDs) that are conformationally hidden internally, and the other a C 
terminal RNA helicase domain which has ATPase activity.  Detection and 
subsequent binding of RNA to the RNA binding motif allows a conformational 
change to occur which exposes the helicase domain for binding of ATP, which 
itself results in the CARD domains being released to bind to the mitochondrion-
associated adaptor protein.  This protein was discovered independently by four 
groups and called IFNβ promoter stimulator protein 1 (IPS-1), mitochondrial 
antiviral signalling protein (MAVS), CARD adaptor inducing IFNβ (CARDif) and 
virus-induced signalling adaptor (VISA) (Fig 1.3 (Kawai et al., 2005; Meylan et 
al., 2005; Seth et al., 2005; Xu et al., 2005)).  The location on the outer 
mitochondrial membrane of IPS-1 is essential for its function as an adaptor for 
the recruitment of signalling molecules that result in IFN induction via the NF-κB 
and IRF3 pathways.  The association of IPS-1 and tumour necrosis factor 
receptor 1 (TNFR1)-associated death domain protein (TRADD) coordinates the 
assembly of the TRAF3-TRAF6-TANK-RIP1-FADD (Fas associated death 
domain containing protein (FADD)) complex (Michallet et al., 2008).  This 
complex further recruits IKKβ which either activates IKK for NF-κB activation or 
activates IRF3 by a TBK1/IKKε dependent pathway (Zhao et al., 2007). 
MDA5 is negatively regulated by dihydroxyacetone kinase whereas RIG-I is not 
(Diao et al., 2007).  However, RIG-I, but not MDA5, must have its Lys63 residue 
ubiquitinated by the tripartite motif-containing protein 25 (TRIM25) E3 ligase, 
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the importance of which was demonstrated by the inability of a TRIM25 
knockout cell line to produce IFNβ in response to infection with Sendai virus 
(SeV) (Gack et al., 2007).  Both RIG-I and MDA5, as well as IPS-1, are 
negatively regulated by Atg5 and Atg12 due to a direct interaction with their 
CARD domains (Jounai et al., 2007).  The same three proteins are also 
targeted for ubiquitination by the ISG product RNF125, an E3 ligase.  This is 
evidence of a negative feedback mechanism for IFN production following 
infection with SeV or stimulation with dsRNA that regulates IFN induction and 
limits or curtails the immune response (Arimoto et al., 2007).  Further negative 
regulation of IPS-1 occurs via co-localisation of IPS-1 and NLRX1 at 
mitochondria, which blocks the association of IPS-1 with both MDA5 and RIG-I 
(Arimoto et al., 2007).  The RIG-I-related IFN inducible helicase LGP2 also 
appears to negatively regulate RIG-I and MDA5 by binding to, and 
sequestering, RNA but not initiating downstream signalling due to the absence 
of a CARD domain (Rothenfusser et al., 2005; Yoneyama et al., 2005).  
However, this is further complicated by studies showing knockout mice lacking 
LGP2 have a normal negative feedback inhibition of IFNβ transcription and are 
more susceptible to viruses that activate MDA5 signalling as opposed to RIG-I 
signalling (Venkataraman et al., 2007). 
To establish the differing roles of MDA5 and RIG-I during a viral infection, they 
were first studied in vitro and stimulated with poly I:C.  Not only did both 
respond equally well to poly I:C (Andrejeva et al., 2004; Cardenas et al., 2006; 
Yamashita et al., 2005; Yoneyama et al., 2004; Yoneyama et al., 2005), but 
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when the helicase domains were switched between the proteins no difference 
could be discerned in their capability to respond to the poly I:C stimulus (Childs 
et al., 2007).  Using knockout mice deficient in either MDA5 or RIG-I, studies 
uncovered that MDA5 dominantly (over RIG-I) recognises poly I:C and that 
dendritic cells, macrophages and embryonic fibroblasts all respond better via 
MDA5 stimulation after poly I:C treatment (Gitlin et al., 2006; Kato et al., 2006), 
whereas RIG-I recognises in vitro transcribed RNAs (Kato et al., 2006).  Further 
studies revealed that RIG-I recognises self from non-self by being activated by 
RNAs bearing uncapped 5’-triphosphates (such as viral genomic RNAs) as 
opposed to cellular RNAs that are post transcriptionally capped (Hornung et al., 
2006; Pichlmair et al., 2006), or those RNAs that are transcribed by 
polymerases I and III which have 5’ monophosphates. 
This difference in PAMP or ligand detected by MDA5 or RIG-I is supported by 
evidence from infections with specific viruses.  Infection of knockout mice with 
influenza A virus (IAV) or paramyxoviruses triggers the activation of the RIG-I 
signalling pathway but not the MDA5 pathway (Kato et al., 2006).  However, 
studies using knockout mice show that infection with picornaviruses leads to the 
activation of the MDA5 pathway for IFNβ induction and not the RIG-I pathway 
(Gitlin et al., 2006; Loo et al., 2008).  The latter is because throughout the 
replicative cycle, picornavirus RNA is covalently bound to the VPg protein and 
thus there is no 5’ end available for RIG-I to detect (Lee et al., 1977).  During 
infection both poliovirus (PV) and encephalomyocarditis virus (EMCV) have 
been shown to produce measurable levels of dsRNA, detectable by MDA5.  
Conversely, IAV and paramyxoviruses do not produce detectable dsRNA 
(Pichlmair et al., 2006).  Separate studies using overexpression and knockout 
cell lines have further corroborated MDA5 involvement, and not RIG-I, with 
picornavirus infection (Kato et al., 2006), but also with measles virus (MeV) 
infection (Berghall et al., 2006), and both proteins, MDA5 and RIG-I, have been 
demonstrated to be used in IFN induction by Newcastle disease virus (NDV) 
and SeV (Andrejeva et al., 2004; Melchjorsen et al., 2005; Yoneyama et al., 
2004; Yoneyama et al., 2005), along with flaviviruses and reoviruses (Loo et al., 
2008). 
DAI detects cytoplasmic DNA 
DNA located in the cytosol elicits an immune response, and one of the PRRs 
responsible for detection is the DNA-dependent activator of IFN regulatory 
factors (DAI) (also known as DLM1 and ZBP1) (Takaoka et al., 2007).  DAI 
subsequently activates the IFN system independently of TLR9 (Fu et al., 1999; 
Stetson & Medzhitov, 2006).  It has been shown that DAI has three domains 
that bind to DNA and that they are essential for activation of DAI in vivo (Wang 
et al., 2008).  Furthermore, this activation leads to the induction of IFN in a 
TLR/RIG-I-independent manner, but by a mechanism that requires the kinases 
TBK1 and IKKε and the transcription factor IRF3 (Ishii et al., 2006; Takaoka et 
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al., 2007).  Knockdown of DAI using RNAi demonstrated a reduction in IFNβ 
when infected, and thus stimulated, with the DNA virus herpes simplex virus 1 
(HSV1) but not with the RNA virus NDV (Takaoka et al., 2007).  AIM2 (absent in 
melanoma 2) is another protein recently shown to directly bind DNA from the 
DNA virus MCMV.  Binding of DNA by AIM2 leads to the interaction of the 
caspase-1-activating adaptor protein ASC (apoptosis-associated Speck-like 
protein) resulting in the formation of a caspase-1-activating inflammasome, 
which is partially responsible for the maturation of IL-1β and IL-18 and leads to 
NK cell-dependent IFNγ synthesis.  Using AIM2 and ASC knockout mice it has 
been shown that MCMV replicates to a higher titre in the knockout mice 
compared with the wild-type mice and thus that the AIM2-ASC pathway is 
essential for the innate immune response to MCMV (Rathinam et al., 2010). 
STING 
More recently the stimulator of interferon genes (STING) protein has been 
found to play a significant role in the innate immune response to viral infections 
by detecting non-CpG intracellular DNA species originating from DNA 
pathogens.  STING is normally resident in the ER and has five putative 
transmembrane domains and is able to stimulate the induction of IFNβ by the 
signalling pathways of IRF3 and NF-κB (Ishikawa & Barber, 2008).  STING 
knockout murine embryonic fibroblast (MEF) cells were highly sensitive to 
negative stranded RNA viruses and unable to produce IFN in response to 
herpes virus infection or B-DNA stimulation, all in a TLR9 independent manner.  
Also, STING was found to interact with the translocon associated protein 
(TRAP) β and with RIG-I, and furthermore, RNAi knockdown of TRAPβ inhibited 
IFN induction by STING (Ishikawa & Barber, 2008). 
Interferon 
Over fifty years ago Isaacs and Lindenmann described the interference of 
influenza virus replication by a cytokine released from chick cells which had 
been infected with a heat inactivated influenza virus (Isaacs & Lindenmann, 
1987).  Thus this cytokine was called IFN, and since then substantial amounts 
of work have shown IFN to be involved in many cellular pathways and 
responses which are generally termed as the IFN response.  The last decade 
has proved enormously successful in providing understanding of the receptors, 
ligands, signalling pathways, genetic elements and effector proteins involved in 
this complex response system, and how this is effective against viruses will be 
discussed in further detail below. 
The IFN family is made up of many glycoproteins which, when secreted by 
cells, are able to elicit an immune response that ultimately leads to the cells 
going into the ‘antiviral state’.  This is achieved by IFN stimulated up-regulation 
of many antiviral genes involved with inhibition of protein synthesis, cell growth 
and programmed cell death, apoptosis.  There are several types of IFN, which 
 1 Introduction: The immune response 
10 
 
are grouped into three classes, types I, II and III, based on the sequence of their 
amino acids and the receptors they bind.  Type I human IFNs are further sub-
divided into five classes, IFN-α (containing 13 different subtypes), IFN-β, IFN-ε, 
IFN-κ, and IFN-ω.  Of the type I IFNs it is only IFN-α and IFN-β that are directly 
induced by viral infection, and the level of induction is variable between differing 
cell types and dependent on the viral stimulus (Pestka et al., 2004).  Type II IFN 
consists of IFN-γ alone, and the type III IFNs consist of IFN-λ1, IFN-λ2 and IFN-
λ3, which are also known as IL-29, IL-28A and IL-28B respectively.  IFN-γ is not 
directly induced by viruses and is secreted by activated T lymphocytes and NK 
cells, whereas type III IFNs are also induced directly by viral infection using 
pathways similar to IFNs α and β for detection (Onoguchi et al., 2007). 
The secreted IFNs α/β bind to the interferon α receptor (IFNAR), which is a 
heterodimeric receptor comprising IFNAR1 and IFNAR2, and eventually 
stimulate the viral innate immune response via genes known as interferon 
stimulated genes (ISGs) (Fig 1.4).  IFN-γ binds to the IFN-γ receptor (IFNGR) 
which is a tetramer comprising two IFNGR1 chains and two IFNGR2 chains, 
thus mediating an overall innate immune response (Fig 1.4).  Type III IFNs bind 
to the heterodimeric receptor consisting of the interleukin 10 receptor 2 (IL-
10R2) and the IFN-λ receptor 1 (IFN-λR1).  Type I and type III IFNs induce a 
similar antiviral response once stimulated, and are induced in many cell types; 
however, there is a reduced number of type III IFN receptors compared with the 
number of IFNARs (Meager et al., 2005).  
Interferon induction 
There exists a vast array of viral infection detection methods, along with 
differing methods of entry into the cell by viruses of different families, and 
hence, an abundant variety of viral stimuli, from viral nucleic acids to viral 
proteins (discussed later), to induce the IFN response. 
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Interferon β induction: the enhanceasome 
Immediately upstream of the IFNβ promoter is the IFNβ enhancer element, 
which controls the activation of IFNβ transcription.  The IFNβ enhancer element 
comprises four binding sites, two for the IRF proteins, one for the activator 
protein 1 (AP-1) and one for the NF-κB protein.  The IRF protein transcription 
factors, essentially IRF3 and IRF7, bind to the positive regulatory domains 
(PRD) I and III, the AP-1 complex binds to PRD IV, and the NF-κB complex, 
comprising of p50/p60 dimers, binds to PRD II.  These proteins are activated in 
the cytoplasm and then translocate to the nucleus where the binding of these 
proteins and the stability of the resulting structure, the enhanceasome, is 
additionally improved by non-histone high mobility group (HMG)-I/Y chromatin 
proteins bending of the DNA.  The enhanceasome structure and conformation 
as it is formed allows for increasing and enhanced recruitment of, and binding 
of, the transcription factors and coactivators, which further increases the self 
assembly of the enhanceasome.  This additionally augments the recruitment of 
cAMP responsive element binding protein (CREB)-binding protein (CBP)/p300 
and RNA polymerase II to the IFNβ promoter, and crucially completes the 
activation and transcription of IFNβ mRNA in the stimulated cells. 
Interferon α induction 
Interferon α induction occurs in leukocytes (by an IFNβ independent pathway) 
and fibroblast cells (by an IFNβ dependent pathway), and, as with IFNβ 
induction, IFNα promoters contain binding sites for AP-1 and IRF proteins 
namely the PRD I site.  Unlike the IFNβ enhancer element there is no binding 
site for NF-κB, but, studies using IFNβ knockout mice have shown that IFNα 
induction is non functional without IFNβ gene expression (Erlandsson et al., 
1998).  Thus, because the IFNα genes are switched on by IRF7, and IRF7 is an 
IFNβ gene product that is induced early on in the IFNβ response (except in 
pDCs as they constitutively express IRF7) by the activation of the IRF3 signal 
transduction pathway, the powerful IFNα response is dependent on the IFNβ 
response (Levy et al., 2002; Marie et al., 1998). 
Interferon γ induction 
Interferon γ induction occurs in NK cells irrespective of antigen presentation 
whereas CD4+ T helper 1 (TH1) cells and most CD8+ cells require antigen 
presentation by antigen presenting cells (APC) (Young, 1996).  Consequently, 
production of IFNγ occurs in these cells but not in cells infected by a virus 
(Takaoka & Yanai, 2006).  This activation is vital for the innate immune 
response of macrophages, and in NK cells is dependent on production of IL-12 
from APCs.  In CD4+ cells the IFN promoter comprises two elements, the distal 
and proximal elements.  The distal element is activated by binding of the GATA 
binding protein 3 (GATA3) and the proximal element is activated by binding of a 
transcription complex that includes AP-1.  However, CD8+ cells only require 
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activation by the distal regulatory element.  Furthermore, both the CD4+ and 
CD8+ cell’s IFN activation is enhanced by the cytokines IL12 and IL18, which 
are secreted by APCs, although neither IL12 or IL18 is sufficient to stimulate a 
response on their own (Goodbourn et al., 2000; Singh et al., 2000; Young, 
1996). 
Interferon λ induction 
Interferon λ induction follows the same course as type I IFN induction. 
IFN signalling pathways 
The STAT proteins 
Humans have seven STAT proteins, called STAT1-STAT4, STAT5a, STAT5b 
and STAT6, which either form stable homodimers or stable heterodimers 
following activation (Schindler & Plumlee, 2008).  The STAT proteins consist of 
seven structurally conserved domains which comprise the amino terminal 
domain, coiled coil domain, DNA binding domain (DBD), linker domain, Src-
homology 2 (SH2) domain, tyrosine activation motif, and transcriptional activator 
domain (TAD).  The amino terminal domain allows unphosphorylated STATs to 
homotypically dimerise, and thus aids the recruitment of STAT dimers during 
receptor activation (Braunstein et al., 2003).   The coiled coil domain is thought 
to control nuclear import and export and to have some involvement with 
regulatory proteins (Schindler et al., 2007).  The DBD is involved in nuclear 
import and export as well as binding to GAS (McBride & Reich, 2003; Schindler 
& Plumlee, 2008).  The linker domain ensures constant nuclear export in resting 
cells and translates conformational changes to the DBD (Bhattacharya & 
Schindler, 2003).  The SH2 domain is responsible for receptor recruitment and 
activation of STAT dimers (Shuai et al., 1994).  The tyrosine activation motif 
assists JAK-dependent phosphorylation of STAT, and then itself is bound to the 
second STAT, to make the dimer, by the SH2 domain (Mao et al., 2005; 
Schindler & Plumlee, 2008).  TADs are important for the recruitment of 
coactivators, and to maintain stability of STAT proteins, as some can be 
targeted for ubiquitination (Schindler & Plumlee, 2008).  With regards to the IFN 
signalling pathway, signalling via STAT1 and STAT2 is the most prominent. 
There are four members of the JAK family, Jak1, Jak2, Jak3 and Tyk2 and they 
have seven JAK homology domains, JH1-JH7.  JH1 is responsible for tyrosine 
kinase catalytic activity.  JH2 is a pseudokinase domain that inhibits JAK 
activation (when no suitable ligand is bound), and thus negatively regulates the 
kinase activity of JH1 (Luo et al., 1997; Saharinen et al., 2000).  JH3 and JH4 
have a SH2 domain with no known function, and the rest, JH4 to JH7 make up 
the FERM (four point one, ezrin, radixin, moesin) domain which provides 
stability and maintains the association with cytokine receptors.  The N terminal 
region of the JAKs allows receptor association in the inactive state (Chen et al., 
1997).  Much of the downstream signalling stimulated by cytokines, including 
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IFNs, involves the JAK family (Burfoot et al., 1997; Platanias et al., 1996).  For 
example, Tyk2 binds IFNAR1, whereas Jak1 binds with IFNAR2 and IFNGR1, 
and Jak3 binds IFNGR2 (Schindler & Plumlee, 2008).  Once IFN binds to the 
receptor, the JAKs are also activated by trans- or auto-phosphorylation (Rane & 
Reddy, 2000), leading to the phosphorylation of specific tyrosine residues on 
the cytoplasmic domain of the receptor.  Receptor phosphorylation leads to 
recruitment of SH2 domain-containing proteins, including STATs and 
phosphatidylinositol 3 kinase (PI3K), resulting in continuation of the signalling 
pathway and culminating in the antiviral response.  JAK knockout mice are 
unable to survive for very long, illustrating the importance of these proteins 
(Karaghiosoff et al., 2000; Park et al., 1995; Rodig et al., 1998).   
Type I IFN signalling 
The ‘classical’ pathway of IFN signalling is via JAK/STAT signal transduction 
and this pathway is thus well characterised.  In unstimulated cells the 
intracellular domains of the IFNAR subunits are physically associated with the 
cytoplasmic Tyk2 and JAK1 kinases as well as both the STAT1 (weakly via 
STAT2) and the STAT2 proteins (Abramovich et al., 1994; Muller et al., 1993; 
Novick et al., 1994; Precious et al., 2005).  Once type I IFNs have bound to the 
IFNARs, they undergo a conformational change which results in Tyr466 of 
IFNAR1 being phosphorylated by Tyk2, leading to a robust interaction between 
IFNAR1 and STAT2.  This stronger interaction allows phosphorylation of Tyr690 
of STAT2 by Tyk2, and consequently the phosphorylation of STAT1 at Tyr701 
by JAK1 (Leung et al., 1995).  The stable heterodimer of STAT1/STAT2 imparts 
a conformational change that reveals the nuclear localisation signal (NLS) 
allowing the dimer to translocate to the nucleus (until it is dephosphorylated and 
the nuclear export signal (NES) is again exposed and the proteins are exported 
back to the cytoplasm) (Banninger & Reich, 2004; Fagerlund et al., 2002; 
McBride et al., 2000; Melen et al., 2003).  Tyrosine phosphorylation of the 
STAT1/STAT2 dimer results in the assembly of the heterotrimeric transcriptional 
activator complex ISGF3 (IFN stimulated gene factor 3), comprising 
STAT1/STAT2/IRF9, which enters the nucleus and binds to the interferon 
stimulated response elements (ISRE) upstream of the type I IFN genes and 
activates transcription of IFN (Kessler et al., 1990; Levy et al., 1989; Martinez-
Moczygemba et al., 1997; Tang et al., 2007; Veals et al., 1992).  Whether IRF9 
binds to the STAT1/STAT2 dimer at the IFNAR is unknown.  However, STAT2 
and IRF9 have been shown to interact with each other both before and after 
IFNα stimulation and in a separate study IRF9 was shown to associate directly 
with IFNAR2, suggesting ISGF3 complex formation is at the IFNAR (Martinez-
Moczygemba et al., 1997; Tang et al., 2007). 
It is not only STAT1 and STAT2 which dimerise in response to type I IFNs; 
homodimers of STAT1, STAT3, STAT4, STAT6, and heterodimers of STAT1/3, 
STAT1/4, STAT1/5, STAT2/3 and STAT5/6 have been described (Farrar et al., 
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2000; Platanias, 2005; Torpey et al., 2004).   When activated these STAT 
dimers initiate transcription of ISGs by binding to the upstream ISRE/GAS 
elements of their promoters.  With this diversity in STAT dimer formation comes 
regulation of which ISGs are upregulated, as expression of some ISGs occurs 
in response to STAT binding to either the ISRE or to GAS or even to both 
regulatory elements.  In this way optimal ISG expression can be achieved by a 
combination of STATs binding to different regulatory elements and conversely, 
some STATs can upregulate one ISG whilst simultaneously downregulating 
another (Nguyen et al., 2002; Platanias, 2005). 
Type II IFN signalling 
Type II IFN (IFNγ) binds and stimulates the type II IFN receptors, IFNGR1 and 
IFNGR2, which are constitutively associated with Jak1 and Jak2, respectively 
(Bach et al., 1997; Chen et al., 2004; Stark et al., 1998).  As for type I IFNs, 
IFNγ binding to IFNGR1 results in receptor dimerisation, and the subsequent 
JAK activation stimulates phosphorylation of IFNGR1.  This results in a 
conformational change and two binding sites for STAT1 become exposed.  The 
subsequent binding of STAT1 proteins is via the SH2 domains.  
Phosphorylation of Tyr701 of STAT1 allows its dissociation from the receptor 
and subsequent SH2 domain-controlled STAT1/STAT1 homodimersiation, the 
homodimer being called gamma activated factor (GAF) (Decker et al., 1991a; 
Nguyen et al., 2002).  GAF then translocates to the nucleus and binds to the 
GAS elements and stimulates ISG expression (Decker et al., 1991b). 
Type III IFN signalling 
Type III IFNs, IFNλ, have their own exclusive receptor, although they still elicit a 
very similar IFNα/β induced signalling pathway.  As with IFNα/β they use the 
JAK/STAT signal transduction pathway, and as such binding of IFNλ to the type 
III IFN receptor triggers phosphorylation of the intracellular domain of the 
receptor by the Janus kinases (JAKs), and subsequently phosphorylation of the 
signal transducer and activator of transcription (STAT) proteins.  These include 
STAT2, STAT3, STAT4, STAT5 and the formation of STAT1 homodimers, and 
consequently activation of the γ IFN activated site (GAS) regulated genes, 
therefore IFNλ induction follows the same course as the typical type I IFN 
induction pathway (Dumoutier et al., 2004).  Thus, both type I and type III IFNs 
are induced by dsRNA and viral infections and both result in the upregulation of 
many antiviral proteins and antigen expressing class I major histocompatibility 
complex (MHC) (Kotenko et al., 2003).  IFNλ, however, is not as potent as the 
other types of IFN due to the low level expression of the type III IFN receptor on 
only a few, specific cells (Meager et al., 2005). 
STAT transactivation 
Additionally, for optimal ISG upregulation by IFNs, the STATs need to be further 
modified either post translationally or by the interaction with other proteins 
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called transcriptional coactivators.  STAT1 needs to be phosphorylated at 
residue Ser727, and this is done by the serine kinase protein kinase Cδ (PKCδ) 
(itself a member of the protein kinase C family).  Additional serine kinases 
involved in an IFN dependent manner that phosphorylate Ser727 are PKCε and 
the calcium/calmodulin dependent protein kinase (PK) II.  Phosphorylation of 
STAT1 in this manner results in enhanced interaction between STAT1 and 
nMYC and STAT interactor (NM1) (Zhu et al., 1999), which itself enhances the 
interaction between STAT1 and transcription factors such as CBP/p300.  The 
latter transcription factor, CBP/p300, further enhances the interactions of 
several other groups of transcription factors (Janknecht & Hunter, 1996).  
STAT2 also binds to CBP/p300 and assists with the activation of transcription, 
although STAT2 is not serine phosphorylated (Bhattacharya et al., 1996) 
Negative regulation of IFN signalling 
There are several IFN-inducible proteins that interact in a negative feedback 
loop to control the IFN response.  The protein inhibitors of activated STATs 
(PIAS) protein PIAS1 interacts with STAT1 homodimers, prevents them binding 
to DNA and therefore inhibits gene expression (Liu et al., 1998).  The ubiquitin-
like protein ISG15, itself an ISG, becomes conjugated to STAT1 and targets 
STAT1 for degradation (Malakhov et al., 2003).  The suppressor of cytokine 
signalling (SOCS) family of protein phosphatases target JAK proteins for 
proteasomal degradation or directly inhibit their activity (Rui et al., 2002; Sasaki 
et al., 1999; Yasukawa et al., 1999).  Furthermore, the protein tyrosine 
phosphatases SHP1 and SHP2 contain SH2 domains and as such are able to 
dephosphorylate the tyrosine residues of both the STATs and the receptor, 
thereby returning the STATs to their inactive state (Mustelin et al., 2005). 
Other interferon signalling mechanisms  
As discussed above the JAK/STAT signal transduction pathway is the ‘classical’ 
and fundamental IFN induction pathway, resulting in the upregulation of many 
antiviral proteins.  However, this is not the complete story; there are other 
pathways that have been shown to produce signalling molecules and cascades 
that help in optimising the IFN response.  These include the mitogen activated 
protein kinase (MAPK) p38 cascade (Platanias, 2005), the CRK proteins which 
are able to interact with Tyk2 (Ahmad et al., 1997; Feller, 2001), and the PI3K 
proteins which exert negative regulatory effects on the JAK/STAT signalling 
pathway (Hawkins et al., 2006; Platanias, 2005). 
ISGs and IFN induced antiviral proteins 
IFN stimulated genes 
Interferon production, secretion and subsequent binding and stimulation of the 
IFN receptors, IFNAR and IFNGR, promote the upregulation of over 300 ISGs 
which mediate the antiviral response within IFN-stimulated cells.  These ISGs 
are involved in numerous functions within the stimulated cell, as well as in 
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neighbouring cells and in cells mediating the adaptive immune response.  The 
ISGs promote the antiviral response as well as being antiproliferative and 
immunomodulatory, and include proteins that regulate transcription and 
translation of gene expression, and proteins that regulate apoptosis and the cell 
cycle such as chemokines, cytokines and enzymes (de Veer et al., 2001; Der et 
al., 1998).  Many of the identified ISGs have not been characterised as yet.  
However, several ISGs that play an essential role in establishing the antiviral 
state have been well characterised, including Mx GTPases, protein kinase R 
(PKR), and 2’, 5’ oligoadenylate synthetases (OAS)/endoribonuclease L 
(RNaseL), while some others, such as viperin, are just beginning to be studied.  
Upregulation of ISGs is an essential aspect of the innate immune response.  
Using knockout mice which are deficient in either IFNAR or IFNGR it was 
shown that despite the mice seeming to be healthy and able to mount an 
adaptive immune response with T cells, they were extremely susceptible to viral 
infections, with Semliki Forest virus (SFV) titres being undetectable after 24 
hours in the wild type mice but extremely high in the knockout mice (Huang et 
al., 1993; Hwang et al., 1995).  Added together, the IFN induced and 
subsequent expression of ISGs, the antiviral state that cells are put into 
becomes a highly inhospitable place for viruses, inhibiting their replicative cycle 
and allowing extra time to be gained by the cell and neighbouring cells in order 
to give the adaptive immune response a chance to be activated.   
The OAS and RNaseL pathway 
The 2’,5’ OAS proteins are IFN inducible though are constitutively present within 
the cytoplasm in small quantities, where they are able to act as PRRs for the 
sensing of viral dsRNA (Fig 1.5 (Hoenen et al., 2007; Sadler & Williams, 2008)). 
They are characterised by their ability to catalyse the polymerisation of ATP into 
oligomers of adenosine by synthesising a 2’,5’-linked phosphodiester linkage 
(Rebouillat & Hovanessian, 1999).  These oligomers then initiate the activation 
of the constitutively expressed endonuclease RNaseL (Zhou et al., 1993)  which 
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is able to degrade RNAs of both cellular and viral origin, and thus inhibit the 
synthesis of proteins.  The smaller RNA molecules can then, in turn, further 
activate the induction of type I IFNs via RIG-I and MDA5, which are also in the 
cytoplasm, leading to an increased antiviral response (Malathi et al., 2007).  
The engineering of RNaseL-deficient mice and the subsequent exposure to 
RNA viruses from the families of Paramyxoviridae, Togaviridae, Picornaviridae, 
Reoviridae, Flaviviridae, Orthomyxoviridae and Retroviridae showed an 
increase in susceptibility to infection (Silverman, 2007).  Furthermore, Zhou et 
al. (1999) showed that parainfluenza virus 3 (PIV3), EMCV, VSV and vaccinia 
virus (VACV) replication was suppressed in the presence of RNaseL over-
expression. 
Mx GTPases 
There are four families of proteins in the class of guanine hydrolysing proteins: 
the p65 GBPs, the very large inducible GTPases, the p47 guanylate-binding 
proteins and the Mx proteins.  It is only the Mx proteins which have a proven 
role in antiviral immunity (Haller et al., 1980).  The Mx GTPase family consists 
of two human proteins, MxA and MxB, and two murine proteins, Mx1 and Mx2.  
These were discovered after inbreeding of mice led to an increase in 
susceptibility to orthomyxovirus infection, which was subsequently shown to be 
due to mutations in the Mx gene (Haller et al., 1979).  Of the four proteins, only 
Mx2 localises to the nucleus, whereas the other three are cytoplasmic, and only 
MxA shows antiviral activity in humans (Haller et al., 1995).  The Mx proteins 
comprise a large N-terminal GTPase domain along with a central interacting 
domain (CID) and a leucine zipper (LZ) domain at the C-terminal end, and the 
latter two domains are essential for recognition of viral targets (Kochs & Haller, 
1999).  Due to the subcellular localisation of Mx proteins next to the smooth ER 
and their apparent affinity for nucleocapsid-like structures, they are able to halt 
viral replication considerably early on in the infection by binding to viral 
components (Fig 1.6 (Accola et al., 2002)).  This has been shown with influenza 
virus, and constitutes a particularly effective mechanism for counteracting the 
generation of viruses able to escape the antiviral mechanisms of MxA (Turan et 
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al., 2004).  More recently Haller et al. have shown MxA tetramers to form 
filamentous or ring-like structures on the viral nucleoprotein consequently 
inhibiting viral polymerase activity (Haller et al., 2010).  Other viruses to be 
affected by Mx proteins include rhabdoviruses, togaviruses, paramyxoviruses, 
orthomyxoviruses and bunyaviruses.  In the latter, animal-infecting viruses from 
each genus (excluding tospoviruses) have been shown to be inhibited by MxA 
(Bridgen et al., 2004; Frese et al., 1996; Kanerva et al., 1996), leading 
Andersson et al. (2004) to conclude that all animal bunyaviruses are restricted 
by MxA. 
PKR 
PKR was first discovered when a translational block was identified in a cell-free 
in vitro translation system using a lysate from VACV-infected cells that had 
been treated with IFN and had been supplemented with exogenous RNA (Kerr 
et al., 1977; Metz & Esteban, 1972).  PKR has been found to be encoded on a 
single gene (Barber et al., 1993) and is constitutively expressed in quiescent 
mammalian cells at relatively low levels, in a monomeric state, and, as expected 
for a translation inhibitor, is associated with ribosomes (Zhu et al., 1997b).  PKR 
belongs to the family of kinases responsible for phosphorylating the eIF2α 
subunit in response to stress, in particular that mediated by viral infections.  It 
has two specific kinase activities, one of which autophosphorylates to activate 
PKR, and the second to phosphorylate the eIF2α subunit of eIF2, which in turn 
blocks eIF2 activity and thus protein synthesis.  As well as the kinase domain, 
PKR also has a dsRNA binding domain which activates PKR when RNA binds 
to it (Fig 1.7).  Activation of PKR can occur by dsRNA of viral, synthetic or 
cellular origin binding to the N terminus of PKR, causing activation by 
autophosphorylation and homodimersiation (Dar et al., 2005).  PKR has been 
shown to be optimally activated by dsRNA longer than 30 bp (base pairs), as 
well as by ssRNAs containing 5’ triphosphates greater than 47 bases in length 
(Nanduri et al., 1998).  This permits PKR to distinguish self from non-self since 
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most cellular RNAs have 5’ monophosphates or 5’ cap structures. In normal 
mammalian cells, eIF2 comprises three subunits, α, β and γ, and is responsible 
for delivering the Met-tRNAi to the ribosome to initiate GTP-dependent 
translation.  On arrival, the GTP is hydrolysed by eIF5, which in turn releases 
the eIF2-GDP from the initiation complex.  The eIF2B then catalyses the 
regeneration of the eIF2-GTP from the eIF2-GDP.  PKR is a serine/threonine 
kinase and as such phosphorylates residue Ser51 of the eIF2α subunit which 
subsequently binds strongly to the eIF2B subunit, inhibiting the capacity for 
eIF2B to catalyse regeneration of eIF2-GTP from eIF2-GDP (Roberts et al., 
1976).  As the ratio of eIF2B to eIF2 is very low, only a small amount of 
phosphorylated eIF2α is required to severely inhibit translation (Hershey, 1991).  
Once the recycling of eIF2 is halted, protein translation is blocked.  Thus, the 
inhibition of protein synthesis is the basic mechanism of antiviral activity of PKR.  
Furthermore, PKR acts as a PRR by detecting and binding dsRNA and initiating 
the IκB/NF-κB signal transduction pathway (Kumar et al., 1994).  Viruses known 
to be affected by PKR are hepatitis C virus (HCV), West Nile virus (WNV), 
human immunodeficiency virus 1 (HIV-1), Sindbis virus (SinV) and EMCV 
(Gorchakov et al., 2004; Nagai et al., 1997; Noguchi et al., 2001; Samuel et al., 
2006; Yeung et al., 1999).    
ISG15 
The highly IFN-inducible protein ISG15 is approximately 15 kDa in size and is a 
ubiquitin homologue (Loeb & Haas, 1992) that was first isolated over 20 years 
ago.  ISG15 expression gives a 165 amino acid precursor which is further 
processed to reveal the C terminal sequence LRLRGG.  Ubiquitylation occurs 
through the adenylation of the two glycine residues within this sequence which 
are then linked via a thioester bond to the cysteine residues on the three 
ubiquitin enzymes, ubiquitin activating enzyme (E1), ubiquitin conjugating 
enzyme (E2), and ubiquitin ligase enzyme (E3).  This ubiquitin ligation complex 
can then attach ubiquitin to the lysine residues on target proteins.  Ubiquitylation 
is essential within the immune response, aiding intracellular signal transduction, 
and, when under the control of IFNs and ISGs, it is termed ISGylation (Fig 1.8).  
The process is much the same as ubiquitylation, however, the ubiquitin E1 
enzyme is unable to form a thioester linkage with ISG15, and it is now known 
that there are several enzymes that catalyse the reactions required to conjugate 
ISG15 to substrate proteins.  UBE1L is the E1-like ubiquitin-activating enzyme 
and is responsible for activating ISG15.  The two enzymes UBE2E1 and 
UBE2L6 serve the equivalent role of E2 in conjugation, and the two E3 ligase 
enzymes HerC5 and TRIM25 are able to conjugate the target proteins to ISG15 
via their HECT and RING domains.  De-ISGylation is the reversal of this 
process and enzymes involved in the hydrolysis of ISG15 are the ubiquitin 
specific proteases such as USP2, USP5, and USP18 (Sadler & Williams, 2008).  
Unlike ubiquitylation, ISGylation leads to protein stabilisation, translocation or 
non-degradative negative feedback (Kim et al., 2008; Loeb & Haas, 1994; Lu et 
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al., 2006).  Many proteins involved in the type I IFN response undergo ISG15 
conjugation, such as JAK1, STAT1, RIG-I, PKR, MxA and RNaseL (Zhao et al., 
2005).  Furthermore, ISG15 has been shown to have cytokine characteristics 
and is secreted in large amounts (D'Cunha et al., 1996).  The antiviral effects of 
ISG15 have been demonstrated with several viruses by using knockout mice 
deficient in ISG15.  Such viruses include HSV-1, SV and IAV and IBV (influenza 
B virus) (Lenschow et al., 2005; Osiak et al., 2005).  In addition, Lenschow et al.    
(2005) showed that IFNAR1 deficient mice infected with an engineered SV that 
expressed ISG15 subsequently protected the mice from a lethal dose of wild 
type SV.  Knockdown of USP18 by siRNA enhances cellular resistance to HCV 
and VSV (Randall et al., 2006).  Furthermore, USP18 knockout mice showed an 
increase in IFN and poly I:C sensitivity compared to wild type mice (Malakhova 
et al., 2003), and Ritchie et al. (2004) demonstrated resistance in these mice to 
LCMV and VSV infection. 
PML 
Promyelocytic leukaemia (PML) protein is an essential component of PML 
nuclear bodies (NBs), although there are many other proteins involved, and 
many of these are also IFN inducible, such as Sp100 and PA28.  PML NBs are 
heterogeneous in both the type of proteins comprising the NBs and the size of 
the bodies.  Treatment with IFN directly induces transcription of PML and leads 
to an increase in the number and size of the NBs (Everett & Chelbi-Alix, 2007).  
The PML protein has been shown to be involved in higher order chromatin loop 
structure organisation and gene regulation (Kumar et al., 2007).  In an over-
expression system, both the PML III protein and the PML IV protein isoforms 
inhibited the replication of RNA and DNA viruses.  PML protein knockout MEFs 
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were more susceptible to infection with LCMV, giving a higher viral titre than the 
naive MEFs, thus demonstrating the importance of PML (Djavani et al., 2001). 
Other ISGs 
Triple knockout mice that are deficient in the Mx, RNaseL and PKR proteins 
were still able to mount a limited IFN-induced antiviral response, providing 
evidence that further mechanisms of innate immunity exist (Zhou et al., 1999).  
There are now known to be numerous IFN-inducible proteins that are involved 
in the antiviral response, including ISG20, Viperin, ISG56, adenosine 
deaminases and the restriction factors apolipoprotein B mRNA-editing enzyme-
catalytic polypeptide-like (APOBEC) 3F and 3G (APOBEC 3F and 3G) and the 
tripartite motif-5α (TRIM5α).  ISG20 is a 3’, 5’ exonuclease that specifically 
degrades ssRNA (Degols et al., 2007).  Viperin has been shown to disrupt lipid 
raft formation and hence to inhibit the budding of IAV (Wang et al., 2007).  
ISG56 (IFN induced protein with tetratricopeptide repeats 1 (IFIT1)) disrupts 
translation through its interaction with multiprotein complexes essential to 
translation.  The interaction of ISG56 with the eIF3e subunit renders it unable to 
stabilise the eIF2-GTP-tRNAiMet complex (Hui et al., 2003).  The adenosine 
deaminases are directly mutagenic to dsRNA, converting adenosines to 
inosines (Zahn et al., 2007).  The APOBEC enzymes both deaminate cytidine 
and hence mutate the viral template and then inhibit the reverse transcription of 
retroviruses (Randall & Goodbourn, 2008; Ying et al., 2007).  TRIM5α binds to 
infectious retroviral capsids and targets them for proteasomal degradation 
(Towers, 2007).  These pathways and many more have yet to be fully 
characterised.  
Control of apoptosis 
Once a cell is infected with a virus, one of the specific functions of IFN is to 
induce apoptosis, not only within the infected cell, but also to induce the pro-
apoptotic state in neighbouring cells, thus ensuring that the spread of the viral 
infection is limited.  The ISG proteins PKR, OAS/RNaseL and PML are all 
involved in the induction of apoptosis.  Furthermore, it is known that IFNs 
induce expression of the cellular enzymes caspases, which are key proteins in 
the induction of apoptosis (Balachandran et al., 2000; Chin et al., 1997; 
Schindler, 1998; Subramaniam et al., 1998). 
Viral countermeasures to IFN 
Soon after Isaacs and Lindenmann’s discovery of IFN, Lindenmann noticed 
another phenomenon in infected cells: prior infection with a live virus was 
enough to suppress the subsequent IFN induction by an attenuated virus.  He 
called it inverse interference (Lindenmann, 1960).  Fifty years later, it is now 
known that all viruses must either circumvent or overcome the IFN response for 
successful replication, and the range of viral IFN antagonists stretches across 
all the components of the IFN system.  There are five ways that viruses use to 
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circumvent the IFN response: global inhibition of cellular gene and or protein 
expression; inhibition of IFN induction by inhibiting signalling pathways or 
masking exposure of viral PAMPs;  blocking signalling of IFN; blocking ISGs; 
and by being inherently insensitive to IFNs.  Some viruses interfere with the IFN 
system with a combination of the above and some encode one or more 
individual viral proteins that antagonise the IFN system in several different ways 
(Randall & Goodbourn, 2008).  Furthermore, there must be a temporal control 
exerted during the viral replicative cycle to ensure that the virus is able to 
produce the IFN antagonist without inducing the IFN response too early by 
producing other viral proteins/PAMPs.  This also demonstrates that the virus will 
be constantly under selective pressure.  Therefore cell tropism is fundamental 
to viral pathogenicity but virulence of the virus depends on the ability of its IFN 
antagonist to counteract the IFN response (Young et al., 2003). 
Protein shutoff 
Inhibition of cellular gene expression and/or protein synthesis is a strategy used 
by several viruses.  This is particularly advantageous as it completely removes 
the inhibitory effects of IFN on the virus, not only in the infected cell but also in 
the neighbouring cells which will not be stimulated into the antiviral response.  
However by “switching off” the cell, apoptosis is induced more rapidly, the virus 
is unable to utilise the cell’s transcriptional and translational machinery and the 
virus will not be able to establish a persistent infection.  The IFN antagonist NSs 
protein of viruses in the family Bunyaviridae is particularly efficient at causing 
host cell protein shut-off and, interestingly, the NSs proteins of viruses in two 
distinct genera have the same function but with a different mechanism 
(discussed later).  The matrix (M) protein of VSV inhibits host cell transcription 
by blocking the basal transcription factor TFIID and then also by inactivating 
translation factors, as well as interfering with the intracellular transport of RNAs 
and proteins (Ahmed & Lyles, 1998; Black & Lyles, 1992; Petersen et al., 2000).  
IFN gene transcription is inhibited by PV, IAV and HSV1 as they encode 
antagonists which shut-off host cell transcription and translation.  Likewise, foot 
and mouth disease virus (FMDV) expresses the leader protein which induces 
host cell protein shut-off (Chinsangaram et al., 1999).  Often, mutations in the 
viral IFN antagonist gene are enough to attenuate these viruses. 
Blocking IFN cascades and PAMPs 
There are several factors to consider when looking at the amount of IFN 
induced in response to viral infection.  The preparation of the virus can have an 
effect, due to a high number of defective interfering particles (DIs) or 
chemokines in the viral innoculum (Strahle et al., 2006).  Factors from the virus 
point of view are, firstly, the type and amount, of IFN inducer, such as dsRNA, 
that is produced.  Secondly, whether the viral antagonist counteracts the 
induction of IFN and its mode of action, and how quickly the virus can express 
the antagonist.  Thirdly, the type of cell that the virus is infecting as specific cell 
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types produce differing amounts of IFN.  Viruses address these factors in 
numerous ways.  PAMPs produced during replication may be protected by 
capping the RNA or ‘cap snatching’ as with paramyxoviruses and influenza 
viruses respectively.  Hantavirus genomic RNA does not have 5’ triphosphates, 
and picornaviruses attach the Vpg protein to the end of their RNAs, both of 
which will protect the RNA from detection by RIG-I.  Furthermore some positive-
stranded RNA viruses replicate in intracellular vesicles, and retroviruses 
integrate their genomes into the host cell genome.  Some viruses express IFN 
antagonists that sequester dsRNA such as the VP35 protein of Ebola virus 
(EBOV) (Cardenas et al., 2006; Hartman et al., 2006), the NS1 protein of IAV 
(Lu et al., 1995), and the vaccinia virus E3 protein (Chang et al., 1992).  There 
are viruses which express IFN antagonists that target specific IFN induction 
pathway points.  For example, HCV virus targets TLR3 signalling by cleaving 
TRIF with NS3/4a (Li et al., 2005a) which also cleaves IPS-1 at Cys508 thus 
disrupting RLR signalling (Li et al., 2005b).  In addition, many paramyxoviruses 
inhibit MDA5 activity by expressing the V protein which directly interacts with 
MDA5 but not RIG-I (Andrejeva et al., 2004).  In contrast, IAV expresses a 
protein called NS1 that inhibits RIG-I-mediated signalling (Mibayashi et al., 
2007).  Inhibition also occurs further downstream, with some viruses blocking 
the regulatory proteins such as IRF3 which is targeted for proteasomal 
degradation by the NPro protein of bovine viral diarrhoea virus (BVDV) and 
classical swine fever virus (CSFV) (Bauhofer et al., 2007), whereas the P 
protein of Borna disease virus (BDV), rabies virus and the Gc protein of 
Hantaan virus (HTNV) target TBK1 to prevent IRF3 activation (Alff et al., 2006; 
Brzozka et al., 2005).  IRF3 is also targeted by Thogoto virus (THOV) at a 
transcriptional level by preventing dimerisation of IRF3 and its association with 
CBP (Jennings et al., 2005). 
IFN signalling inhibition 
Blocking the IFN signalling pathway enables some viruses to inhibit more than 
one type of IFN pathway, as the three known pathways do have some overlap, 
and it further reduces the response of cytotoxic T cells through lack of MHC I 
upregulation, and hence the infected cells would no longer respond to the IFNs.  
There are many ways in which viruses are able to inhibit IFN signalling, and 
many do it on several different levels.  Firstly, viruses such as Japanese 
encephalitis virus (JEV), Dengue virus (DENV) and Langat virus (LGTV) all 
interfere with IFN receptors.  JEV protein NS5 impedes protein tyrosine kinase 
Tyk2 (Lin et al., 2006), while DENV and LGTV disrupt IFNGR complexes (Ho et 
al., 2005; Park et al., 2007).  Type I and II IFN signalling is inhibited by 
polyomavirus T antigen binding to JAK1 (Weihua et al., 1998).  Several 
poxviruses, such as cowpox virus (CPXV) and camelpox virus (CMLV), express 
proteins that are usually secreted by infected cells and that can bind directly to 
extracellular IFNγ.  Other poxviruses, such as VACV, express proteins that can 
bind to IFNα/β and some even express proteins that mimic the IFNGR which 
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are able to sequester IFNγ, thus preventing neighbouring cells from entering the 
antiviral state (Alcami & Smith, 1995; Alcami et al., 2000; Symons et al., 1995).  
Many viruses inhibit the function of the STAT proteins; rabies virus P protein 
binds to, and thereby inactivates, STAT1 and STAT2 (Vidy et al., 2007).  The 
paramyxoviruses use several different mechanisms to block the STAT proteins; 
mumps virus targets STAT1 and STAT3 for degradation, whereas PIV5 targets 
STAT1, and human parainfluenza virus 2 (HPIV2) targets STAT2.  However, 
the henipaviruses V and P proteins sequester the STAT1 and STAT2 proteins 
(Conzelmann, 2005; Horvath, 2004; Nagai & Kato, 2004).  Additionally, PIV5 is 
able to overcome cells in the antiviral state because the virion-associated V 
protein begins to target STAT1 for degradation immediately after infection, thus 
dismantling the antiviral state (Carlos et al., 2005).  The EBOV protein VP24 
inhibits nuclear import of STATs by binding to the nuclear localisation signal 
receptor karyopherin α1 (Reid et al., 2006), whereas HSV1 inhibits JAK/STAT 
signalling by inducing SOCS3 expression soon after infection (Yokota et al., 
2004).  Human papillomavirus (HPV) inhibits the formation of the ISGF3 
complex and subsequent IFNα/β activation by a direct interaction between IRF9 
and the viral E7 protein (Barnard & McMillan, 1999). 
Viral inhibitors of ISGs 
Many viruses have also evolved ways of overcoming the ISGs that they induce 
through their earlier infection.  As stated above, there are over 300 ISGs 
identified and many of them still have unknown functions and mechanisms, so 
some of the counter measures that different viruses use for the more 
characterised pathways shall be briefly described.  Clearly ISG15 has antiviral 
properties as several viruses specifically target it for inhibition, most notably 
IBV.  This virus prevents ISG15 from being conjugated to its target proteins by 
expressing the viral protein NS1 which interacts with, and sequesters, the E3 
ligase (Yuan & Krug, 2001).  The cytidine deaminase proteins APOBEC 3G and 
3F are targeted by the virion infectivity factor (vif) protein of many lentiviruses 
(including HIV) which recruits E3 ligases to ubiquitinate the APOBECs and thus 
ensure their subsequent proteasomal degradation (Soros & Greene, 2007).  
HIV-1 also inhibits the OAS RNaseL response by activating the inhibitor of 
RNaseL, thus eliminating the activation of the OAS response (Martinand et al., 
1999).  Due to the low affinity of OAS for dsRNA, the OAS ISGs can be easily 
targeted for inhibition by viral proteins that sequester dsRNA, like the NS1 
protein of IAV.  Numerous other viruses express viral proteins that are able to 
sequester dsRNA and not only inhibit the OAS response, but they are also 
particularly useful in counteracting the PKR and ADAR ISG responses. 
Known effects of IFN on viruses 
Many viruses have been intensively studied over the past few years for the virus 
specific effects of IFNs on their replication cycle, and this has led to successful 
treatments of some viral diseases such as hepatitis caused by HCV.  The 
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paramyxovirus PIV5 encodes the viral V protein that inhibits IFN signalling by 
targeting STAT1 for proteasomal degradation and also limits the amount of IFN 
synthesised by blocking the nuclear translocation of IRF-3 (Andrejeva et al., 
2002; He et al., 2002).  The PIV5 strain CPI- is unable to block IFN signalling 
and was used to study the effects of IFN in cells unable to synthesise IFN that 
were infected with CPI- or CPI+ (the latter is able to block IFN signalling) 
strains.  The study showed several results: the virus protein synthesis profile 
was altered and proteins encoded downstream of the V/P gene were 
downregulated; the transcription gradient was altered such that an increase in 
viral genes at the 3’ end of the genome occurred, whilst there was a decrease in 
transcription of genes towards the 5’ end of the genome (Carlos et al., 2005); 
the polymerase was also affected as the mRNAs of CPI- virus were shown to 
have longer poly(A) tails; and viral proteins were shown to be redistributed 
within IFN treated infected cells which further enhanced the formation of 
inclusion bodies (Carlos et al., 2005).  Treatment of Vero cells with IFNγ 
downregulated the mRNA and cellular expression of the SARS-Co-V receptor 
angiotensin-converting enzyme 2 (ACE2) thereby inhibiting the virus at the level 
of attachment (de Lang et al., 2006).  Primary human macrophages that were 
infected with HIV-1 and subsequently treated with IFNα were shown to have a 
reduced accumulation of nascent cDNA which correlated with a loss of 
infectivity of the virus, and was linked to the ubiquitin-proteasomal degradation 
pathway (Goujon & Malim, 2010).  IFNβ treated neuronal cells infected with the 
highly IFN sensitive VSV produced viral particles with hyperphosphorylated 
matrix proteins, detected in both the cell lysate and the budded virions 
(D'Agostino P et al., 2009).  Further analysis showed that hyperphosphorylation 
of the matrix protein inhibited its interaction with the nucleocapsid protein 
thereby disrupting viral assembly.  These studies show that the viral specific 
effects of IFNs cover the whole spectrum across the viral replication cycle from 
adsorption right through to egress. 
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The Bunyaviridae 
Classification 
In 1975 the family Bunyaviridae was formally established and now contains over 
350 serologically-distinct viruses.  All the viruses in this family share 
morphological and molecular characteristics (Fenner, 1976) in that the genome 
is tri-segmented and comprises single stranded negative sense RNA; they are 
surrounded by a membrane-derived lipoprotein envelope containing viral 
glycoprotein spikes; each virion is usually spherical in shape and is between 80 
nm and 100 nm in diameter; viral replication occurs in the cytoplasm and viral 
morphogenesis takes place at the smooth inner membranes of the Golgi 
apparatus without prior core formation (Schmaljohn, 2007).  There are five 
genera within this family: Hantavirus, Nairovirus, Phlebovirus, Orthobunyavirus 
and Tospovirus.  While the term bunyaviruses refers to the whole family, each 
genus is usually referred to individually as hantaviruses, nairoviruses, 
phleboviruses, orthobunyaviruses and tospoviruses, respectively (Elliott, 1997).  
Excluding the hantaviruses, which are spread via aerosolised rodent excreta, all 
the viruses are arthropod-borne viruses.  Aside from the tospoviruses, which 
infect plants, all members of the bunyavirus family infect animals, and viruses in 
each of the five genera cause huge socio-economical costs annually, with over 
60 causing disease in livestock and humans (Schmaljohn, 2007). 
Genus Hantavirus 
The name for the Hantavirus genus is derived from the prototype virus of this 
genus, Hantaan virus (HTNV), which was so named after the river near the 
initial outbreaks of the disease known then as Korean haemorrhagic fever.  This 
virus was originally discovered during the Korean war with over 3000 reported 
cases of an acute febrile illness, of which approximately 33% progressed into 
haemorrhagic fevers, with a  5% to 10% mortality rate (Lee, 1989).  The disease 
is now known as haemorrhagic fever with renal syndrome (HFRS) and there are 
several etiological viruses, such as Hantaan, Seoul and Puumala virus.  The 
latter was identified as the causative agent of a milder illness known for over 50 
years in northern Europe before the virus that caused it was isolated (Niklasson 
et al., 1987).  In 1993 another outbreak of disease occurred in the south 
western USA in an area known as the four corners (southwest Colorado, 
northwest New Mexico, northeast Arizona and southeast Utah), but this time the 
disease progressed rapidly to severe respiratory problems resulting in death in 
over 50% of the people infected.  The etiological agent of the outbreak was 
quickly isolated and analysed and found to be another new hantavirus causing 
what is now known as hantavirus pulmonary syndrome (HPS).  It was 
subsequently named Sin Nombre (Spanish for “no name”) virus (Nichol et al., 
1993).  Since then HPS has been diagnosed across the USA and more than ten 
separate strains of hantaviruses have been isolated from various species of 
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rodent, which are now known to be the animal reservoir of this genus (Childs et 
al., 1994; Douglass et al., 2005; Khan et al., 1996; Smithee et al., 2007).  Unlike 
the other four genera of the Bunyaviridae, the hantaviruses are not transmitted 
by arthropods but instead by the excreted faeces, urine and saliva from rodents.  
The route of transmission is through the respiratory tract for rodents and 
humans via inhalation of dust and or aerosolised excreta (Elliott, 1996). 
Genus Nairovirus 
Apart from some isolates from culicoid flies and mosquitoes, the nairoviruses 
are exclusively tick-borne viruses, and are so called after the original isolation of 
the etiological agent in the outbreak of Nairobi sheep disease in Kenya in 1910 
(Schmaljohn, 2007).  Nairobi sheep disease virus (NSDV) has a mortality rate of 
over 90% in sheep and goats, causing acute haemorrhagic gastroenteritis 
(Davies, 1997; Marczinke & Nichol, 2002).  Crimean-Congo haemorrhagic fever 
virus (CCHFV), infects humans and a variety of livestock, and has a mortality 
rate of 10% in humans but is asymptomatic in livestock.  The first known 
outbreak occurred in the 1940s in the Crimean peninsula, and since then there 
have been several more outbreaks throughout Europe, Asia and Africa, with the 
first isolation of the virus in 1956 in Kisangani, Africa.  Recent studies of the age 
and evolution of CCHFV using virus strains from a wide geographical area and 
spanning nearly fifty years (1956-2005) suggest that the virus is over 3000 
years old (Carroll et al., 2010).  The predominant reservoir of these viruses is 
the arthropod host, in which transovarial transmission (vertical transmission 
from mother to offspring) occurs thus maintaining the viral reservoir.  
Transmission to vertebrates occurs primarily through biting by infected ticks but 
can also occur via contact with infected blood and tissues.  The subsequent 
replication of the virus in vertebrates results in amplification of the virus which 
itself further increases the likelihood of transmission to more ticks. 
Genus Phlebovirus 
Most of the viruses in this genus are transmitted via the phlebotomine sandfly, 
hence the name of the genus, and are found throughout the world except in 
Australia.  However, the most notable member of this genus, Rift Valley fever 
virus (RVFV), is transmitted primarily by the Aedes mosquito species and was 
first isolated from a newborn lamb in 1930.  This disease causes huge 
devastation to livestock as infection results in abortion and high mortality.  
Infection of humans often occurs through close contact with livestock and 
causes haemorrhagic fever and death in 0.5% of cases.  Uukuniemi virus 
(UUKV) is carried by the Ixodes ricinus tick and is non-pathogenic for humans, 
making it a good model virus for studying this genus under minimal 
containment.  Sandfly fever Sicilian and Naples viruses were first isolated in the 
1940s in Italy and are known to cause self limiting febrile illnesses throughout 
Europe, Asia and Africa and are suspected to have done so for many years.  
From this genus, transovarial transmission of RVFV has been shown in Aedes 
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mcintoshi mosquitoes suggesting a possible reservoir, which can also explain 
the seasonal nature of the outbreaks of RVFV (Schmaljohn, 2007). 
Genus Tospovirus 
The isolation of the tomato spotted wilt virus (TSWV) was in 1930, although the 
associated disease was first recognised in Australia in 1915, and this virus also 
gives the genus name (Schmaljohn, 2007).  There are 8 species of tospovirus, 
which are transmitted by several species of thrips, and they are found 
worldwide, in the wild as well as in greenhouses of more temperate zones 
(Wijkamp et al., 1993).  Despite several campaigns to reduce the thrips  vector 
population, tospoviruses account for more than one billion US dollars of crop 
losses each year as they infect in excess of 900 species of plants belonging to 
82 distinct botanical families (Schmaljohn, 2007).  Thus there is an enormous 
economic impact of tospovirus infection on agricultural production.  Intriguingly, 
transmission between plants and thrips differs from other members of the family 
Bunyaviridae in that infectious viral particles are not thought to be required.  The 
ribonucleoprotein (RNP) forms aggregates within the plant cells which are 
subsequently consumed by the thrips (Kitajima et al., 1992).  Complete viral 
replication then occurs in the thrips enabling them to infect new plant hosts.  
Once new plant host cells are infected the virus no longer needs to complete its 
full replication cycle to further infect neighbouring cells as cell-to-cell spread of 
RNP is achieved with just the movement protein NSm (Kormelink et al., 1994; 
Sin et al., 2005).  Furthermore, only the larvae of the thrips can be infected as 
during the maturation process the midgut muscle tissue and the salivary glands 
are separated, but the infection does survive through these stages (transstadial 
transmission).  Thus both adults and larvae can infect plants, and there is no 
reported vertical transmission (Schmaljohn, 2007). 
Genus Orthobunyavirus 
The Orthobunyavirus genus is by far the largest genus in the family 
Bunyaviridae, containing over 170 isolates that are found throughout the world.  
Most members of this genus are carried by mosquitoes and are transmitted to a 
vast range of vertebrate hosts.  The prototype virus, Bunyamwera virus (BUNV), 
for the genus and the family Bunyaviridae was originally isolated in the 1940s in 
Uganda and causes acute febrile illness (Smithburn et al., 1946).  BUNV is now 
known to infect many mammals, such as goats, horses, cows and humans, and 
recently neutralising antibodies for BUNV were found in birds, in particular the 
red ovenbird Furnarius rufus (Tauro et al., 2009).  The viruses of this genus 
were originally categorised by their serological properties, giving rise to such 
groups as the California, Simbu and Bunyamwera serogroups.  Further, viruses 
in this genus are responsible for many diseases of humans and livestock.  
Cache Valley virus (CVV), now endemic across North America, causes 
abortions and congenital deformations in sheep and was isolated in Utah in 
1956 (Chung et al., 1990).  California encephalitis virus (CEV) has been linked 
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with three cases of encephalitis in California, although not recently.  After the 
death from encephalitis of a child in the USA in 1960 La Crosse virus (LACV) 
was isolated from his brain and is now known to be a significant contributor to 
viral encephalitis in the USA (Schmaljohn, 2007).  Jamestown Canyon virus 
(JCV) was isolated in Colorado from Culiseta inornata mosquitoes and found to 
cause many cases of encephalitis in adults (Schmaljohn, 2007).  Oropouche 
virus (OROV) was isolated in 1955 in Trinidad and is responsible for many 
acute febrile illness epidemics in South America, particularly Brazil 
(Schmaljohn, 2007).  The isolation of Akabane virus (AKAV) in Japan in 1959 
established the cause of foetal malformations of cattle in Australasia, Israel and 
Japan.  Snowshoe hare virus (SSHV), now found across North America, causes 
encephalitic disease in both children and adults, and was isolated in 1959 in 
Montana (Schmaljohn, 2007).  
Transmission of orthobunyaviruses occurs when an infected mosquito bites a 
vertebrate host in which the virus can then replicate to a high titre, possibly 
resulting in disease symptoms like the examples given above.  Humans are 
considered dead end hosts as they are unlikely to transmit the virus back into 
the mosquito population thus, the transmission between mosquitoes is essential 
to the maintenance of the infected mosquito population and survival of the virus 
(Gonzalez-Scarano, 1996).  However, the high viremia in humans infected with 
OROV allows transmission to uninfected midges.  There is horizontal 
transmission of orthobunyaviruses via the infection of a vertebrate host followed 
by the subsequent feeding on the same host by other mosquitoes.  In addition, 
systemic infection of the mosquito allows transovarial vertical transmission and 
venereal transmission from males to females (Thompson & Beaty, 1977; Watts 
et al., 1975).  Thus, transmission of viruses between mosquitoes, either with or 
without a vertebrate intermediate, allows the persistence of the virus in a vector 
which itself shows no symptoms of infection and thus makes it difficult to 
eradicate only the infected mosquitoes.   
Virion structure 
Virions range in size between 80-120 nm in diameter; Orthobunyavirus virions 
are about 100 nm and are spherical to pleiomorphic in shape (Martin et al., 
1985; Murphy et al., 1968).  Viruses assemble at the Golgi apparatus and thus 
take their membrane envelope from the Golgi membrane.  The envelope of 
LACV is a single lipid bilayer 4 nm thick containing heterodimeric glycoprotein 
spikes (glycoproteins Gn and Gc) that are 10 nm long and constitute an even 
distribution across the surface of the whole virion (Obijeski et al., 1976a; 
Talmon et al., 1987)(Fig 1.9).  Contained within the envelope of bunyaviruses 
are three RNPs comprising the nucleocapsid protein (N) which encapsidates 
the three single stranded RNA (ssRNA) genomic segments designated small 
(S), medium (M) and large (L), in a ratio of 12 nucleotides per monomer of N, 
and in a helical formation (Mohl & Barr, 2009; Obijeski et al., 1976b).  Bound 
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onto the ends of the RNPs is the L protein which is the viral RNA-dependent 
RNA polymerase, completing the RNPs into the appearance of a closed circle 
(Obijeski et al., 1976b).  For the viral particle to be infectious it must contain at 
least one of each segment, however, these are not necessarily in equimolar 
quantities and could help to explain the variety in particle size which is seen in 
electron microscopy (Hutchinson et al., 1996; Talmon et al., 1987). 
The surface structure of the virion appears to differ significantly across the 
genera (Fig 1.10).  The orthobunyaviruses appear with small knob-like 
protrusions, whilst HTNV shows a gridlike pattern and CCHFV has very small 
morphological units forming a fringe around the virions (Martin et al., 1985).  
Recently the MP-12 vaccine strain of RVFV, a phlebovirus, has been analysed 
using cryo-electron microscopy which showed that the glycoproteins are 
arranged in an icosahedral formation with T=12 symmetry.  There are 122 
individual capsomers consisting of 110 hexons and 12 pentons comprising 12 
and 10 glycoproteins each respectively.  However, the specific composition and 
location of Gc and Gn within the capsomers was not found (Sherman et al., 
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2009).  Furthermore, they were unable to resolve RNPs, but did observe 
transmembrane densities of Gn cytoplasmic tail domains crossing the lipid 
bilayer and interacting with the RNPs that were situated directly below these 
transmembrane densities which is consistent with other studies on UUKV and 
BUNV (Huiskonen et al., 2009; Overby et al., 2007; Sherman et al., 2009; Shi et 
al., 2007).  Similar work on UUKV also showed the spikes to have two distinct 
pH dependent conformations; being 8 nm at pH 6.0 and 13 nm at pH 7.0 
(Overby et al., 2008). 
Genome organisation and viral proteins 
Bunyavirus genomes range in size from ~12 kb to ~19 kb (Table 1.1) and all 
members of the Bunyaviridae have a negative-sense coding strategy for their 
structural proteins: the L protein (the RNA dependent RNA polymerase) is       
encoded on the L segment; the glycoproteins Gc and Gn are encoded on the M 
segment; and the nucleocapsid (N) protein is encoded on the S segment 
(Nichol et al., 2005).  Additionally, viruses in the genera Orthobunyavirus,  
Table 1.1: Terminal nucleotide sequences of the S, M, and L genome 
segment of representative members of the 
family Bunyaviridae. 
Genus- Virus Consensus S, M, L terminal nucleotides 
Genome 
size 
L 
segment 
M 
segment 
S 
segment 
Orthobunya- 
Bunyamwera 
3’ UCAUCACAUG- 
5’ AGUAGUGUGC- 12294 6875 4458 961 
Hanta- 
Hantaan 
3’ 
AUCAUCAUCUG- 
5’ 
UAGUAGUAUGC- 
11845 6533 3616 1696 
Nairo- 
Dugbe 
3’ AGAGUUUCU- 
5’ UCUCAAAGA 18855 12255 4888 1712 
Phlebo- 
Rift Valley fever 
3’ UGUGUUUC- 
5’ ACACAAAG- 11979 6404 3885 1690 
Tospo- 
Tomato spotted 
wilt 
3’ UCUCGUUA- 
5’ AGAGCAAU- 16634 8897 4821 2916 
       Size and segments are in nucleotides.  Taken from (Schmaljohn, 2007). 
Phlebovirus and Tospovirus all encode a non-structural (NSs) protein on their S 
segment.  The tospoviruses and phleboviruses use an ambisense coding 
strategy for the NSs protein, whereas the orthobunyavirus NSs protein is in an 
overlapping reading frame with the N protein.  Furthermore, orthobunyaviruses, 
tospoviruses and some phleboviruses encode another non structural protein, 
NSm, on their M segment.  Thus, bunyaviruses use both negative sense and 
ambisense coding strategies.  Some viruses also encapsidate some anti-
genomic RNAs in to the virions; the UUKV virion contains S segment anti-
genomic RNA, while RVFV has anti-genomic RNA for all three segments in the 
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virion (Ikegami et al., 2005; Simons et al., 1990).  TSWV virions contained S 
and M segment anti-genomic RNAs, and LACV progeny from insect cells had S 
segment anti-genomic RNA in the virions (Kormelink et al., 1992a; Raju & 
Kolakofsky, 1989). 
The untranslated regions 
The coding region of each segment is flanked by a 3’ and a 5’ untranslated 
region (UTR).  There are several mini-replicon based systems in use to study 
bunyaviruses and these have helped to elucidate the role of the UTRs in the 
bunyavirus replication cycle.  Within each genus the viral UTR terminal 
sequences are not only complementary but also conserved (Table 1.1), 
however they are not conserved either by sequence, length, or degree of 
complementarity across the different genera.  The 11 terminal nucleotides (nt) 
of the orthobunyavirus UTRs are complementary except at position 9 where the 
pair is G-U, and as the segment size increases so too does the extent of 
complementarity.  This complementarity leads to pan handle structures and the 
non-covalently linked circularisation of each segment, as observed by electron 
microscopy (Hewlett et al., 1977; Kolakofsky & Hacker, 1991; Obijeski et al., 
1976b; Pardigon et al., 1982; Patterson et al., 1983; Samso et al., 1975). 
The UTRs have a direct effect on transcription and replication of bunyavirus 
RNAs.  Mutagenesis of the UTRs that altered the complementarity of the 
segments by changing either nucleotide identity or base-pairing potential 
inhibited transcription and translation and demonstrated the importance of the 
UTRs in promoter strength (Barr & Wertz, 2004; Kohl et al., 2004).  
Furthermore, the strength of the promoters for transcription of each segment is 
different, with a ratio of 100:10:1 for the S, M and L segments of LACV, 
respectively (Rossier et al., 1988).  However, the genomic RNA levels were 
found to be equimolar.  Studies into the RNA synthesis of BUNV genomic and 
antigenomic RNA synthesis showed that the promoter strength decreased in the 
order M>L>S (Barr et al., 2003), which was later shown for UUKV also (Flick et 
al., 2004).  Thus the UTRs play an essential role in initiating transcription but 
also with distinguishing the different degrees of gene expression for each 
segment. 
In addition to the aforementioned role of the UTRs in the initiation of 
transcription and translation, they have also been found to have critical 
functions in termination of transcription, as well as in viral RNA encapsidation 
and packaging.  Transcription termination signals have been mapped to the 
UTRs, and for those phleboviruses and tospoviruses using an ambisense 
strategy, hairpin structures within the intergenic regions act as termination 
signals.  Barr et al. (2006) mapped a 6 nt termination signal within a 33 nt 
region of the UTR of the BUNV S segment.  Further investigation revealed a 
second termination signal that was also found in the L segment UTR.  Using 
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competitive binding assays, the terminal 32 nt of the 5’ end of the BUNV S 
segment were found to be essential for the encapsidation of RNA by the N 
protein and thus to contain an RNA encapsidation signal (Osborne & Elliott, 
2000).  Studies have demonstrated that the UTRs are sufficient to mediate 
packaging of the genome segments although the specific sequences and the 
mechanism have yet to be elucidated.  Furthermore, the efficiency of packaging 
by the UTRs of UUKV was found to vary by segment, with it being greater for 
the L segment than the M and S segments (L was stable over seven passages 
compared with M and S segments being lost after three passages) (Blakqori et 
al., 2003; Flick et al., 2004).  Thus, while the UTRs do not encode viral proteins, 
they do provide necessary signals for the modulation of viral gene expression, 
as well as packaging RNA segments into new virions. 
Viral genes and expression 
The L segment and the L protein 
As mentioned above, the L segments of all the orthobunyaviruses encode the L 
protein, which is the viral RNA dependent RNA polymerase.  There is no 
evidence of any other coding within these segments and they have a negative 
sense coding strategy.  The L segments of the orthobunyaviruses, hantaviruses 
and phleboviruses are about 6.5 kb in length, whereas the tospoviruses and 
nairoviruses have L segments of about 9 kb and 12 kb respectively (Table 1.1 
(Schmaljohn, 2007)).  The L proteins expressed by the nairoviruses are the 
largest at 459 kDa, followed by the tospovirus L protein which is 331 kDa, and 
the L protein from hantaviruses, orthobunyaviruses and the phleboviruses are 
250 kDa (Table 1.2 (de Haan et al., 1991; Elliott, 1989; Marriott & Nuttall, 1996; 
Muller et al., 1991; Schmaljohn, 1990)).  The shape of the L protein polymerase 
domain resembles a right hand, in that it has a thumb, palm and fingers domain, 
and sequence alignments also show that four motifs within the palm domain are 
conserved.  In fact these “polymerase motifs” are conserved among many 
different viral polymerases as they are involved in binding divalent cations, 
selection of nucleosides and sugars, and in catalysis.  However, despite this 
conservation based on the functional requirements of the enzyme, there is 
evidence that some sequence motifs are found only in some genera.  For 
example, first identified in RVFV the L protein contains two regions at the N 
terminus which are only conserved in the Bunyaviridae and the Arenaviridae 
(Muller et al., 1994).  To prove the RNA dependent RNA polymerase function of 
the bunyavirus L protein, it was first expressed in recombinant vaccinia virus 
and subsequently used to synthesise RNA from transfected BUNV RNPs (Jin & 
Elliott, 1991).  The authors did further analysis using the same system and 
found that the mRNAs contained non-viral heterogeneous sequences, 
demonstrating that the L protein has endonuclease activity to generate the 
primers as well as transcriptional activity.  They further showed that the L 
protein utilises the method of “cap snatching” to generate capped 5’ mRNAs 
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(Jin & Elliott, 1993).  Shi and Elliott (2009) generated two recombinant viruses 
with the V5 epitope tag positioned towards the C terminus of the L protein, that 
were infectious and also functional in a minireplicon assay.  They further 
showed that the L protein was distributed in the cytoplasm, colocalised with N 
protein, and was more concentrated in the perinuclear region of the cell.   
The M segment and the glycoproteins Gn and Gc 
All members of the Bunyaviridae family encode the two glycoproteins (Gn and 
Gc) as a polyprotein from a single ORF on the M segment. 
The glycoproteins are located within the membrane-derived envelope of the 
virion and constitute the viral projections (spikes) (Schmaljohn, 2007).  Initially 
the glycoproteins were named G1 and G2 based on their migration through a 
polyacrylamide gel.  However, it was subsequently found that these proteins 
were interchangeable between genera of some viruses, and thus the 
nomenclature was changed to the current system based on the coding location  
Table 1.2: Viral proteins of representative members of the 
family Bunyaviridae 
Genus Virus 
 
L segment M segment S segment 
Protein Size Protein Size Protein Size 
Orthobunya- 
Bunyamwera L 259 
Gn 
Gc 
NSm 
32 
110 
18 
N 
NSs 
26 
11 
Hanta- 
Hantaan L 247 
Gn 
Gc 
 
70 
55 N 48 
Nairo- 
Dugbe L 459 
Gn 
Gc 
 
35 
73 N 50 
Phlebo- 
Rift valley fever L 238 
Gn 
Gc 
NSm 
55 
62 
14 
N 
NSs 
28 
32 
Tospo- 
Tomato spotted wilt L 332 
Gn 
Gc 
NSm 
46 
75 
37 
N 
NSs 
29 
52 
          Protein sizes are in kDa 
either at the N terminus or the C terminus of the polyprotein (Lappin et al., 
1994).  The polyprotein precursor is co-translationally cleaved to give the two 
integral transmembrane glycoproteins which are further modified by N-linked 
glycosylation (Nichol et al., 2005; Shi et al., 2005).  The existence of conserved 
cysteine residues (comprising around 4-7% of the expressed gene product) 
implies the polypeptide secondary structure is determined by disulphide bridges 
(Schmaljohn, 2007).  The N terminus of the glycoproteins protrudes from the 
virion while the C terminus of the proteins anchors them into the envelope.  
Each of the glycoproteins is preceded by a signal peptide, indicating that 
polyprotein cleavage is carried out by a cellular signal peptidase.  The 
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glycoproteins are transported to the Golgi complex via a Golgi targeting and 
retention signal in the Gn protein and not in the Gc protein (which does not 
traffic to the Golgi without interacting with Gn) (Erickson et al., 2007; Shi et al., 
2004; Shi et al., 2005).  As mentioned above, the two glycoproteins are not 
equal in molecular mass and the sizes vary among the bunyaviruses (Table 
1.2).  BUNV encodes a Gn protein that, at 32 kDa, is considerably smaller than 
the 110 kDa Gc protein.  The BUNV Gn comprises 302 residues and has a 
cytoplasmic tail of 78 residues, whereas the Gc protein comprises 957 residues 
and has a cytoplasmic tail of just 25 residues (Elliott, 1990; Lees et al., 1986).  
The M segment and the NSm protein 
For members of the Orthobunyavirus, Phlebovirus and Tospovirus genera, the 
M segment also encodes the non-structural protein NSm (Table 1.2).  BUNV 
encodes an NSm protein that co-localises to the Golgi with other viral proteins.  
It has been found to be able to interact with other viral proteins and to be 
essential for virion assembly.  The loss of NSm or the selective deletion of any 
of 3 of the 5 putative domains within NSm (identified as domains I, II and V) 
prevents synthesis of virus-like particles, showing that NSm has a crucial role in 
BUNV assembly (Shi et al., 2006). 
While one or more NSm proteins have been identified in other genera within the 
bunyavirus family, the function of all of these proteins has not been determined.  
The phleboviruses produce a variety of NSm proteins, from the UUKV which 
does not express an NSm protein (but does produce a Gn protein analogous to 
the NSm-Gn fusion polypeptide of RVFV) to the 30 kDa NSm protein produced 
by the Punta Toro virus (PTV) (Matsuoka et al., 1988; Schmaljohn, 2007).  
RVFV encodes two NSm proteins: a distinct 14 kDa protein and a 78 kDa NSm 
protein, which is cleaved from the N-terminus of the M segment precursor 
polyprotein.  Studies established that there are two start codons upstream of the 
N terminus of the Gn protein that produce either the NSm protein or the NSm-
Gn uncleaved polyprotein of 78 kDa, with no precursor/product relationship 
between the two proteins (Kakach et al., 1989).  The function of both of the 
NSm proteins is not yet clear for RVFV.  Nairoviruses have a more complex 
processing of the M segment proteins compared with the rest of the family 
(Marriott et al., 1992).  CCHFV polyproteins are proteolytically cleaved to yield 
the precursor proteins of pre-Gn (140 kDa) and pre-Gc (85 kDa) which contain 
the cellular protease cleavage site SKI-1 and are subsequently cleaved to the 
mature Gn (37 kDa) and Gc (75 kDa) by cellular secretory pathway proteases 
(Bergeron et al., 2007; Schmaljohn, 2007).  The NSm protein is cleaved from 
the precursor protein pre-Gn.  The tospovirus TSWV synthesises an NSm 
protein using an ambisense coding strategy and thus an anti-genomic template-
derived mRNA.  The TSWV NSm facilitates virus spread from one plant cell to 
another since NSm localises to the cell wall and interacts with the 
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plasmodesmata-penetrating tubules to allow transport of the RNPs across the 
cell wall (Kormelink et al., 1992b). 
The S segment and the N protein 
The size of the S segment varies across the five genera from the smallest, in 
the orthobunyaviruses (around 1 kb) to the largest in the tospoviruses (around 3 
kb (Table 1.2)).  In the Orthobunyavirus genus, the S segment encodes two 
proteins: the N protein and the NSs protein from overlapping open reading 
frames in the sub-genomic mRNA.  Translation occurs via the recognition of the 
distinct start codons by the ribosome and thus the synthesis of two separate 
proteins (Bishop et al., 1982). 
All viruses in the family Bunyaviridae encode an N protein on their S segment 
and this is the most abundant protein found in both the virions and infected 
cells.  The functions of the N protein are to protect the viral RNA from 
degradation and to facilitate the replication of the RNA, both of which are 
achieved by the encapsidation of both genomic and anti-genomic RNA into the 
RNPs, which are required for replication by the L protein.  The encapsidation of 
RNA by the N protein depends upon the ability of individual N protein 
monomers to oligomerise and this process of oligomerisation differs among the 
genera.  The N proteins of hantaviruses and nairoviruses are the largest in the 
family.  It has been shown that the homotypic interactions between the C and N 
termini of the N protein of hantaviruses is responsible for the trimerisation of the 
N protein, which can then encapsidate the RNA (Alfadhli et al., 2002; Alminaite 
et al., 2008; Yoshimatsu et al., 2003), whereas the RVFV N protein forms stable 
dimers for encapsidation (Le May et al., 2005).  However, TSWV appears to 
encapsidate RNA by building multimers of the N protein by one N protein 
addition at a time (Kainz et al., 2004; Uhrig et al., 1999).  BUNV N 
multimerisation also occurs by the addition of one N protein at a time, and the 
first 10 and last 17 residues are responsible for this process (Leonard et al., 
2005). 
The S segment and the NSs protein 
Only nairoviruses have not been shown to produce a functional NSs protein, 
ergo viruses in the Tospovirus, Phlebovirus, Hantavirus, and Orthobunyavirus 
genera encode a NSs protein and these vary in size from 10 kDa for the 
orthobunyaviruses to greater than 50 kDa for the tospoviruses (Table 1.2).  The 
NSs proteins in the four genera show no sequence homology; indeed, there is 
little conservation within the same genus, with the exception of some highly 
conserved domains within several strains of a single virus (Giorgi et al., 1991; 
Sall et al., 1997).  Unlike the orthobunyaviruses, both the tospoviruses and 
phleboviruses translate their NSs protein from mRNA transcribed from anti-
genomic RNA and thus use an ambisense coding strategy.  Furthermore, 
studies have shown that RVFV NSs is transcribed from anti-genomic RNA 
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which is carried in the virion (anti-genomic RNAs for all three segments of 
RVFV have been found in virions) (Ikegami et al., 2005).  The NSs protein of 
the orthobunyaviruses has been shown to play a role in the control of the L 
protein and decreasing transcription, whereas the NSs protein of RVFV has 
been shown to enhance RNA transcription (Ikegami et al., 2005; Weber et al., 
2001).  Importantly, in all four genera, the NSs proteins display roles in 
antagonising the host cell antiviral responses and for some the mechanism of 
antagonism has been widely studied. 
One well characterised example is that of the RVFV NSs protein, a potent IFN 
antagonist with several distinct mechanisms.  Uniquely the RVFV NSs protein 
forms ribbon like structures within the nucleus of infected cells (Struthers et al., 
1984).  This observation was subsequently linked to a critical function of RVFV 
NSs in host cell protein shut-off.  This is achieved through the interaction of 
RVFV NSs with the p44 subunit of transcription factor TFIIH, resulting in the 
production of the filamentous structures seen in the nucleus.  As a 
consequence of this interaction of TFIIH and NSs, there is a reduction in the 
concentration of TFIIH and a subsequent decrease in transcription mediated by 
both polymerases I and II (Bouloy & Weber, 2010; Le May et al., 2004).  
Furthermore, NSs interacts with the cellular protein SAP30 in the nucleus and 
thus disrupts IFNβ transcription (Le May et al., 2008).  Several RVFV mutants 
have been propagated in order to examine the effects of NSs protein on the 
host cell and viral infection, such as a virus that was engineered to lack the 
SAP30 interaction domain on the NSs protein and as such was avirulent for 
mice and unable to counteract the IFN response (Le May et al., 2008).  The 
natural RVFV isolate Clone 13 contains a large deletion in the NSs gene and as 
such is a strong IFNα/β inducer and is highly pathogenic in IFNAR-/- knockout 
mice (Bouloy et al., 2001).  Subsequently Habjan et al. (2009) and Ikegami et 
al. (2009) showed that the NSs protein of RVFV targets PKR for proteasomal 
degradation whereas Clone 13 NSs does not (discussed later). 
The NSs protein of BUNV has also been targeted for further analysis.  In 
minireplicon assays, inhibition of BUNV NSs translation was shown to enhance 
reporter activity while over-expression of NSs reduced reporter activity (Weber 
et al., 2001).  In the same study, BUNV NSs protein was shown to localise 
predominantly in the cytoplasm with some found in the nucleus, which was 
further confirmed more recently by Thomas et al. (2004).  Further to this, the 
rescue of a NSs-deficient recombinant BUNV showed the NSs protein to be 
non-essential to viral viability, although the virus was severely restricted in IFN 
competent cell lines and was shown to be a strong inducer of the IFNβ promoter 
(Bridgen et al., 2001).  Moreover, Weber et al. (2002) demonstrated that the 
NSs-deficient virus induced over 1000 units (U) of IFNα/β per ml of medium 
(compared with under 50 U IFNα/β for BUNV) and was dependent on virally 
produced dsRNA and IRF3.  Subsequently a study has shown that IFN 
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treatment prior to infection has more effect on BUNV replication and that the 
loss of NSs confers a 10-fold reduction in viral titre (Streitenfeld et al., 2003).  
Interestingly the same study showed BUNV NSs inhibited dsRNA-dependent 
IFN induction and yet was ineffectual on the dsRNA-activated PKR and RNase 
L systems.  Like the NSs of RVFV, BUNV NSs protein has been found to cause 
host cell protein shut-off and the mechanism is by interacting with the cellular 
protein MED8, a component of the mediator complex which is involved in 
mRNA synthesis.  This interaction ultimately leads to inhibition of 
phosphorylation of the C terminal domain (CTD) of RNA polymerase II and 
subsequently to the inhibition of transcription mediated by RNA polymerase II 
(Leonard et al., 2006; Thomas et al., 2004).  Consequently, BUNV NSs blocks 
the IFN response at the level of transcription.  Additionally, the NSs protein of 
BUNV inhibits the induction of apoptosis by interacting with the IRF3 signalling 
pathway and inhibiting an IRF3-dependent promoter (Kohl et al., 2003).  The 
inhibition of apoptosis is another mechanism by which BUNV NSs counteracts 
the host antiviral response. 
Finally, the NSs protein of TSWV forms into fibrils or fibrous structures within 
the cytoplasm of plant cells and sequesters siRNAs and miRNAs, thereby 
preventing the cellular RNAi pathway from counteracting the infection 
(Schnettler et al., 2010).  Thus, even the bunyaviruses that infect plants have 
been shown to use the NSs protein to block cellular antiviral mechanisms, 
suggesting a conservation of function for NSs despite divergent sequences and 
coding strategies. 
The replication cycle 
There are several stages to the replication cycle of bunyaviruses: adsorption 
and entry; primary transcription and translation; amplification of genomic RNA; 
assembly, budding and release (Fig 1.11). 
Adsorption and entry 
Many enveloped viruses employ similar mechanisms to gain internal access to 
the host cell.  The projections comprising the two viral glycoproteins interact 
with receptors on the cell surface.  For most members of the family, the cell 
surface receptors have yet to be identified.  However, it has been demonstrated 
that pathogenic hantaviruses bind to β3 integrins and non-pathogenic 
hantaviruses bind to β1 integrins on endothelial cells (Gavrilovskaya et al., 
1999).  The orthobunyavirus Gc protein principally mediates the attachment and 
entry of virus into mammalian and mosquito cells (Plassmeyer et al., 2005).  
Once bound to the cell surface, entry is by receptor-mediated endocytosis and 
uncoating occurs by Gc-mediated fusion with endosomal membranes in a pH-
dependent manner (Shi et al., 2009).  Entry of CCHFV is dependent on clathrin-
associated endocytosis, and requires the presence of cholesterol in the plasma 
membrane and the acidic pH of the endosomal lumen (Simon et al., 2009).  
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OROV has also been shown to gain entry via clathrin-coated pits and 
endocytosis into HeLa cells, which further requires low pH in the endosome 
(Santos et al., 2008). 
Primary transcription and translation  
After uncoating and release of the viral genome into the cytoplasm, primary 
transcription of genomic RNA to mRNA can take place.  There are promoters 
for genome transcription in the 3’- and 5’- termini of each segment which show 
high sequence complementarity and only the RNA encapsidated by the N 
protein can act as a template for transcription (Bouloy & Hannoun, 1976; Dunn 
et al., 1995; Lopez et al., 1995).  Minigenome assays with BUNV revealed that 
complementary 3’- and 5’- termini  and some sequence was required for optimal 
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transcription (Kohl et al., 2004), and Lowen and Elliott (2005) deleted parts of 
the S segment UTR sequence and revealed that the minimal UTR sequence 
required for viable BUNV is 29/85 at the 3’ end, and 112/174 at the 5’ end 
(where 85 and 174 are the full length 3’ and 5’ UTRs respectively).  Thus, 
optimal transcription requires the panhandle structure formed by the terminal 
regions, while specific sequences define promoter strength (Barr & Wertz, 
2005).  Additionally, minigenome RNAs co-expressed with viral proteins 
established that only the L and N proteins are required for successful 
transcription (Dunn et al., 1995).  Initially, the L protein functions as an 
endonuclease and cleaves cytoplasmic host cell mRNA to produce capped 
primers to initiate mRNA transcription, which produces viral mRNA with a 10-20 
heterogeneous nucleotide 5’ terminal extension (Bishop et al., 1983; Patterson 
et al., 1984).  Nascent mRNAs are truncated by approximately 50-100 nt 
compared with the full transcript (anti-genome RNA), implying a specific signal 
for termination of transcription, and the transcripts are not polyadenylated (Dunn 
et al., 1994; Patterson & Kolakofsky, 1984; Patterson et al., 1984).  BUNV 
translation is mediated by the UTRs and occurs independently of poly(A) tails 
and poly(A) binding protein (PABP) as BUNV targets PABP for degradation in 
order to stop host protein synthesis (Blakqori et al., 2009).  The transcription 
termination signal for BUNV has been mapped to a 33 nt sequence in the 5’- 
UTR of the S segment.  Smaller regions and individual nucleotides within this 
sequence have been shown to be essential.  Furthermore, a second termination 
signal, of 9 nt in length, has been mapped 32 nt downstream of the BUNV S 
segment UTR and this second signal has also been found in other 
orthobunyavirus S segments (Barr et al., 2006). 
For optimal efficiency of bunyavirus transcription there must be simultaneous 
translation.  This was demonstrated by the synthesis of incomplete viral 
transcripts when translation was blocked with protein synthesis inhibitors (such 
as cycloheximide) (Patterson & Kolakofsky, 1984; Raju & Kolakofsky, 1986) and 
further by in vitro studies showing viral mRNA synthesis only occurred in the 
presence of actively translating rabbit reticulocyte lysate (Bellocq & Kolakofsky, 
1987; Bouloy, 1991).  The initial transcription and translation of the viral genes 
occurs very rapidly, with the M segments being translated at the rough ER 
(RER) and the S and L segments at the cytosolic (or free) ribosomes.  Newly-
synthesised viral proteins can be detected within two hours of infection (Kariwa 
et al., 2003; Madoff & Lenard, 1982; Pennington et al., 1977).     
Viral genome amplification  
Eventually, the polymerase L protein must change from primed transcription of 
mRNAs to the transcription of full length RNA transcripts, and thus change from 
viral transcription to viral replication.  As with primary transcription above, this 
requires both the L and N proteins.  However, transcription must now be 
initiated from the precise start of the 3’ terminal end to synthesise a full-length 
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transcript, which is encapsidated as it is synthesised and not translated.  The 
transcription termination signals within the sequences are overcome by 
encapsidation with the N protein for viruses such as VSV and SeV (Lamb, 2007; 
Lyles, 2007) and it is hypothesised that the same occurs for bunyavirus 
replication.  It was also shown with VSV that the polymerase complex the 
transcriptase, involved with primary transcription, comprised viral L and P 
proteins along with two cellular proteins and submolar amounts of mRNA cap 
guanylyltransferase (Qanungo et al., 2004).  However, the replicase, the 
polymerase complex involved with genome replication, was different to the 
transcriptase and comprised viral L, P and N proteins only.  Therefore a similar 
mechanism of using distinct enzyme complexes for transcription and replication 
could be employed by bunyaviruses.   
The mechanism of prime and realign for genome replication has been proposed 
to be used by hantaviruses and nairoviruses to justify the monophosphorylated 
U residue at the 5’ end of HTNV genomic RNA.  In this case, without a host-
derived oligonucleotide primer, the polymerase initiates transcription with pppG 
and proceeds with the addition of several nucleotides, and then slips backwards 
and realigns.  This produces an overhang with the initial G residue which can 
then be cleaved off the transcript by the L protein (Garcin et al., 1995b; Prehaud 
et al., 1997). 
Assembly, budding and release 
Morphogenesis and subsequent maturation by budding of virions occurs at the 
smooth Golgi membrane for members of the Bunyaviridae (Kuismanen et al., 
1982; Salanueva et al., 2003; Smith & Pifat, 1982), although budding at the 
plasma membrane has been observed for some hantaviruses and RVFV 
(Anderson & Smith, 1987; Goldsmith et al., 1995; Ravkov et al., 1997).  As 
described above, both of the BUNV glycoproteins localise in the Golgi, though 
only the Gn protein has a Golgi targeting signal.  Thus, without the complex 
formation of Gn and Gc, Gc would remain in the ER.  The Golgi-targeting signal 
for BUNV has been mapped to the transmembrane domain of the Gn protein, 
while for two phleboviruses PTV and RVFV it was mapped to the 
transmembrane domain and part of the cytoplasmic tail of Gn (Gerrard & Nichol, 
2002; Matsuoka et al., 1994; Shi & Elliott, 2002; Shi et al., 2004).  For HTNV it 
was shown that mutations in both the Gn and Gc sequences resulted in loss of 
transport of the Gn-Gc complex to the Golgi, demonstrating the importance of 
the correct conformation of this complex for transport (Shi & Elliott, 2002).  
However, studies on nairoviruses revealed that loss of the transmembrane 
domain and cytoplasmic tail of Gn did not result in the loss of Gn-Gc 
dimerisation or subsequent transport to the Golgi, thus nairoviruses could have 
a targeting signal in their Gn ectodomain (Erickson et al., 2007; Haferkamp et 
al., 2005). 
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The glycoproteins of PTV and BUNV are transported to the cis/medial Golgi 
compartment, followed by transport through the Golgi and the acquisition of 
resistance to endoglycosidase H (endo H), an enzyme that cleaves sugars high 
in mannose.  Since BUNV has endo H resistance, it is likely that it progressed 
through the trans-Golgi network (TGN), whereas HTNV and CCHFV retain their 
susceptibility to endo H and thus likely have not passed through the TGN 
(Bertolotti-Ciarlet et al., 2005; Novoa et al., 2005a; Shi & Elliott, 2004).  
Mutational studies of the glycosylation sites of HTNV Gn and Gc proteins 
revealed the importance of the sites for the ER exit signal and Golgi targeting 
signal.  Further investigation into the glycosylation sites of BUNV Gn and Gc 
revealed that the Gn site N60 is essential for trafficking both glycoproteins (Gn 
and Gc) through the Golgi.  In contrast, the two glycosylation sites identified on 
the Gc protein increase viral infection efficiency but are not essential for viral 
replication (Shi et al., 2005). 
Assembly can only occur when the N protein and the two glycoproteins have 
been transported to the same location, the RNPs are on the cytoplasmic side of 
the Golgi membrane and the glycoproteins are on the luminal side (Pettersson, 
1991; Smith & Pifat, 1982).  The interaction between the transmembrane 
domains of the glycoproteins and the RNPs is the facilitator of virion envelope 
development, while it is the cytoplasmic tails of the glycoproteins that attract the 
RNPs to the Golgi membrane.  Bunyaviruses are able to concentrate their 
replication complexes and assembly sites in specific locations inside a cell 
building a viral factory (Novoa et al., 2005a; Novoa et al., 2005b; Salanueva et 
al., 2003).  The factory consists of multiple units of Golgi stacks, RER elements, 
mitochondria and tubular structures (tubes) which provide links between these 
organelles.  The structure and function of the tubes are dependent on viral NSm 
protein and have been shown to number 50 or more per cell.  Aggregation of 
the NSm protein stimulates inward movement from the cytosolic face of the 
Golgi thus the interaction of the viral NSm protein with host cell actin and giantin 
provides a scaffold for the assembly of virus particles (Fontana et al., 2008). 
Release of the virions occurs by exocytosis; immature particles bud into the 
Golgi cisternae, where they are transported in vesicles in the secretory 
pathway, to the plasma membrane where the vesicles fuse and release the 
virions to the exterior (Fontana et al., 2008). 
Assembly and release of tospoviruses differs from the other viruses in the 
family.  The glycoproteins accumulate Golgi membranes which surround the 
viral RNPs forming double enveloped particles (DEVs).  The DEVs then fuse 
with other DEVs or with the ER and are subsequently released by exocytosis or 
are ingested by thrips (Kikkert et al., 1999; Wijkamp et al., 1993). 
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Effects of infection on the host cell and the host response 
Excluding the hantaviruses, the viruses of the other four genera all have 
alternating replication cycles in vertebrate (plant cells for the tospoviruses) and 
invertebrate host cells, and cytopathology is only seen in the vertebrate/plant 
cells as opposed to the invertebrate cells (Beaty & Calisher, 1991; Carvalho et 
al., 1986; Wijkamp et al., 1993).  As discussed above, viruses from the 
Orthobunyavirus and Phlebovirus genera encode and express a NSs protein 
that causes host cell protein synthesis to cease.  This is known as host cell 
protein shut-off and can be extremely acute (Bridgen et al., 2001; Thomas et al., 
2004).  However, UUKV is not able to cause protein shut-off (despite encoding 
a NSs protein), while the nairoviruses do not cause protein shut-off and, not 
surprisingly, also do not encode an NSs protein (Pettersson, 1974).  For BUNV, 
host cell protein shut-off is clearly visible by 5 hours post infection and at 7 
hours there is little host cell protein synthesis at all, whereas for RVFV the 
reduction in host cell protein synthesis occurs from 4 to 20 hours post-infection 
(depending on the MOI used (Pennington et al., 1977)).  The hantaviruses are 
able to cause persistent infections both in their rodent hosts and in mammalian 
cells in tissue culture, while the members of the family transmitted by 
arthropods cause persistent infections in the arthropod host and in insect cells 
in tissue culture. 
The primary mammalian host cell response to a viral infection is the IFN 
response and many bunyaviruses have evolved ways of counteracting this very 
powerful response.  The NSs protein of BUNV is the primary interferon 
antagonist during the viral replicative cycle.  Expression of NSs is predominantly 
in the cytoplasm, where it interacts with and disrupts the C-terminal domain of 
RNA polymerase II by inhibiting phosphorylation of the residue serine 2 of the 
heptapeptide repeat YSPTSPS (Thomas et al., 2004).  The C-terminal domain 
of RNA polymerase II contains 52 repeats of the heptapeptide repeat 
YSPTSPS; phosphorylation of the serine 2 residue is required for elongation of 
the mRNA and 3’ end processing, and phosphorylation of the serine 5 residue is 
required for transcription initiation (Ahn et al., 2004; Kobor & Greenblatt, 2002; 
Komarnitsky et al., 2000).  RNA polymerase II-directed protein synthesis 
requires the multiprotein Mediator complex for mRNA synthesis activation and 
repression (Kornberg, 2005).  The Mediator complex is comprised three 
modules called the head, middle and the tail (Blazek et al., 2005; Chadick & 
Asturias, 2005; Conaway et al., 2005; Dotson et al., 2000).  The tail interacts 
with transcriptional activators and repressors and, as such, is the sensor 
element.  The middle module of the complex binds to the polymerase and is in 
contact with the C-terminal domain of RNA polymerase II, and facilitates the 
transfer of information from the tail to the head modules.  The head module 
contains the protein MED8 which interacts directly with the polymerase enzyme 
and appears to regulate the polymerase by recruiting it to the promoter-bound 
preinitiation complex (Myers et al., 1998).  The transcription factor TFIIH kinase 
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phosphorylates serine 5 residues, and the Cdk9 kinase activity of P-TEFb 
phosphorylates serine 2 residues of RNA polymerase II, both kinases being 
activated first by Mediator.  Mutational studies showed that the C-terminus of 
BUNV NSs protein directly interacts with MED8 resulting in inhibition of 
transcription and, further, that the region stipulated contains amino acids 
conserved among many orthobunyavirus NSs proteins (Leonard et al., 2006).  
Several mutant viruses that either lack NSs or express a truncated form of NSs 
have been shown to be potent IFN inducers and are severely attenuated in IFN 
competent cell lines.  Additionally, the mutant virus mBUNNSs22 is unable to 
block RNA polymerase II activity even though it contains the MED8 interaction 
domain, implying a further role of the N-terminus of NSs in counteracting the 
IFN response (van Knippenberg et al., 2010). 
Virus evolution  
The capability of this family of viruses to evolve is clearly demonstrated by the 
numerous serologically distinct virus members and the high divergence seen 
amongst the viruses.  For segmented RNA viruses, there are two methods by 
which genetic variation can occur, namely genetic drift and genetic shift.  
Genetic drift arises from deletions, inversions, duplications and point mutations 
that are accumulated over time through the lack of the proof-reading ability of 
RNA dependent RNA polymerases.  Genetic shift occurs through the dual 
infection of the same cell and subsequent reassortment of one or more of the 
viral segments, resulting in a large and immediate genetic change.  Genetic 
reassortment amongst the Bunyaviridae is possible in the laboratory, although 
only between serologically similar viruses.  Garissa virus is a natural reassortant 
orthobunyavirus, isolated in Africa from haemorrhagic fever cases in 1997-98, 
that had L and S segments from BUNV and an M segment from Ngari virus 
(Gerrard et al., 2004).  Ngari virus itself is a reassortant virus containing BUNV 
L and S segments and an M segment that Briese et al. suggest to be donated 
by Batai virus (Briese et al., 2006).  Recent studies show reassortment in nature 
with LACV with 25% of mosquitoes infected with a LACV reassortant (Briese et 
al., 2007; Elliott, 1996; Reese et al., 2008).  It is common that reassortants 
retain their original S and L segments but change their M segment, which can 
lead to variants with altered pathogenicity and new tropisms.  The chances of 
reassortment occurring in nature are greatly increased by the requirement for 
arthropod vectors, since the arthropods feed on a variety of vertebrates thereby 
increasing the possibility of a dual (or more) infection.  Furthermore, the 
possibility of genetic variation within the arthropod vectors is enhanced by 
transovarial transmission of viruses over several generations that can 
accumulate genetic alterations (drift), thus making the resulting population of 
progeny viruses even more distinct (Briese et al., 2006; Gerrard et al., 2004; 
Kobayashi et al., 2007; Reese et al., 2008).  
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Reverse genetics of bunyaviruses  
Virologists use reverse genetics systems to manipulate cDNAs of viral genomes 
to better understand the replicative cycle of a virus.  It is extremely useful with 
regards to RNA viruses as direct manipulation of RNA is very difficult.  Reverse 
genetics permits mutational analysis of the viral genomic RNA which would 
otherwise be impossible.  The system of reverse genetics with negative-strand 
RNA viruses is yet more complicated as the viral genome is not sufficient for 
replication; the genome needs to be encapsidated by the N protein and there 
needs to be an RNA dependent RNA polymerase present.  The first negative 
strand RNA virus to be rescued by reverse genetics was rabies virus in 1994 
(Schnell et al., 1994).  The method used was to infect cells with a recombinant 
vaccinia virus encoding T7 RNA polymerase (vTF7-3) and then to transfect into 
the cells four plasmids each under the control of a T7 promoter, one consisting 
of the full length rabies virus anti-genome followed by a ribozyme, and three 
expression plasmids encoding the rabies virus L, P and N protein.  This led to 
the production of fully infectious rabies virus ‘de novo’ and also some 
genetically modified recombinant (r) rabies virus, thus fully proving the 
methodology.  Subsequently other non segmented negative strand RNA viruses 
were rescued: VSV (Lawson et al., 1995), MeV (Radecke et al., 1995), SeV 
(Garcin et al., 1995a), and  RSV (Collins et al., 1995).  Having established 
reverse genetics systems for non-segmented negative-strand RNA viruses, the 
next step was to overcome the inherent difficulties of rescuing a segmented 
virus, notably the efficiency of the large number of plasmids thought to be 
required to be transfected into cells.  This was overcome by Bridgen and Elliott 
(Bridgen & Elliott, 1996) who managed to rescue the trisegmented BUNV from 
cloned cDNAs.  The method that they used was very similar to the rabies virus 
rescue system:  HeLa cells were infected with vTF7-3 for T7 RNA polymerase 
expression, followed by transfection of plasmids containing the BUNV L, M and 
S ORFs under a T7 promoter, to express all the viral proteins of BUNV.  Next, 
an additional transfection was carried out using plasmids containing the full 
length anti-genomic BUNV L, M and S segments, also under a T7 promoter and 
with a hepatitis δ ribozyme and T7 terminator immediately after the viral 
sequence, to produce BUNV anti-genomes for transcription and replication.  
Approximately 42 hours later the cells and supernatant were harvested, clarified 
and used to infect the Aedes albopictus C6/36 insect cell line in order to isolate 
BUNV from VACV since only BUNV can replicate in the insect cells.  Several 
days later, released virions were plaque purified on BHK21 cells.  Since the first 
breakthrough, not only have several other bunyaviruses been rescued, LACV, 
(Blakqori & Weber, 2005) RVFV, (Billecocq et al., 2008; Gerrard et al., 2007; 
Habjan et al., 2008; Ikegami et al., 2006) and AKAV (Ogawa et al., 2007), but 
viruses from other families have as well, namely the orthomyxovirus IAV (Fodor 
et al., 1999; Neumann et al., 1999).  The systems have also been updated and 
are constantly being refined.  The current BUNV rescue protocol is based on 
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the work of Lowen et al. (2004) who significantly improved the yield of virus and 
decreased the time taken for the whole rescue (Lowen et al., 2004).  This 
method uses the BSR-T7/5 cell line which constitutively expresses the T7 RNA 
polymerase.  These cells are transfected with the pT7ribo plasmids, which 
express anti-genomic viral L, M and S segments under a T7 promoter and with 
the hepatitis δ ribozyme immediately after the coding sequence.  There is also a 
T7 termination signal.  This system generates high viral yield several days later.  
With the establishment of a reverse genetics system, comes the opportunities 
for rescuing mutant viruses, and the first significant virus of this sort was a 
BUNV with the NSs ORF mutated such that NSs was no longer expressed.  
This allowed investigations into the functions of NSs, and the differences 
between the wild-type and deletion viruses.  To date many recombinant viruses 
have been rescued and used in studies to establish if they can be propagated 
and to investigate the consequences of the mutations on all stages of the virus 
replication cycle.  Furthermore, many viruses now have reporter genes inserted 
such as renilla luciferase or GFP, so that expression can be quantified using a 
luminometer and or visualised using microscopy. 
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Aims 
To investigate the effect of type I IFNs on BUNV replication in more detail and 
to identify specific ISGs that show inhibitory effects on BUNV. 
To define the efficacy of fluorescently tagged viruses for screening cell lines for 
their anti-BUNV properties, and to increase the number of tools available for 
such purposes.  Thus attempt to engineer, rescue and characterise a GcGFP 
tagged NSs deletion virus, rBUNGceGFPdelNSs. 
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2 Materials and Methods 
Materials and reagents 
All chemicals and reagents were purchased from BDH chemicals ltd or Sigma 
unless otherwise stated.  Plastic-ware was purchased from Greiner and Nunc.  
 
The antibiotics (Table 2.1), antibodies (Table 2.2), viruses (Table 2.3), cells 
(Table 2.4), plasmids (Table 2.5), enzymes (Table 2.6) and media (Table 2.7) 
used in this study are tabulated below. 
 
Table 2.1: Antibiotics 
 
Antibiotic Description Manufacturer 
Ampicillin 
Inhibits bacterial cell wall synthesis by 
acting as a competitive inhibitor of the 
transpeptidase enzyme 
Promega 
Blasticidin 
Inhibits protein synthesis at a 
translational level in prokaryotes and 
eukaryotes 
Invivogen 
Geneticin 
(G418) 
Inhibits polypeptide synthesis by 
inhibiting the elongation step in 
prokaryotes and eukaryotes 
Invitrogen 
Hygromycin B 
Inhibits protein synthesis by 
interfering with translocation and 
promoting mistranslation at the 80S 
ribosome 
Invitrogen 
Puromycin 
Inhibits protein synthesis by 
disrupting peptide transfer resulting in 
premature chain termination on both 
prokaryotic and eukaryotic ribosome 
Invivogen 
Tetracycline Inhibit protein synthesis by blocking the attachment of aminoacyl-tRNA Sigma 
 
Table 2.2: Antibodies 
 
Antibody Species Dilution Supplier 
BUN  Rabbit IP:1 µl, WB:1/3000 R.M.Elliott 
Cy5 Mouse IF:1/400 Chemicon International Inc 
Digoxigenin-AP 
fab fragment  1/10,000 Roche 
GRO Mouse 1/1000 R.M.Elliott 
IgG HRP Mouse 1/3000 Sigma 
IgG HRP Rabbit 1/3000 Cell signalling 
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Antibody Species Dilution Supplier 
IRF1 Rabbit 1/500 Santa Cruz Biotech 
LACV N rabbit IP: 1 µl R.M.Elliott 
M2 FLAG Mouse 1/1000 Sigma 
MxA Rabbit 1/500 Santa Cruz Biotech 
BUN N 592 Rabbit WB:1/6000 IF:1/200 R.M.Elliott 
PKR Mouse 1/3000 Abcam 
P-STAT1 Rabbit 1/750 Cell signalling 
STAT1 Rabbit 1/750 Cell signalling 
Texas red Rabbit 1/200 AbD Serotec 
Tubulin Mouse 1/3000 Sigma 
Viperin Rabbit 1/500 Abcam 
 
Table 2.3: Viruses 
 
Virus Description 
Wild type Bunyamwera 
(BUNV) 
Naturally occurring Bunyamwera virus. 
Supplied by R.M.Elliott. 
rBUNdelNSs BUNV with the S segment encoded NSs protein deleted.  Supplied by R.M.Elliott. 
rBUNGc-eGFP BUNV with part of the Gc protein replaced 
with GFP.  Supplied by Xiaohong Shi. 
rBUNGceGFPdelNSs 
rBUNdelNSs virus with part of the Gc 
protein replaced with GFP.  Generated in 
this study. 
rBUNMNSmeGFP 
BUNV with part of the NSm protein 
replaced with GFP.  Supplied by Xiaohong 
Shi. 
rBUNM-NSm-
EGFPDelNSs 
rBUNdelNSs with part of the NSm protein 
replaced with GFP.  Supplied by Xiaohong 
Shi. 
Guaroa  (GROV) Orthobunyavirus isolated in Colombia.  Supplied by R.M.Elliott. 
La Crosse (LACV) Naturally occurring  Orthobunyavirus.  Supplied by R.M.Elliott. 
La Crosse del NSs 
(LACdelNSs) 
LACV with the S segment encoded NSs 
protein deleted.  Supplied by R.M.Elliott. 
 
 
Table 2.4: Cell lines and their maintenance 
 
Cell line Description Maintenance Selection Reference 
2FTGH Human diploid fibroblast cells 
DMEM + 10% 
(v/v) FBS N/A 
(Pellegrini et 
al., 1989) 
2FTGH/PIV5/V 
2FTGH cells 
that express 
the V protein of 
PIV5 w3 
DMEM + 10% 
(v/v) FBS 
2 µg/ml 
blasticidin for 
PIV5/V protein 
expression 
(Andrejeva et 
al., 2002) 
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Cell line Description Maintenance Selection Reference 
A549 
Human 
epithelial cells 
from a human 
lung carcinoma 
DMEM + 10% 
(v/v) FBS N/A ECACC 
A549/PIV5/V (w3) 
A549 cells that 
express the V 
protein of PIV5 
w3  
DMEM + 10% 
(v/v) FBS 
2 µg/ml 
puromycin for 
PIV5/V protein 
expression 
(Andrejeva et 
al., 2002; 
Hilton et al., 
2006) 
A549/BVDV/NPro 
A549 cells that 
express the 
BVDV/Npro 
protein  
DMEM + 10% 
(v/v) FBS 
2 µg/ml 
puromycin for 
BVDV/NPro 
protein 
expression 
(Hale et al., 
2009; Hilton 
et al., 2006) 
A549shPKR 
A549 cells that 
express shRNA 
that knocks 
down PKR 
expression 
DMEM + 10% 
(v/v) FBS 
2 µg/ml 
puromycin for 
shPKR 
expression 
Prof R 
Randall, 
University of 
St Andrews, 
UK 
BHK-21 clone 13 Baby hamster kidney cells 
GMEM + 10% 
(v/v) NCS N/A 
(Macpherson 
& Stoker, 
1962) 
BSR-T7/5 
BHK-21 clone 
13 cells that 
have been 
stably 
transfected with 
the T7 RNA 
polymerase 
gene 
GMEM + 10% 
(v/v) FBS 
1 mg/ml G418-
SO4 
(Buchholz et 
al., 1999) 
HEK 293 ISG * 
Human embryo 
kidney 
epithelial cells 
that express an 
ISG 
DMEM + 10% 
(v/v) FBS 
250 µg/ml 
hygromycin, 5 
µg/ml 
blasticidin,       
1 µg/ml 
tetracycline for 
ISG expression 
(Jiang et al., 
2008) 
HEp2 Human cervix 
carcinoma cells 
DMEM + 10% 
(v/v) FBS N/A ECACC 
HEp2/PIV5/V 
Human cervix 
carcinoma cells 
that express 
the V protein of 
PIV5 w3 
DMEM + 10% 
(v/v) FBS 
2 µg/ml 
puromycin for 
PIV5/V protein 
expression 
(Andrejeva et 
al., 2002; 
Young et al., 
2003) 
MA104 
Epithelial 
African green 
monkey foetal 
kidney cells 
DMEM + 10% 
(v/v) FBS N/A ECACC 
MA104/PIV5/V 
MA104 cells 
that express 
the V protein of 
PIV5 w3 
DMEM + 10% 
(v/v) FBS 
2 µg/ml 
puromycin for 
PIV5/V protein 
expression 
Prof R 
Randall, 
University of 
St Andrews, 
UK 
P2.1 
Derived from 
U4C cells and 
are deficient in 
dsRNA 
signalling 
DMEM + 10% 
(v/v) FBS N/A 
(Leaman et 
al., 1998) 
U4C Derived from 2FTGH cells 
DMEM + 10% 
(v/v) FBS N/A 
(Kohlhuber 
et al., 1997) 
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Cell line Description Maintenance Selection Reference 
and are 
unresponsive 
to all IFN 
Vero 
Fibroblast-like 
African green 
monkey kidney 
cells 
DMEM + 10% 
(v/v) FBS N/A 
ATCC  
No. CRL-
1586 
*These cells were used to make 29 ISG inducible cell lines, which are   
listed in the reference. 
 
Table 2.5: Plasmids 
 
Plasmid Description Manufacturer 
pT7ribo 
Bacteriophage T7 promoter 
followed by Stu I and Sma I 
restriction enzymes and the 
hepatitis δ ribozyme 
sequence 
(Dunn et al., 
1995) 
pT7riboBUNL(+) 
Contains the full BUNV L 
sequence in the positive 
sense allowing expression 
of anti-genomic L  
(Bridgen & Elliott, 
1996) 
pT7riboBUNL(-) 
Contains the full BUNV L 
sequence in the negative 
sense allowing expression 
of anti-genomic L 
Anice Lowen 
pT7riboBUNM(+) 
Contains the full BUNV M 
sequence in the positive 
sense allowing expression 
of anti-genomic M 
(Bridgen & Elliott, 
1996) 
pT7riboBUNM(-) 
Contains the full BUNV M 
sequence in the negative 
sense allowing expression 
of anti-genomic M 
Anice Lowen 
pT7riboBUNS(+) 
Contains the full BUNV S 
sequence in the positive 
sense allowing expression 
of anti-genomic S 
(Bridgen & Elliott, 
1996) 
pT7riboBUNS(-) 
Contains the full BUNV S 
sequence in the negative 
sense allowing expression 
of anti-genomic S 
Anice Lowen 
pT7riboBUNN 
Contains the full BUNV S 
sequence but only encodes 
the N ORF 
(Bridgen & Elliott, 
1996) 
TVT7R-BUNM-∆7-E 
The glycoprotein precursor, 
in pT7riboBUNM(+), 
residues 501 to 826 were 
replaced with eGFP 
Xiaohong Shi 
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Table 2.6: Enzymes 
 
Restriction enzymes Description Manufacturer 
BamHI G
▼GATC  C 
C   CTAG▲G Promega 
ClaI AT
▼CG   AT 
TA   GC▲TA Promega 
EcoRI G
▼AATT   C 
C   TTAA▲G Promega 
HpaI GTT
▼AAC 
CAA▲TTG Promega 
NcoI C
▼CATG  G 
G  GTAC▲C Promega 
PmeI GTTT
▼AAAC 
CAAA▲TTTG NEB 
StuI AGG
▼CCT 
TCC▲GGA Promega 
XmnI GAANN
▼NNT TC 
CT TNN▲NNAAG Promega 
Other Enzymes   
Benzonase® Nuclease 
Endonuclease that attacks 
and degrades all forms of 
DNA and RNA 
Novagen 
RQ1 RNase-Free 
DNase 
Endonuclease that 
degrades DNA Promega 
RNasin  ribonuclease inhibitor Promega 
T7 RNA polymerase RNA polymerase Promega 
 
Bacterial strains 
E.coli DH5α: Φ80d lacZ ∆M15, recA1, endA1, gyrA96, thi-1, hsdR17 (rk-, mk+), 
supE44, relA1, deoR, ∆(lacZYA-argF) U169, phoA. 
 
JM109: endA1, recA1, gyrA96, thi-1, hsdR17 (rk-, mk+), relA1, supE44, ∆(lac-
proAB), [F’, traD36, proAB, lac/qZ∆M15]. 
 
Bacterial culture 
• LB agar: L-broth plus 1.5% (w/v) agar 
• L-broth (LB): 10 NaCl, 10 g bactopeptone, 5 g yeast extract per 
litre 
• Z-Competent™ cells (Zymo Research): generated as per the 
manufacturer’s instructions 
 
Cell and virus culture 
• Overlay: 50% (v/v) 2x MEM (supplemented with FBS (10%)), 50% 
(v/v) 1.2% HAS agarose (Park Scientific ltd) 
• Neutral red: 0.06% (w/v) in PBS 
• Giemsa’s stain: 10% (v/v) Giemsa’s stain in dH2O 
• Fixing buffer: 4% (v/v) formaldehyde in PBS 
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Transfection reagent 
Lipofectamine™ 2000 (Invitrogen) 
 
Table 2.7: Media 
 
Media Manufacturer 
Dulbeccos modified Eagle’s medium (DMEM) Gibco BRL 
DMEM without methionine Gibco BRL 
Glasgow modified Eagle’s medium (GMEM) Gibco BRL 
Foetal bovine serum (FBS) Lonza 
2x Modified Eagle’s medium (MEM) Gibco BRL 
Newborn calf serum (NCS) PAA 
Opti-MEM® Invitrogen 
Tetracycline free FBS Invitrogen 
Tryptose phosphate buffer Gibco BRL 
 
Immunofluorescence 
• 4% Paraformaldehyde fixing buffer 
• Permeabilisation buffer: 0.1% (v/v) Triton X-100 in PBS 
• Mowiol 4-88 
• Phosphate buffered saline (PBS): 170 mM NaCl, 3.4 mM KCl, 10 
mM Na2HPO4 1.8 mM KH2PO4, pH 7.12-7.3, 0.68 mM CaCl2, 0.49 
mM MgCl2 
• 3x PBS: Mix A and B:  A.  72 ml of 30 mM NaHPO4/ 390 mM NaCl 
      B.   28 ml of 30 mM NaH2PO4/ 390 mM 
NaCl 
• PBS 2%: PBS supplemented with 2% FBS 
 
Protein analysis 
In vitro protein labelling, polyacrylamide gel electrophoresis (PAGE) and 
Western blotting 
• 0.5% (w/v) Bromophenol blue 
• 2x protein dissociation mix: 12.5% (v/v) SGB, 2% (v/v) SDS, 10% 
(v/v) β- mercaptoethanol, 20% (v/v) glycerol, 0.02% (v/v) 
bromophenol blue, 33.5% (v/v) dH2O 
• 10x Tris-glycine running buffer: 2.4 M Tris, 1.9 M glycine 
• Acrylamide/bis-acrylamide: 30% (w/v) acrylamide, 0.8% bis-
acrylamide 37.5:1 (BioRad) 
• 10% (w/v) Ammonium persulphate (APS) (BioRad) 
• Blocking buffer: 5% skimmed milk powder (Tesco), 0.1% Tween-
20 in PBS 
• Chemiluminescent substrate: SuperSignal West Pico 
Chemiluminescent Substrate (Pierce) 
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• 25x Complete protease inhibitor (Roche): 1 tablet in 2 ml dH2O 
• Fixing buffer: 20% (v/v) acetic acid, 20% (v/v) methanol, 60% (v/v) 
dH2O 
• Magic mark XP protein ladder (Invitrogen) 
• Transfer buffer: 10% (v/v) methanol, 10% (v/v) 20x NU-PAGE 
transfer buffer 
• Phosphate buffered saline (PBS): 170 mM NaCl, 3.4 mM KCl, 10 
mM Na2HPO4 1.8 mM KH2PO4, pH 7.12-7.3, 0.68 mM CaCl2, 0.49 
mM MgCl2 
• PBS-Tween: 0.1% Tween-20 in PBS 
• RIPA buffer: 5 mM EDTA, 300 mM NaCl, 50 mM Tris pH 7.4, 1% 
(v/v) Triton X-100 
• RIPA wash buffer: 5 mM EDTA, 300 mM NaCl, 50 mM Tris pH 
7.4, 0.1% (v/v) Triton X-100 
• Resolving gel buffer (RGB): 0.4% (w/v) SDS, 1.5 M Tris, pH 8.9 
• 10% (w/v) Sodium dodecylsulphate (SDS)  
• Stacking gel buffer (SGB): 0.4% (w/v) SDS, 0.5 M Tris, pH 6.7 
• TEMED (N, N, N’, N’ tetremethylethylenediamine) 
• 1.5 M Tris pH 8.9: 181.71 g Trizma Base, 900 ml dH2O, 21 ml 
HCl, pH adjusted to 8.9 and volume made up to 1L with dH2O 
• 0.5 M Tris pH 6.7: 60.57 g Trizma Base, 900 ml dH2O, 34 ml HCl, 
pH adjusted to 6.7 and volume made up to 1L with dH2O 
 
Radiochemical 
 
[35S]-methionine (10 µCi/µl) was purchased from (Amersham Pharmacia 
Biotech) 
 
RNA analysis 
Northern blotting and RNA preparation 
• 20x SSC: 3 M NaCl, 0.3 M sodium citrate, pH 7.0 
• 50% formamide hybridisation buffer: 50% deionised formamide 
(Ambion), 5x SSC, 0.1% (w/v) n-lauroyl-sarcosine, 0.02% (w/v) 
SDS, 2% (v/v) blocking buffer 
• Agarose electrophoresis grade 
• Blocking buffer: 10x blocking powder (Roche) diluted in maleic 
acid buffer 
• Detection buffer: 0.1 M Tris, 0.1 M NaCl, pH 9.5 
• Ethidium bromide (Promega) 
• RNA loading buffer: 50 mM Tris-HCl, pH 7.6, 0.25% bromophenol 
blue, 60% glycerol 
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• Maleic acid buffer: 0.1 M maleic acid, 0.15 M NaCl, ph 7.5 
• Sodium dodecylsulphate (SDS): 10% (w/v) in dH2O 
• 10x Tris-acetate-EDTA (TAE) buffer: 400 mM Tris-acetate, 10 mM 
EDTA 
• TRIzol® Reagent (Invitrogen) 
• Washing buffer: 0.1 M maleic acid, 0.15 M NaCl, ph 7.5, 0.3% 
(v/v) Tween-20 
 
Methods 
Cell and virus culture 
Cell Culture 
Mammalian cell lines were maintained in medium (T75) 75cm2 and or large 
(T175) 175cm2 tissue culture flasks and were passaged regularly (when 
confluent).  All medium was removed, and the monolayer was washed with 5 ml 
(T75) or 10 ml (T175) of PBS and discarded.  Next, 3 ml (T75) or 5 ml (T175) of 
Trypsin was washed over the monolayer and discarded, leaving 1 ml in the 
flask, which was incubated at 37°C for 5 minutes.  Cells were re-suspended in 5 
ml (T75) or 10 ml (T175) of growth medium.  Further flasks were seeded using 
1 ml of this cell stock into 10 ml (T75) or 20 ml (T175) of growth medium 
supplemented with 10% FBS and when required, selection antibiotics (see table 
1).  HEK293 ISG cells were constantly maintained in growth medium containing 
hygromycin and blasticidin, and for induction of the ISG tetracycline was added 
for 48 hours. 
 
Cells treated with IFNs were either treated with Roferon recombinant human 
IFNα-2a (Roche Diagnostics) or Recombinant Human IFNβ 1a mammalian (Hu 
IFN-β 1a) (PBL Interferon Source) at a concentration of 103 U/ml unless 
otherwise stated. 
 
Cell freezing 
Cells were passaged as above only after re-suspension the cells were 
centrifuged at 3000 rpm for 5 minutes and the supernatant was discarded.  The 
cells were re-suspended in 3 ml (T75) or 6 ml (T175) of growth medium 
containing 10% DMSO and divided into 1 ml aliquots and stored overnight at -
80°C, after which they were transferred to storage in liquid nitrogen. 
 
Cell resuscitation 
The vial of cells from the liquid nitrogen store was thawed in a 45°C water bath 
and then transferred to a 15 ml falcon tube containing 10 ml of growth medium 
and centrifuged at 3000 rpm for 5 minutes.  The supernatant was removed and 
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the cell pellet was re-suspended in 5 ml of growth medium and transferred to a 
small (T25) 25cm2 tissue culture flask and incubated at 37°C until confluent. 
 
BUNV rescue from cloned DNA 
Infectious recombinant BUNV rescue was carried out based on Lowen et al. 
(2004).  In a 35 mm diameter dish 1x106 BSR-T7/5 cells were transfected with 
1.0 µg each of pT7riboBUNL (+), pT7riboBUNM (+) and pT7riboBUNS (+) as 
stated below (Transfection).  Recombinant viruses were rescued by replacing 
the relative pT7riboBUN plasmid with the plasmid containing the required 
mutation.  The dish was then incubated at 33°C for several days until significant 
cytopathic effect (CPE) was observed, at which point the culture medium was 
collected and clarified by centrifugation at 1700 rpm for 3 mins.  One hundred 
microlitres was used for virus infection and elite stock preparation as below 
(Virus infection, Elite stock preparation/plaque purification). 
  
Virus infection 
The growth medium was removed and replaced by the inoculum (see below for 
volume) and returned for incubation at 37°C for 60 minutes with rocking every 
10 minutes.  Next, the inoculum was removed and replaced with either growth 
medium or overlay.  Unless otherwise stated the volume of inoculum added was 
as follows: 
 
100 µl per 24-well plate well 
200 µl per 35 mm well 
400 µl per T25 flask 
500 µl per 60 mm well 
 
Virus amplification 
One hundred microlitres of elite stock was added to 5 ml of growth medium and 
transferred to a 90% confluent T175 flask of BHK, Vero or A549/PIV5/V (w3) 
cells.  The flask was incubated at 37°C for 60 minutes with rocking every 10 
minutes.  Then, 15 ml of growth medium was added and the flask placed in 
incubation at 33°C.  Approximately three days post infection (once 70% CPE or 
GFP was observed) the growth medium was removed to a 50 ml falcon tube 
and centrifuged at 3000 rpm to remove the cell debris.  The supernatant was 
divided into 0.5 ml and 1 ml aliquots and stored at -80°C until use. 
 
Titration by plaque assay 
One hundred microlitres of virus was serially diluted from 10-1 to 10-6 in 900 µl 
PBS 2%.  A 35 mm well of confluent cells was inoculated with 200 µl of each 
dilution and incubated at 37°C for 60 minutes with rocking every 10 minutes.  
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Next, the inoculum was aspirated and 2 ml of overlay (see below) was added 
and left to set, and then placed in an incubator at 37°C for four days. 
 
To make the overlay; 25 ml aliquots of 2x MEM supplemented with 4% FBS 
were warmed to 45°C in a water bath.  Sterile 100 ml aliquots of 1.2% HSA 
agarose were melted in the microwave and then placed in a 55°C water bath for 
the duration of infection.  Next, immediately prior to use, 25 ml agarose was 
added to 25 ml growth medium and inverted 5 times. 
 
After incubation the cells were fixed by the addition of 2 ml of 4% formaldehyde 
for 2 to 24 hours.  Then, the fixation solution was discarded and the overlay 
removed by squirting PBS onto the side of the well.  One ml of Giemsa’s stain, 
diluted 1/10 with water, was added for 10 minutes and then washed off with tap 
water and the plates were inverted and left to dry.  Plaques were counted, and 
used to calculate titre in pfu/ml by dividing the number of plaques (n) by the 
dilution factor (d) multiplied by the inoculum volume (V) in ml: 
 
pfu/ml = n/dV 
 
Elite stock preparation/plaque purification 
As for titration by plaque assay except that after four days incubation at 37°C, 1 
ml of 0.6% neutral red was added to each well for 2 hours and then removed.  
Up to 4 hours later live cells had taken up the neutral red and plaques were 
visible as clear spots.  Using a 200 µl pipette a plaque was picked with an 
overlay plug and added to 1 ml of growth medium and vortexed to release the 
virions from the overlay.  Next, 500 µl of the plaque pick solution was used to 
inoculate a T25 flask of confluent cells for 60 minutes at 37°C, with rocking 
every 10 minutes.  Then, 4.5 ml growth medium was added and the flask 
incubated at 33°C until good CPE was observed.  The growth medium was then 
centrifuged at 3000 rpm to remove the cell debris and the supernatant was 
divided into 200 µl aliquots and stored at -80°C. 
 
Virus purification by ultracentrifugation 
As for virus amplification except that after clarification the supernatant was 
carefully added to a Beckman tube already containing 18 ml of 20% sucrose 
(sucrose cushion) and weighed to ensure balance.  These were then 
centrifuged at 26,000 rpm for 120 minutes in a Beckman Coulter centrifuge 
using the SW28 rotor.  Next, the supernatant was aspirated and the virus pellet 
resuspended in TRIzol for RNA extraction. 
 
Transfection 
Transfection was carried out using Lipofectamine™ 2000.  Using a previously 
seeded six-well plate; initially the growth medium was removed and replaced 
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with 1 ml of fresh medium.  DNA (µg) and liposomes (µl) were prepared using a 
1:3 ratio.  The liposomes were added to 50 µl Opti-MEM® per reaction and left 
to incubate at room temperature for five mins.  The plasmid DNA was added to 
50 µl Opti-MEM® per reaction and mixed.  The liposome mix was added drop-
wise to the DNA mix and gently pipetted up and down five times, and then 
incubated at room temperature for 20 mins.  The DNA-liposome complex (100 
µl per reaction/well) was gently added to the well and gently rocked from side to 
side.  The cells were then incubated at 33°C for five hours and 1 ml of fresh 
growth medium was added. 
 
Transformation 
E.coli transformations were done using E.coli previously prepared for 
transformation using the Z-Competent™ cell kit as per the instruction manual.  
Fifty microlitres of E.coli sample was thawed and incubated at room 
temperature for 30 mins and then 0.5 µg plasmid DNA was added and mixed by 
flicking 5 times and further incubated on ice for 30 mins.  The E.coli were then 
pipetted onto an ampicillin agar plate and streaked using 5 glass beads and 
incubated overnight at 37°C.  
 
Plasmid preparation 
Plasmid preparation was done using the Qiagen midi- and maxi-prep kits as per 
the manufacturer’s instructions.  Midi-preps were started with 100 ml and maxi-
preps were started with 300 ml overnight culture grown in LB broth containing 
50 µg/ml ampicillin. 
 
Immunofluorescence 
Mowiol Mounting Medium 
Whilst continually stirring: 4.8 g of Mowiol 4-88 was added to 12 g of glycerol 
and mixed.  This was followed by the addition of 12 ml of ddH2O and stirring for 
several hours at RT.  Next, 24 ml of 0.2 M Tris-HCl (pH 8.5) was added and 
stirred, with occasional heating for 10 mins in a 55°C water bath, until the 
Mowiol was dissolved.  Once dissolved the solution was clarified by 
centrifugation at 5000 g for 15 mins and the supernatant aspirated and the 
aliquots stored at -20°C. 
 
4% Paraformaldehyde 
One gram of paraformaldehyde was dissolved in 16ml H2O and 100µl 1N NaOH 
at 55°C and stirred occasionally.  Once dissolved the pH was adjusted to 7.2 by 
the addition of dilute HCl and then 8 ml of 3x PBS was added and mixed. 
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Slide preparation 
Coverslips were placed in 24-well plates and seeded with cells.  After 
treatments and or infections (see virus infections above) the coverslips were 
ready for fixing and mounting onto slides. 
 
For fixing, the growth medium was removed and replaced with 1 ml of 4% 
paraformaldehyde for 30 mins.  The paraformaldehyde was then carefully 
aspirated and the coverslips were washed 3 times with PBS 2%.  One millilitre 
of permeabilisation solution was added and left at room temperature for 30 mins 
after which it was aspirated and the coverslip washed 3 times with PBS 2%.  
Thirty microlitres of the primary antibody stain was then dropped onto the 
coverslip and left at 4°C for 60 mins after which the coverslip was washed 3 
times with PBS 2%.  Thirty microlitres of the secondary antibody stain was 
dropped on to the coverslip and left at 4°C for 60 mins after which the coverslip 
was washed 3 times with PBS 2%.  The coverslip was then washed 3 times in 
dH2O and placed on 10 µl Mowiol on a glass slide, labelled  and left to dry at 
4°C.  Slides were then visualised using a Zeiss LSM 5 Pascal confocal 
microscope. 
 
Live cell imaging was carried out in a six-well plate.  Cells were infected (see 
virus infections) and then visualised at the required time points using an AMG 
Evos microscope.  
 
Protein analysis 
In vitro protein labelling, PAGE and Western blotting 
SDS-PAG preparation 
The required percentage resolving gel solution was prepared (Table 2.8) and 6 
ml pipetted into a Novex® empty cassette and isopropanol was layered on top 
to produce a smooth surface.  Once the resolving gel had polymerised, the 
isopropanol was removed and replaced with 3 ml of stacking gel (Table 2.9) and 
a comb (10 or 15 well) was inserted and the stacking gel was left to polymerise.  
 
Table 2.8: Resolving gel 
 
Reagents 5% 8% 10% 12.5% 15% 18% 
30% Acrylamide 2 ml 3.2 ml 4 ml 5 ml 6 ml 7.2 ml 
RGB 3 ml 3 ml 3 ml 3 ml 3 ml 3 ml 
H2O 7 ml 5.8 ml 5 ml 4 ml 3 ml 1.8 ml 
10% APS 100 µl 100 µl 100 µl 100 µl 100 µl 100 µl 
TEMED 10 µl 10 µl 10 µl 10 µl 10 µl 10 µl 
 
 
 
 
 
 2 Materials and Methods 
60 
 
Table 2.9: Stacking gel 
 
Reagents 3 gels 6 gels 9 gels 
30% Acrylamide 1.0 ml 2.0 ml 3.0 ml 
SGB 1.5 ml 3.0 ml 4.5 ml 
H2O 3.5 ml 7.0 ml 10.5 ml 
10% APS 55 µl 110 µl 165 µl 
TEMED 10 µl 20 µl 30 µl 
0.5% Bromophenol blue 30 µl 30 µl 30 µl 
 
Metabolic labelling of BUNV proteins 
Cells at 90% confluency in a 35 mm diameter dish were infected as above and 
returned to the incubator at 37°C.  Two hours prior to the desired time-point the 
cells were starved of methionine by replacing the culture medium with 1 ml of 
DMEM without methionine (met-) and incubating at 37°C for 60 minutes.  Next, 
the met- DMEM was replaced with 500 µl of met- DMEM containing 50 µCi 
[35S]-methionine and the cells were incubated at 37°C for 60 minutes with 
rocking every 10 minutes. 
 
To lyse the cells the labelling medium was aspirated and the cells were washed 
once with ice cold PBS and 150 µl of RIPA buffer containing 1/25 Complete was 
added.  The plate was rocked several times and incubated at 4°C for 10 
minutes.  The cell lysate was transferred to a 1.5 ml microcentrifuge tube and 
vortexed for 5 seconds and returned to 4°C for 10 minutes.  Next, the lysate 
was centrifuged at 16,000 g for 10 minutes, and then the supernatant was 
transferred to a fresh microcentrifuge tube, and stored at -20°C until use. 
 
Protein expression 
Fifty microlitres of lysate was added to 50 µl of 2x dissociation mix and mixed by 
pipetting 5 times.  Five microlitres of pre-stained protein ladder (Fermentas) or 
10 µl of sample was loaded into each well of a 12.5% acrylamide mini-gel.  The 
samples were electrophoresed at 180 V for 50 to 60 minutes in a 1x Tris-glycine 
running buffer, in the Nu-PAGE tank apparatus (Invitrogen).  Gels were then 
fixed, dried, exposed and developed (see below). 
 
Immunoprecipitation 
Antibody conjugated protein A Sepharose beads 
To prepare 50% protein A Sepharose beads, 100 mg were added to 800 µl of 
RIPA buffer, mixed and incubated for 30 mins at room temperature.  Then, 30 µl 
of the 50% protein A Sepharose beads were transferred to a fresh 
microcentrifuge tube and combined with 1 µl of anti-BUN antibody and 0.5 ml of 
ice cold PBS and then put on a rotating wheel for 16 hours at 4°C.  The 
microcentrifuge tube was then centrifuged at 16,000 g for 1 min and then the 
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supernatant was carefully removed and discarded.  The antibody conjugated 
beads were washed three times using 900 µl ice cold RIPA wash buffer and 
finally once with RIPA buffer.    
 
Immunoprecipitation 
Fifty microlitres of lysate was added to the microcentrifuge tube containing the 
30 µl of protein A Sepharose beads from the previous step along with 220 µl ice 
cold PBS and mixed.  The microcentrifuge tube was then put on a rotating 
wheel for 16 hours at 4°C, after which the tube was centrifuged at 16,000 g for 1 
min and then the supernatant was carefully removed and discarded.  The beads 
were then washed 4 times with 900 µl of ice cold RIPA wash buffer.  One final 
wash with ice cold PBS was followed with carefully removing the supernatant 
completely, and discarding it.  The beads were resuspended in 30 µl of 
Dissociation mix and boiled for three mins and then analysed. 
 
Gel Fixing and drying 
The stacking gel was cut off and the resolving gel transferred to a plastic box 
containing 100 ml of fixing buffer, and placed on a rocker for 30 minutes.  The 
gel was then placed on a piece of plastic with a sheet of Whatman on top and 
dried for 60 mins at 80°C and then exposed to x-ray film or phosphorimager 
screen overnight, and  then developed. 
 
Western blotting 
Cells at 90% confluency in a 35 mm diameter dish were infected as above and 
returned to the incubator at 37°C until the required time for lysis.  To lyse the 
cells the medium was aspirated and the cells were washed once with ice cold 
PBS and 150 µl of RIPA buffer containing 1/25 Complete was added.  The plate 
was rocked several times and incubated at 4°C for 10 minutes.  The cell lysate 
was transferred to a 1.5 ml microcentrifuge tube and vortexed for 5 seconds 
and returned to 4°C for 10 minutes.  Next, the lysate was centrifuged at 16,000 
g for 10 minutes, and then the supernatant was transferred to a fresh 
microcentrifuge tube, and stored at -20°C until use. 
 
Fifty microlitres of lysate was added to 50 µl of 2x dissociation mix and mixed by 
pipetting 5 times.  Five microlitres of pre-stained protein ladder (Fermentas) or 1 
µl of MagicMark XP or 10 µl of sample was loaded per well of a 12.5% 
acrylamide mini-gel.  The samples were electrophoresed at 180 V for 50 to 60 
minutes in a 1x Tris-glycine running buffer, in the Nu-PAGE tank apparatus. 
 
Semi-dry transfer 
The nitrocellulose membrane and two pieces of blotting pad (Roche) were 
equilibrated in transfer buffer for 5 mins.  Then, using a Trans-Blot® SD Semi-
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Dry Electrophoretic Transfer Cell (BioRad), one piece of blotting pad was 
placed on the platinum anode and then the membrane on top.  Having removed 
the stacking gel the gel was placed on the membrane and a second piece of 
blotting pad placed on top and rolled with a 10 ml pipette to remove air bubbles.  
The cathode was then carefully placed on the stack and secured with the 
latches followed by the safety lid.  The transfer was conducted at 20 V for 20 
mins. 
 
Detection 
The membrane was rinsed three times in PBS-Tween and incubated in blocking 
buffer for 60 mins, then rinsed three times in PBS-Tween and washed for five 
mins in PBS-Tween.  The three rinse and wash process was repeated three 
times after which the membrane was incubated with the primary antibody in 
blocking buffer (Table 2.2).  Next, the membrane was rinsed and washed three 
times as above and incubated with the secondary antibody in blocking buffer for 
60 mins.  After the secondary incubation the membrane was rinsed and washed 
three times as above followed by treatment with chemiluminescent substrate for 
five mins and placed in a cassette with a piece of plastic on top and exposed to 
x-ray film for 1 s to overnight as required, and developed. 
 
RNA analysis 
RNA isolation 
Total cell RNA was extracted from a cell cultured monolayer in a T25 flask by 
removing the growth medium and adding 1 ml of TRIzol.  After vigorous shaking 
and pipetting the resuspended monolayer was transferred to a 1.5 ml 
microcentrifuge tube and incubated at room temperature for five mins.  
Subsequently, 200 µl of chloroform was added to the cell lysate, vortexed for 15 
s and incubated at room temperature for three mins.  Next, the lysate was 
centrifuged for 15 mins at 4°C and 12,000 g, after which the upper aqueous 
layer was transferred to a fresh microcentrifuge tube and 0.5 ml isopropanol 
was added, mixed, and incubated at room temperature for 15 mins to allow 
precipitation of the RNA.  The RNA was then pelleted by centrifugation at 4°C 
and 12,000 g for 20 mins after which the supernatant was removed and 
replaced with 1 ml of 75% ethanol.  If the RNA was not to be used immediately 
it was stored at -80°C and then, or otherwise, it was centrifuged for 10 mins at 
4°C and 7,500 g.  Finally the ethanol was aspirated and the pellet allowed to air 
dry and subsequently resuspended in RNase-Free H2O.  The concentration and 
quality (260/280 ratio) was measured using the NanoDrop™ 2000 (Thermo 
Scientific). 
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Northern blotting 
To make a 1.2% agarose gel, 1.2 g agarose was added to 100 ml of autoclaved 
water and dissolved by heating in a microwave oven, and then cooled to 55°C 
in a water bath.  This was poured into a gel casting tray with a comb to produce 
a fourteen well slab, 11x14x0.6 cm.  Once solidified, 1 L of 1x TAE running 
buffer was added to the gel tank. 
 
Preparation of RNA samples 
Ten µg of total cellular RNA was diluted in 20 µl of deionised formamide, 3 µl of 
10x loading dye, 1 µl of ethidium bromide and made up to 32 µl with autoclaved 
water and mixed.  The samples were heated to 65°C for 5 minutes and then 
rapidly cooled on ice and briefly centrifuged to collect condensation.  Thirty 
microlitres of sample was loaded into a well, and the gel was run at 75 V for 3-5 
hours. 
 
Capillary transfer 
The gel was washed for 5 minutes and a photograph taken on a UV 
transilluminator (UVP) to check the rRNA bands.  The gel casting tray was 
inverted and placed in a shallow tray, which was filled up with 10x SSC.  Eight 
centimetres of blotting pad (Roche) was placed on top of the casting tray, 
followed by 3 pieces of 3MM Whatman paper soaked in 10x SSC which was 
then rolled with a 10 ml pipette.  A piece of positively charged nylon membrane 
(Sigma), cut to the size of the gel, was soaked in 10x SSC and placed on top of 
the 3 MM Whatman paper.  The gel was carefully placed onto the nylon 
membrane and rolled using a 10 ml pipette to remove air bubbles.  Three more 
pieces of 3MM Whatman paper were soaked in 10x SSC and placed on top, 
and then two pieces of 3MM Whatman paper cut to 40 cm long were soaked in 
10x SSC and draped over the whole blotting sandwich to act as a wick.  A 1 kg 
weight was placed on top and the tray was covered with cling film to minimise 
evaporation, and the whole apparatus was left overnight. 
 
U.V crosslinking 
Once blotting was complete, the top right hand corner of the membrane was 
clipped for orientation, and the membrane was washed in 2x SSC for 5 minutes, 
and hung up to dry.  When dry, the membrane was placed face down in the 
transilluminator and irradiated for 3 minutes at 305 nm and RNA transfer was 
confirmed by visualising the rRNA bands.  The membrane was then stored in a 
plastic bag at 4°C until use. 
 
Hybridisation using DIG labelled probes 
The membrane was placed in a cylindrical hybridisation bottle with 10 ml of pre-
warmed to 68°C 50% formamide hybridisation buffer.  The membrane was pre-
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hybridised at 68°C for 30 minutes in a hybridisation oven with constant rotation.  
The DIG labelled RNA probes were made up to 30 µl with autoclaved water and 
denatured by boiling for 5 minutes, and then cooled rapidly on ice.  The probes 
were added to 10 ml of prewarmed to 68°C 50% formamide hybridisation buffer 
and this was used to replace the pre-hybridisation buffer.  Hybridisation was 
carried out overnight at 68°C under constant rotation. 
 
Washes 
The membrane was washed under: 
 
Low stringency conditions:  2x10 minutes in 25 ml 2x SSC, 0.1% SDS at 
RT 
 
High stringency conditions: 2x25 minutes in 25 ml 0.1x SSC, 0.1% SDS 
at 68°C 
 
Detection 
Detection was largely based on the DIG Northern Starter kit (Roche) instruction 
manual and was optimised as follows: 
 
5 minutes in 25 ml washing buffer 
60 minutes in 10 ml 1x blocking solution 
60 minutes in 10 ml 1x antibody solution 
2x30 minutes in 25 ml washing buffer 
5 minutes in 25 ml detection buffer 
 
The membrane was placed on a piece of translucent plastic and 1 ml of CDP 
Star (Roche) was added drop-wise and the plastic folded over to give a uniform 
film of CDP Star over the membrane, and left for 5 minutes at room 
temperature.  The excess liquid was squeezed out and the membrane sealed 
inside the plastic.  The membrane was then exposed to x-ray film for 1 second 
to overnight as required, and developed. 
 
Generation of DIG labelled probes 
The plasmid containing the desired probe sequence downstream of a T7 
promoter was linearised approximately 1 kb downstream of the T7 promoter by 
restriction endonuclease digestion.  More efficient in-vitro transcription is 
achieved with a 5’ overhang at the cleavage site (Roche), thus enzymes that 
produce a 5’ overhang were chosen over those that produce a 3’ overhang or 
blunt end.  The digested DNA was then run on an agarose gel, the desired band 
excised and purified using the wizard PCR gel purification kit (Promega). 
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Restriction endonuclease digestion 
One microgram of plasmid DNA was added with 1 µl 10x RE buffer, 5-10 units 
of RE and made up to 10 µl with dH2O in a microcentrifuge tube and mixed 
gently by pipetting.  The mixture was centrifuged for a few seconds and 
incubated at the optimum temperature for 2 hours.  The mixture was centrifuged 
again for a few seconds and 2 µl of 6x loading buffer was added and mixed 
before being electrophoresed on a TAE 1% agarose gel containing ethidium 
bromide for ~60 mins. 
 
In-vitro transcription 
The following was mixed in an RNase free microcentrifuge tube: 
 
1 µg DNA in 20 µl dH2O 
8 µl 5x transcription buffer (Promega) 
4 µl 100 mM DTT (Promega) 
4 µl DIG labelling mix (Roche) 
80 U T7 RNA polymerase (Promega) 
 
The reaction mixture was incubated at 37°C for 2 hours.  Two units of RQ1 
RNase-free DNase was added and the mixture incubated at 37°C for 15 
minutes, then diluted up 10 fold to 400 µl and stored at -80°C until use. 
 
Quantification of DIG labelled probes 
Quantification of the DIG labelled probes was carried out as per the 
manufacturer’s instructions in the DIG Northern Starter kit (Roche) manual. 
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3 The effect of type I IFN on Bunyamwera   
virus replication 
Introduction 
Chapter One described the IFN system and the anti-viral proteins that are 
upregulated via IFN signalling.  Over the last decade, much progress has been 
made in studying the effects of IFNs on viruses and the mechanisms viruses 
use to counteract the IFN response.  Infection by most viruses is known to 
trigger IFN production and the Bunyaviridae family is no exception.  To this end, 
human-disease causing viruses from each genus have been studied in more 
detail in order to determine how they escape the IFN response.  For example, 
type I IFNs have been shown to inhibit CCHFV (Andersson et al., 2006), OROV, 
Caraparu, Guama, GROV and Tacaiuma viruses (Livonesi et al., 2007), BUNV 
(Streitenfeld et al., 2003) and several other members of the Bunyaviridae family.  
Successful replication within mammalian cells means that bunyaviruses must 
overcome the IFN response.  The primary IFN antagonist for BUNV is the NSs 
protein, which blocks host transcription thereby blocking transcription of type I 
IFNs, and also causes host cell protein synthesis shut-off (Chapter One).  
Further to this, research into viral countermeasures has helped to elucidate 
details of the induction of the IFN response to viruses, as well as greatly 
improving our understanding of the molecular mechanisms of viral 
pathogenesis.  The aim of the work described in this chapter was to investigate 
the IFN response to BUNV in more detail.                                                                                     
Plaque assays 
The most direct method of detecting inhibition of virus replication in host cells is 
to carry out plaque assays.  The plaque assays described here were carried out 
exactly as stated in Chapter Two; each virus was fully titrated on each cell line 
at 37°C.  BUNV and rBUNdelNSs produce characteristic plaque phenotypes 
following infection of different cell lines (Fig 3.1, compare the top row (BUNV) to 
the bottom row (rBUNdelNSs) for each cell line indicated).  A549 cells are a 
human lung carcinoma cell line with a fully functional immune response.  Since 
BUNV is able to antagonise the innate immune response via the expression of 
NSs protein, infection of A549 cells produces large (3 mm or more in diameter) 
plaques (Fig 3.1, top row).  In contrast, rBUNdelNSs is unable to express NSs 
protein and therefore no plaques are detected in A549 cells (Fig 3.1).  HEp2 
cells are human cervix carcinoma cells that are also IFN competent.  Infection 
of HEp2 cells with BUNV produced small (1 mm or less in diameter) irregular 
shaped plaques, while infection with rBUNdelNSs produced no plaques (Fig 
3.1).  HEp2/PIV5/V cells are HEp2 cells that have been transduced to express 
the PIV5 V protein which targets STAT1 for degradation, thereby blocking IFN 
signalling.  Plaque assays with HEp2/PIV5/V cells infected with either BUNV or 
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rBUNdelNSs produced small irregular plaques which were difficult to distinguish 
from uninfected cells (Fig 3.1).  MA104 cells are African green monkey foetal 
kidney cells that are IFN competent, while MA104/PIV5/V cells have been 
transduced to express the V protein of PIV5 and thus have an attenuated IFN 
response.  The BUNV plaques on MA104 and MA104/PIV5/V cells were 
medium-sized (2 mm in diameter) and rounded whereas rBUNdelNSs did not 
form visible plaques on MA104 cells but did form small, irregular shaped 
plaques on MA104/PIV5/V cells (Fig 3.1). 
Vero cells are African green monkey kidney epithelial cells that are IFN deficient 
as they cannot produce type I IFNs but they do have the IFNAR and can 
respond to exogenous IFN.  The plaques produced by BUNV on Vero cells 
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were typically large and rounded, while those of rBUNdelNSs were of similar 
shape but were only medium-sized (Fig 3.2, compare top row (BUNV) to bottom 
row (rBUNdelNSs) for each cell line indicated).  The 2FTGH cell line is a human 
fibrosarcoma cell line that is able to produce and respond to IFN.  BUNV 
plaques on 2FTGH cells were medium-sized and round, whereas rBUNdelNSs 
did not produce any plaques in these cells.  However, both viruses do plaque on 
2FTGH/PIV5/V cells (Young et al., 2003).  U4C cells are derived from the 
2FTGH cell line and lack JAK1 and as such are unable to respond to any IFN 
(Kohlhuber et al., 1997).  P2.1 cells are derived from U4C cells and are not only 
unable to respond to IFN but are also deficient in dsRNA signalling (Leaman et 
al., 1998).  Both BUNV and rBUNdelNSs produced plaques on U4C cells that 
were small and rounded.  BUNV produced plaques on P2.1 cells that were 
medium-sized and rounded, whereas rBUNdelNSs plaques were small and 
round-shaped (Fig 3.2).  Thus, BUNV was able to infect all cell lines whereas 
those with an intact IFN response (A549, HEp2, MA104 and 2FTGH) were less 
permissive to rBUNdelNSs infection unless they expressed the PIV5 V protein 
to restrict IFN signalling (see table 3.1).   
Table 3.1: Summary of plaque morphology, size and titre from various 
mammalian cell lines infected with either BUNV or 
rBUNdelNSs. 
              Virus 
 
Cell line 
BUNV rBUNdelNSs 
Morphology Size* Titre† Morphology Size* Titre† 
A549 Round Large 1.45x108 NP - - 
HEp2 Irregular Small 9x106 NP - - 
HEp2/PIV5/V Irregular Small 7x103 Irregular Small UC 
MA104 Round Medium 5x106 NP - - 
MA104/PIV5/V Round Medium 5x106 Irregular Small 4.5x106 
Vero Round Large 8.5x108 Round Medium 2.95x106 
2FTGH Round Medium 2.25x106 NP - - 
U4C Round Small 1.06x107 Round Small 6.4x105 
P2.1 Round Medium 4.8x106 Round Small 1.51x105 
* Large is 3 mm or greater, medium is 2 mm, small is 1 mm or less. 
†
 Titre (from stock) is in pfu/ml.  
NP denotes no plaques and UC denotes plaques were uncountable.   
 
Growth kinetics 
Plaque size and morphology is variable between different cell lines and 
depends on many factors, particularly the IFN response system.  Furthermore, 
investigating the effects on growth of the virus by plaque assay titration is both 
sensitive and informative.  Thus, cells were infected at an MOI of 0.01 pfu/cell, 
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incubated at 37°C and the released virus was titrated by plaque assay (Fig 3.3).  
Initially, 2FTGH cells were infected with BUNV and after 48 hours the yield of 
virus plateaued and the final titre was 2.37x107 pfu/ml, whilst rBUNdelNSs 
followed a similar growth pattern but the final titre was 65-fold lower at 3.62x105 
(Fig 3.3A).  Growth of BUNV in 2FTGH/PIV5/V cells was not as high as in the 
naïve cells, at 1.03x107 pfu/ml at 72 hours, however the growth of rBUNdelNSs 
was enhanced to 1.08x106 pfu/ml but was still 10-fold lower than BUNV (Fig 
3.3B).  The growth kinetics in A549 cells for BUNV showed the virus released 
peaked and plateaued at 48 hours with a titre of 4.5x108 pfu/ml, while 
rBUNdelNSs was more restricted and released virus plateaued after 24 hours 
with the titre being over 100-fold lower than BUNV, around 1x106 pfu/ml (Fig 
3.3C).  Further to this, the growth kinetics observed in Vero cells showed that 
BUNV-infected cells produced a final titre of 7.17x107 and rBUNdelNSs was 
completely unrestricted and produced a similar titre of 4.83x107 (Fig 3.3D). 
Effect of IFN concentration and treatment periods 
To further investigate the effects of IFN on BUNV, Vero cells were used since 
they do not synthesise IFN but are able to respond to IFN. 
Vero cells were treated with increasing doses of IFN at different times either 
pre- or post-infection, and incubated at 37°C.  The viral titre was then 
determined at 24 hours post infection by plaque assay, and protein production 
in infected cells was analysed by Western blotting (Fig 3.4).  For BUNV, IFN 
treatment with 0 or 10 U/ml at any time either before or after infection had no 
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effect on the titre of virus after 24 hours (Fig 3.4A).  Similar results were 
observed at 100 and 1000 U/ml for all treatments started after 2 hours prior to 
infection.  However, when pre-treatment began 12 hours prior to infection, a 
small reduction in viral titre was observed when 100 U/ml were used and a 
dramatic 400-fold reduction was observed when 1000 U/ml were used.  
Furthermore, pre-treatment of 100 and 1000 U/ml that began 24 hours prior to 
infection reduced the BUNV titre 6-fold and more than a 1000-fold respectively 
(Fig 3.4A).   
Western blot analysis showed faint N protein bands in cells treated with 100 
U/ml started at 24 and 12 hours prior to infection and also for 1000 U/ml 
treatment started at 2 hours prior to infection (Fig 3.4C, top panel).  Treatment 
of 1000 U/ml that started 12 and 24 hours prior to infection completely inhibited 
N protein synthesis (Fig 3.4C, top panel), but when started at 0 hours there was 
a slight reduction in the amount of N protein, but treatments that started after 
infection showed no reduction in the amount of N protein detected (Fig 3.4C, 
bottom panel).   
For rBUNdelNSs, treatments of 0 and 10 U/ml at any time point also had little 
effect on the viral titre after 24 hours and, like BUNV, treatment of 100 U/ml at 
12 and 24 hours prior to infection showed only a small reduction in titre (Fig 
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3.4B).  However, unlike BUNV, treatment that began 2 hours prior to infection 
also showed a small reduction in titre.  As was seen with BUNV infection, 
treatment with 1000 U/ml substantially reduced the titre of rBUNdelNSs when 
the treatment was started 12 (700-fold) and 24 (~800-fold) hours prior to 
infection, but further reductions in titres were also observed from treatments that 
began 2 and 0 hours prior to infection.  Additionally, as with BUNV, treatment 
with IFN after infection had no effect on viral titre. 
Western blot analysis showed a similar pattern to BUNV but was more 
pronounced (Fig 3.4D).  Treatment with 100 U/ml started 24 and 12 hours prior 
to infection resulted in almost no N protein (Fig 3.4D, top panel).  Treatment 
with 1000 U/ml that started 24 and 12 hours before infection resulted in no 
detectable N protein, and less N protein was detected when started 2 hours 
before infection.  A small reduction in the amount of N protein was observed 
when IFN was added at 0 hours.  Post-infection treatments had no effect on the 
amount of N protein detected/synthesised/accumulated (Fig 3.4D, bottom 
panel). 
Thus, the virus titres correlate with viral N protein production as analysed by 
western blotting and show that both the dose and time of IFN treatment are 
important variables when investigating the effects of IFN on the virus replication 
cycle. 
To investigate the effects of both IFNα and IFNβ for their inhibitory effect on 
BUNV at 37°C, Vero cells were treated at various times with either or both IFNs 
and then infected with either BUNV or rBUNdelNSs at an MOI of 5 pfu/cell.  The 
cells were harvested and lysed 24 hours post-infection for Western blot analysis 
(Fig 3.5).  Treatment with IFNα had little effect on BUNV (Fig 3.5, top panel); 
likely because the IFNα response is dependent on IFNβ induction and Vero 
cells cannot produce IFNβ.  However, when the cells were pre-treated with 
IFNα for 24 or 12 hours, rBUNdelNSs infected cells showed some reduction in 
the amount of N protein produced.  In contrast to treatment with IFNα alone, 
pre-treatment for 24 or 12 hours with IFNβ considerably restricted both BUNV 
 3 The effect of type I IFN on Bunyamwera virus replication 
72 
 
and rBUNdelNSs (Fig 3.5, middle panel) and, as predicted, pre-treatment with 
both IFNα and IFNβ showed the same inhibition as treatments with IFNβ alone 
(Fig 3.5, bottom panel).  The higher MOI used, compared with an MOI of 1 
previously, revealed that BUNV was able to overcome IFNβ when the virus 
concentration was increased. 
To establish if exogenous IFNβ has the same effect on BUNV at 37°C in A549 
cells, the cells were pre-treated at various times with IFNβ and then infected 
with BUNV or rBUNdelNSs at an MOI of 1 pfu/cell.  The cells were then 
harvested 24 hours after infection, lysed and subjected to Western blotting (Fig 
3.6).  N protein was undetectable after pre-treatment for 24 or 12 hours with 
IFNβ in BUNV (Fig 3.6A) and rBUNdelNSs (Fig 3.6B) virus-infected cells.  
Additionally, treatment that started at 0 hours also showed a reduction in the 
amount of N protein and there was no observable effect from post-infection 
treatment for both viruses.  
Virus titre in IFNβ pre-treated A549 cells 
Pre-treating cells with IFN clearly had a major impact on the replication of 
BUNV.  To elaborate the effect of IFN on viral replication, the growth kinetics of 
BUNV and rBUNdelNSs at 37°C were monitored in two cell lines, Vero and 
A549.  After the cells were pre-treated with IFNβ, they were infected with either 
BUNV or rBUNdelNSs at an MOI of 1 pfu/cell and over a 24 hour period 
released virus was determined by plaque assay (Fig 3.7A and B).  The BUNV 
titre in untreated Vero cells after 24 hours was 1.1x108 pfu/ml (a yield around 
1x108 pfu/ml is relatively standard for BUNV) (Fig 3.7A).  However, in the pre-
treated cells the BUNV titre did not increase above 3.5x104 pfu/ml.  The 
rBUNdelNSs virus is attenuated in comparison with BUNV and usually produces 
a virus titre 10- to 100-fold lower.  In the untreated Vero cells the rBUNdelNSs 
titre was 4.5x106 pfu/ml.  Pre-treatment with IFNβ restricted the virus from 
producing a titre above 9.5x104 pfu/ml.  The peak BUNV titre in A549 untreated 
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cells was 9x107 pfu/ml but from cells pre-treated with IFNβ the titre did not 
increase above 6.5x104 pfu/ml (Fig 3.7B).  The peak titre from rBUNdelNSs in 
untreated A549 cells was 3x106 pfu/ml and from pre-treated cells the titre did 
not increase above 7x104 pfu/ml (Fig 3.7B).  Thus, pre-treatment with IFNβ 
appears to fully restrict BUNV replication in both cell lines. 
Protein expression in IFNβ pre-treated A549 cells 
In order to establish that the restriction on viral titre equates to restriction on 
viral protein synthesis, A549 cells were pre-treated with IFNβ (1000 U/ml) and 
then infected with either BUNV or rBUNdelNSs at an MOI of 1 pfu/cell.  The 
cells were then labelled with [35S]-methionine for 1 hour at different times and 
subsequently analysed by SDS-PAGE and autoradiography (Fig 3.8).  All the 
viral proteins (L, Gc, Gn, N, NSm, and NSs) were observed in the untreated 
cells; however, after IFNβ treatment, none of the viral proteins were readily 
identified (Fig 3.8, BUNV).  As with BUNV infection, the untreated rBUNdelNSs-
infected cells produced detectable levels of all the viral proteins (except NSs as 
it has been deleted) but after pre-treatment with IFNβ no viral proteins were 
detected (Fig 3.8, rBUNdelNSs). 
Figure 3.8 suggests limited viral protein expression occurred.  Therefore, some 
of the remaining cell lysates from the experiment described above (Fig 3.8) 
were immunoprecipitated with anti-BUN antibody and the immunoprecipitates 
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analysed by SDS-PAGE and autoradiography (Fig 3.9).  As was observed in 
figure 3.8, viral proteins were detected by 4 hours post infection in untreated 
cells infected with either BUNV or rBUNdelNSs and the viral proteins L, Gc and 
N were all clearly visible (Fig 3.9, - IFN panels).  However, as with earlier data, 
no viral proteins were detected in the pre-treated cells infected with either virus.  
This confirmed that pre-treatment with IFNβ completely restricted detectable 
viral proteins. 
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RNA analysis in IFNβ pre-treated A549 cells 
The inability of BUNV to produce virions or any detectable viral proteins may 
stem from a block in virion morphogenesis and or viral protein translation.  
However, the viral restriction observed previously may have been at the level of 
RNA transcription and replication.  A549 cells were pre-treated with IFNβ (1000 
U/ml) and then infected with either BUNV or rBUNdelNSs at an MOI of 1 
pfu/cell.  Over a 24 hour time period total cellular RNA was extracted at various 
times and analysed by Northern blotting (Fig 3.10 and 3.11).  In the untreated 
cells infected with either BUNV (Fig 3.10A) or rBUNdelNSs (Fig 3.10B) there 
were detectable levels of S segment genomic RNA at 4 hours post infection.  
The M segment was observed in BUNV infected cells by 8 hours whereas the L 
segment from either virus infection was not detected. From the pre-treated cells 
infected with either virus there was no detectable viral genomic RNA (Fig 3.10A 
and B, +IFN). 
Furthermore, the experiment was repeated for probing with negative orientation 
probes to detect anti-genomic and mRNA to see whether a block in genome 
replication and viral protein expression was at the level of transcription (Fig 
3.11A and B).  In untreated cells infected with BUNV S, M and L RNAs were 
easily detected (Fig 3.11A).  Cells infected with rBUNdelNSs also showed 
strong signals and the expected migration pattern for each segment (Fig 3.11B) 
along with two other RNA species whose origin is unknown.  After 16 hours the 
detectable RNA decreased due to virus-induced cell death resulting from a lack 
of the NSs protein (Kohl et al., 2003).  In the IFNβ treated cells, no viral RNAs 
were detected (Fig 3.11A and B, +IFN).  Thus, pre-treatment with IFN is 
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effective at blocking viral replication at the level of RNA synthesis, as well as 
abrogating viral protein synthesis. 
Quantification of the DIG labelled probes showed differing signal intensities 
between the L, M and S segment probes.  However, the signal intensities of 
both negative and positive sense probes for each segment were similar.  Thus 
the levels of RNA can be compared for each segment, although this does not 
account for inefficient RNA transfer from the gel to the membrane. 
Protein expression in IFNβ pre-treated Vero cells 
Pre-treatment of A549 cells with IFNβ puts the cells in to the antiviral state 
priming them for defence against a viral infection.  However, while Vero cells 
are unable to synthesise their own IFN, they are able to respond to IFN and can 
still go into the antiviral state if pre-treated with IFNβ.  To investigate whether 
pre-treated Vero cells are still susceptible to BUNV infection, Vero cells were 
treated with IFNβ (1000 U/ml) and then infected with either BUNV or 
rBUNdelNSs at an MOI of 1 pfu/cell.  The cells were harvested at various times 
over 24 hours and the proteins analysed by SDS-PAGE and autoradiography 
(Fig 3.12).  The viral proteins L, Gc, Gn, N, NSm and NSs were detected from 
untreated cells infected with either BUNV or rBUNdelNSs (no NSs) and the N 
protein was observed by 8 hours post infection.  In the BUNV-infected cells, 
there was visible shut-off at 20 hours post infection (Fig 3.12, BUNV -IFN) 
whereas in rBUNdelNSs infected cells shut-off was barely visible (Fig 3.12, 
rBUNdelNSs –IFN).  As seen earlier in A549 cells, there was no discernible viral 
protein synthesis in IFNβ treated cells infected with either BUNV or 
rBUNdelNSs (Fig 3.12, BUNV and rBUNdelNSs +IFN).  For a more specific 
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examination of the level of protein synthesis in IFNβ treated cells, the samples 
were immunoprecipitated with anti-BUN antibody and analysed by SDS-PAGE 
and autoradiography.  Figure 3.13 shows that viral protein synthesis of L, Gc 
and N protein was detected in untreated cells as early as 4 hours post infection.  
However, there was no observed viral protein synthesis in the IFNβ treated cells 
(data not shown).  Thus, treating either A549 or Vero cells with IFNβ 24 hours 
prior to infection puts the cells into the antiviral state and they appear to be no 
longer permissive for BUNV replication. 
Protein expression in Vero cells subjected to post infection IFNβ 
treatment 
Having ascertained that BUNV is incapable of replicating in Vero cells that have 
been primed with IFNβ, the next question was whether BUNV would be 
restricted by the treatment of IFNβ after infection had started.  Therefore, Vero 
cells were infected with either BUNV or rBUNdelNSs at an MOI of 1 pfu/cell and 
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then treated with IFNβ (1000 U/ml) immediately (synchronous treatment) or 6 or 
12 hours post infection.  The cells were harvested 24 hours post infection and 
analysed by SDS-PAGE and autoradiography (Fig 3.14).  Synchronous 
treatment with IFNβ considerably restricted both BUNV and rBUNdelNSs 
protein synthesis: L and NSm proteins were not detectable after treatment, and 
the Gc and N proteins were only faintly present (Fig 3.14A).  The level of host 
cell protein synthesis shut-off observed in the treated BUNV infected cells was 
similar to untreated rBUNdelNSs infected cells but the treated rBUNdelNSs 
infected cells showed even less shut-off.  When treatment was started 6 hours 
post infection there was no observable effect on BUNV viral protein synthesis 
although the level of shut-off was slightly reduced (Fig 3.14B).  However, the 
treated cells infected with rBUNdelNSs produced less intense viral L, Gc and N 
protein bands and there was little shut-off observed.  As with treatment started 6 
hours post infection, treatment that was started 12 hours post infection had no 
observable effect on BUNV protein synthesis or host protein shut-off (Fig 
3.14C).  Furthermore, cells infected with rBUNdelNSs were only slightly 
restricted.  The level of shut-off was the same as untreated but there was 
reduced synthesis of all the viral proteins. 
The cell lysates were immunoprecipitated with anti-BUN antibody and analysed 
by SDS-PAGE and autoradiography to gain further understanding of the 
restriction on protein synthesis observed above (Fig 3.15).  It was clear that the 
later the treatment started, the smaller was the effect observed (Fig 3.15A to B 
to C).  For BUNV, the level of L, Gc and N protein was reduced considerably by 
synchronous addition of IFN but not by post-infection treatments.  For 
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rBUNdelNSs, the level of restriction observed on L, Gc and N protein synthesis 
decreased the longer it was before treatment began; synchronous IFN addition 
clearly inhibited viral protein synthesis whereas treatment at 12 hours post 
infection had little effect on protein levels (Fig 3.15, compare A to C). 
BUNV protein expression from cells synchronously treated with IFNβ  
BUNV replication was restricted by synchronous treatment with IFNβ but not by 
post infection IFNβ treatment.  Therefore, to try to establish at what point in the 
replication cycle of BUNV the IFN-mediated restriction occurred, Vero cells 
were infected with BUNV at an MOI of 1 pfu/cell, synchronously treated with 
IFNβ (1000 U/ml) and labelled for 1 hour with [35S]-methionine at different times 
over a 24 hour period.  Radiolabelled cell extracts were analysed by SDS-
PAGE and autoradiography (Fig 3.16).  The level of detectable viral proteins 
from untreated cells increased until 12 hours after which the level of N 
decreased but the level of Gc increased.  The level of host cell protein synthesis 
shut-off increased from 12 hours onwards (Fig 3.16, BUNV –IFN).  However, 
the infected treated cells showed an alteration in the pattern of viral protein 
synthesis.  Compared with untreated cells, the level of N and Gc protein 
synthesis increased 1.7- and 3-fold, respectively (Fig 3.16B and C).  By 12 
hours the addition of IFNβ resulted in a decrease in the level of protein 
synthesis, and by 24 hours the decrease equated to a 3- and 5-fold reduction 
for N and Gc protein synthesis, respectively.  Following the addition of IFNβ the 
level of shut-off observed was also reduced by 24 hours post infection (Fig 
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3.16A).  Therefore, these data show that IFNβ treatment alters the level of N 
and Gc protein synthesis in cells infected with BUNV.  
Analysis of BUNV RNA from cells synchronously treated with IFNβ  
The observed effect of IFNβ treatment on viral protein synthesis could be at the 
level of transcription or translation.  Therefore, to distinguish these possibilities, 
Vero cells were infected with BUNV at an MOI of 1 pfu/cell and stimulated 
synchronously with IFNβ (1000 U/ml), and subsequently, total cellular RNA was 
extracted at different times post-infection and analysed by Northern blotting (Fig 
3.17).  The level of BUNV genomic RNA in untreated cells was detectable for 
each segment by 4 hours, and peaked by 12 hours post-infection (Fig 3.17A, –
IFN).  In the IFNβ-treated cells the RNA levels increased from detection at 4 
hours throughout the 24 hour period (Fig 3.17A, +IFN).  In untreated cells the 
level of positive-stranded S and M segment RNA was detected at 4 hours and 
increased up to 8 hours and remained constant, while the L segment RNA was 
not detected until 8 hours and increased thereafter (Fig 3.17B, -IFN).  However, 
all three RNAs were detected in IFNβ-treated cells at 4 hours post infection and 
at much higher levels suggesting that IFNβ induces increased early 
transcription of anti-genomic and or mRNA (Fig 3.17B, +IFN).  This observation 
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correlates with data described above that showed an increase in early viral 
protein synthesis of N and Gc protein (Fig 3.16C).  Protein synthesis shown in 
figure 3.16C, however, showed significant reduction by 24 hours but the positive 
sense RNA observed in figure 3.17B shows increased RNA synthesis 
suggesting that IFNβ induced restriction on N and particularly Gc protein 
synthesis occurs post-transcriptionally.  
IFNβ pre-treated Vero cells infected with GRO, LAC or LACdelNSs virus 
The above data established that the effect of pre-treating cells with IFNβ 
renders them non-permissive for BUNV infection.  To investigate whether IFNβ 
has a similar effect on other viruses in the same genus as BUNV, Vero cells 
were infected with either GROV, LACV or rLACdelNSs virus at an MOI of 1 
pfu/cell.  The cells were labelled with [35S]-methionine for 1 hour at different 
times through 24 hours and then harvested for SDS-PAGE and autoradiography 
analysis.  Virus released into the growth medium was titrated by plaque assay. 
GROV is an orthobunyavirus first isolated in Colombia and thought to be 
responsible for a mild febrile illness in humans (Groot et al., 1959).  The NSs 
protein of GROV has a considerably shorter amino acid sequence and is 
truncated at both N and C termini, compared with other orthobunyaviruses 
(Elliott, 1996).  In untreated Vero cells infected with GROV, N protein synthesis 
was observed by 8 hours post infection and host-cell protein synthesis shut-off 
by 12 hours post infection (Fig 3.18A, -IFN).  At 24 hours, due to significant 
shut-off, most of the viral proteins were visible.  However, in IFNβ-treated cells, 
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viral proteins were indistinguishable from host cell proteins (Fig 3.18A, +IFN).  
Immunoprecipitation of the same samples using an anti-GRO antibody showed 
that in untreated cells GROV N protein synthesis was underway by 4 hours post 
infection and Gc protein synthesis by 8 hours (Fig 3.18B, -IFN).  After pre-
treatment of cells with IFNβ, GROV was still able to infect and synthesise viral 
proteins, albeit with greatly reduced levels of viral proteins produced (Fig 3.18B, 
+IFN).  This correlates with the viral titre in untreated cells which reached 
9.5x107 pfu/ml but was significantly reduced in treated cells and only reached 
5x105 pfu/ml (Fig 3.18C). 
LACV was first isolated in 1960 in the USA (Thompson et al., 1965).  It is an 
Orthobunyavirus responsible for La Crosse encephalitis and is one of the 
leading contributors to viral encephalitis in the USA (Schmaljohn, 2007).  IFNβ 
untreated cells infected with LACV showed strong host cell protein synthesis 
shut-off by 12 hours (Fig 3.19A, -IFN).  Synthesis of viral N protein was 
detected at 4 hours post infection, peaked at 8 hours, and decreased thereafter 
(Fig 3.19B, -IFN).  In IFNβ treated cells, there was no discernible viral protein 
synthesis or shut-off observed (Fig 3.19A, +IFN).  After immunoprecipitation 
with LACV anti-N antibody trace amounts of N protein was detected by 12 hours 
 3 The effect of type I IFN on Bunyamwera virus replication 
83 
 
post-infection (Fig 3.19B, +IFN), though much less protein was produced 
compared to the same time-point in the untreated cells (Fig 3.19B, compare –
IFN and +IFN).  Furthermore, cells infected with LACV and pre-treated with 
IFNβ produced infectious virus (4x104 pfu/ml) but the titre was 1000-fold lower, 
thus correlating with the other data presented here (FIG 3.19A and B).   
rLACdelNSs is a recombinant LACV that is unable to express the NSs protein 
and therefore cannot antagonise the IFN response as efficiently as LACV.  
Untreated cells infected with rLACdelNSs still showed some level of host cell 
protein synthesis shut-off, despite the lack of NSs protein, but not as much as 
the wild type virus, and in the pre-treated cells there was no observable shut-off 
or viral protein synthesis (Fig 3.20A).  Immunoprecipitation with LACV anti-N 
antibody showed that N protein synthesis was similar to that of the wild type 
virus, and from IFNβ treated and infected cells trace amounts of N protein were 
detected (Fig 3.20B).  Further, rLACdelNSs was severely restricted by IFNβ 
from producing infectious virus as the viral titre barely increased from 3x103 
pfu/ml and was 6000-fold lower than the titre from untreated cells (Fig 3.20C). 
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Discussion 
BUNV was able to plaque on all cell lines used in this report, and there are also 
other cell lines that are permissive to BUNV where infection results in viral 
plaque formation.  Van Knippenberg et al. (2010) showed that impairment of the 
innate immune response, especially the IFN response, in A549 cells results in 
BUNV producing larger plaques while the NSs deletion virus rBUNdelNSs is 
also able to plaque on the IFN incompetent cells.  Chapter Four shows that 
rBUNdelNSs grows to a higher titre in A549/BVDV/Npro and A549/PIV5/V cells, 
both of which have their IFN system impaired (Andrejeva et al., 2002; Hale et 
al., 2009; Hilton et al., 2006), compared to naïve cells (Fig 4.11A).  
Furthermore, the data described earlier (Fig 3.3) suggests that the innate 
immune response in A549 cells is more restrictive on BUNV as there was a 
100-fold difference in the BUNV to rBUNdelNSs titre (Fig 3.3C) compared with 
a 10-fold difference in BUNV to rBUNdelNSs titre in 2FTGH cells (Fig 3.3A).  
Also, when the IFN induction system was inhibited by the V protein in 
2FTGH/PIV5/V cells, the rBUNdelNSs titre was still 10-fold lower than BUNV, 
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while lack of IFN production, when using Vero cells, resulted in the titres of both 
viruses being similar. 
Therefore, these data effectively demonstrate the importance of the NSs protein 
in the fight against the IFN response and how fundamentally vital the IFN 
response is against BUNV infection.  However, as seen here, it is essential that 
the target cells are able to initiate the antiviral response as early as possible 
and enter into the antiviral state prior to infection as BUNV appears then to be 
completely restricted in viral functions.  If the cells are pre-treated with IFN, the 
virus is able to attach and enter the cell (preliminary data not shown) but is then 
unable to synthesise any RNA and consequently viral proteins and therefore 
cannot produce any virions.  On the other hand, if BUNV infection is already 
underway before IFN is applied there is little chance of the cell overcoming the 
virus.  The early expression of the viral NSs protein rapidly leads to inhibition of 
host cell protein synthesis and further exacerbates viral infection.  Interestingly 
though, synchronous treatment with IFNβ enabled partial restriction of BUNV 
replication by both enhancing positive-strand RNA synthesis and diminishing 
protein synthesis.  The increase in anti-genomic and mRNA did not result in an 
increase in genomic RNA, but the increase in mRNA appeared to result in a 
spike in viral protein synthesis which was followed by a decrease.  
Viral RNA synthesis requires the N protein and morphogenesis of infectious 
virus cannot occur without the Gc protein.  The early enhancement of Gc and N 
protein synthesis, as well as positive sense RNA, shows that the block is not 
initially at the primary transcriptional or the subsequent translational level, 
suggesting that Gc is sequestered and or degraded.  However, the early spike 
in Gc and N protein synthesis was followed by a considerable reduction, whilst 
the level of positive sense RNA remained elevated, suggesting translational 
inhibition of viral mRNA.  Therefore, it appears likely that one of the 
mechanisms of IFNβ induced BUNV inhibition is to enhance the synthesis (and 
or stability) of BUNV positive sense RNA. 
Analysis of Vero cells infected with either of two other orthobunyaviruses, 
GROV and LACV, showed some faint viral protein bands and slightly elevated 
titres after pre-treatment with IFNβ.  However, an MOI of 1 pfu/cell means that 
approximately 2/3 of the cells will be infected and therefore slight differences in 
cell number and or virus titre could result in the differences observed but at the 
same time a higher MOI allows the virus to overcome the IFN response.  It is 
possible that orthobunyaviruses express protein(s) that have the capability to 
disassemble the IFN response if given enough time.  The paramyxovirus PIV5 
has been shown to be able to dismantle the IFN response as the viral V protein 
targets STAT1 for degradation thus once STAT1 levels drop, the cells are 
unable to maintain the antiviral state thereby allowing the virus to undergo 
normal viral replication (Carlos et al., 2005; Carlos et al., 2009; Precious et al., 
2007).  Perhaps BUNV is able to infect cells and maintain a low, thus far 
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undetected, level of viral RNA and protein synthesis that eventually could 
overcome the antiviral state.  Since there is no evidence to suggest that BUNV 
virions are unable to attach and enter the cells in the antiviral state, it is feasible 
that BUNV could maintain a low level of replication in cells with a robust IFN 
response. 
The concentration of IFN had an impact on virus replication when used to 
induce the antiviral state.  Small doses of IFN such as less than 10 U/ml had no 
effect on either wild type or mutant virus tested here.  However, 100 U/ml was 
enough to impair both viruses, rBUNdelNSs more so than BUNV, but only when 
pre-treatment occurred 12 hours or more before infection.  Also, the restriction 
was observed in both A549 (competent IFN system) and Vero (unable to 
synthesise IFNα/β) cells, although a high MOI did enable detection of some viral 
N protein even from pre-treated cells.  Thus, the loss of NSs was one factor in 
virus inhibition but as the effect was similar for both BUN and rBUNdelNSs it 
suggests that there is another more significant factor, which could quite simply 
be that the antiviral state, once established, is too strong for BUNV to fully 
overcome unless the cells are saturated with virus.  This could be tested by 
investigating the effects of IFN on protein and RNA synthesis in cells infected 
over a long time period.  
Influenza A virus encodes a non structural protein termed NS1 which has been 
shown to be a multifunctional protein, though it was originally thought to be 
primarily an IFN antagonist.  The NS1 protein both limits IFNβ production and 
also limits the activity of the ISGs PKR and OAS.  Influenza A virus IFNβ 
induction is restricted by NS1 as it blocks the activation of IRF3 or the post-
transcriptional processing of cellular mRNAs (Kochs et al., 2007).  PKR is 
inhibited by NS1 binding to PKR and preventing the conformational change 
required for the activation of PKR by either dsRNA or PACT (Li et al., 2006b).  
Also, OAS antiviral activity is restricted as the NS1 RNA binding domain 
competes with OAS for dsRNA (Min & Krug, 2006).  The RVFV NSs protein is 
multifunctional as it inhibits host cell protein synthesis, is responsible for 
suppressing IFN induction, and targets PKR for proteasomal degradation 
(reviewed in Bouloy and Weber (2010)).  Thus it is likely that either BUNV NSs 
has more than one function in IFN antagonism or that another BUNV protein 
antagonises the IFN response.  This is further evidenced by the observation 
that there is some host cell protein shut-off in rBUNdelNSs infected cells, 
probably mediated by the endonuclease cap snatching activity of the 
polymerase protein.  Furthermore, many hantaviruses do not encode functional 
NSs proteins and therefore have other processes for counteracting the IFN 
response.  The non-pathogenic hantavirus Tula virus (TULV) has recently been 
shown to inhibit IFN induction via the cytoplasmic tail of the Gn glycoprotein 
interacting with TBK1 (Matthys et al., 2011).  The Gn tail of the pathogenic 
hantavirus NY-1 inhibits RIG-I- and TBK1-dependent IFNβ induction and Andes 
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virus (ANDV) restricts IFNβ induction by expression of the N protein and the 
glycoprotein precursor, whereas Sin Nombre virus (SNV) restricts IFNβ 
induction by expression of the glycoprotein precursor (GPC) alone (Alff et al., 
2008; Levine et al., 2010).  Furthermore the ANDV N or GPC and the SNV GPC 
are able to inhibit JAK/STAT signalling (Levine et al., 2010).   
Thus, viruses in the family Bunyaviridae express several proteins that have 
been shown to antagonise the IFN response and it is highly possible that the 
viral proteins of BUNV have more than one function and particularly may be 
involved in the viral antagonism of the innate immune response of the host cell. 
Summary 
This chapter shows: 
 BUNV is completely inhibited by pre-treatment of cells with IFNβ. 
 BUNV is unaffected by post-infection IFNβ treatment. 
 BUNV is partially restricted in cells synchronously infected with IFNβ 
treatment. 
 Positive-stranded RNA synthesis increased after synchronous IFNβ 
treatment. 
 Synchronous IFNβ treatment caused an initial spike in N and Gc protein 
synthesis followed by a drastic reduction of N and particularly Gc protein. 
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4 The rescue and characterisation of the 
GFP-tagged virus rBUNGceGFPdelNSs 
Introduction 
As described in Chapter One, the BUNV rescue system is now very efficient 
and it takes only a few days to recover infectious virus.  Briefly, the method is to 
transfect 106 BSR-T7/5 cells with 1.0 µg each of the plasmids pT7riboBUNL(+), 
pT7riboBUN(M+) and pT7riboBUN(S+), and then the cells are incubated for four 
days or until CPE is observed.  Thus, direct manipulation of the plasmids and 
introduction of specific mutations within the cDNA of the virus is possible prior to 
transfection.  The subsequent generation of engineered viruses permits study of 
the effects, both genotypically and phenotypically, of a mutation on the virus 
compared with the wild-type strain. 
Since the breakthrough of a reverse genetics system for the recovery of BUNV 
from cDNA in 1996 many mutant viruses have been engineered, most 
significantly the rBUNdelNSs virus (Bridgen et al., 2001).  In addition, the 
benefits of tagging viruses with GFP have been realised across virology.  One 
group successfully recovered a vaccinia virus that they had engineered to 
express the envelope glycoprotein BR5 fused to enhanced green fluorescent 
protein (eGFP) and were then able to track the intracellular movement of the 
virus in real-time (Ward & Moss, 2001).  Bosch et al. produced a chimeric 
mouse hepatitis coronavirus (MHV) that had GFP fused onto the end of the 
spike (S) protein which was then used to investigate coronaviral entry into cells 
(Bosch et al., 2004).  Thus, the advantages of creating a GFP tagged BUNV for 
tracking the infectious cycle were clear. 
Shi et al. (2006) used the reverse genetics system to attempt to generate 
recombinant viruses containing deletions in the NSm gene.  The study found 
that only viruses with deletions in domains II, III and IV of NSm could be 
rescued and that deletion of residues 377-426 had no effect on the efficiency of 
formation of virus like particles (VLPs) compared with wild-type NSm.  Thus, 
they proposed that the internal region of NSm may tolerate insertion of a foreign 
gene such as GFP.  They demonstrated that introduction of a foreign sequence 
at this point did not interfere with processing of the M segment precursor 
polyprotein or the function of NSm, and were able to rescue a recombinant virus 
containing the eGFP ORF fused to the NSm gene between residues 403 to 420 
called rBUNM-NSm-EGFP (Shi et al., 2006).  This work was taken further by 
engineering the NSs deletion virus rBUNdelNSs to have an eGFP tag fused to 
the NSm protein in the same way and the subsequent rescue of an infectious 
virus called rBUNM-NSm-EGFPDelNSs (Shi et al. unpublished). 
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In more recent work Shi et al. looked at the effects of deleting sections of the N 
terminus of the glycoprotein Gc (Shi et al., 2009).  Twelve cDNA clones were 
generated with deletions of the N terminus of Gc ranging in size from 50 to 600 
amino acid residues, and the authors were able to rescue four mutant viruses.  
The rescued viruses were attenuated but they still produced Gc protein that 
would traffic through the Golgi apparatus and achieve cell fusion.  Thus, they 
demonstrated that the N-terminal half of the Gc ectodomain is not required for 
virus replication.  Of the four rescued viruses, the virus with residues 480 to 826 
deleted was the least attenuated and thus chosen to have either eGFP or 
mCherry fluorescent protein inserted.  To achieve this, the amino acid residues 
from 501 to 826 of the glycoprotein precursor were replaced with either foreign 
gene in the pT7riboBUNM(+) plasmid by using a unique SacI restriction site that 
was inserted on the M segment at nt 2534 and a natural Bsu36I site that was 
found at nt 1549.  Both constructs yielded viable viruses by reverse genetics, 
although both viruses were attenuated in plaque size, growth kinetics and viral 
titre when compared with wild-type virus (Shi et al., 2010).  Due to the high 
number of Gc molecules per virion (approximately 650; Obijeski et al., 1976b) it 
was possible to see virus particles in clarified supernatant from cells infected 
with either of the tagged viruses under a fluorescence microscope.   
The Gc fluorescently tagged viruses have been shown to be invaluable tools in 
the study of BUNV entry, assembly, intracellular trafficking, egress and host cell 
interactions (Shi et al., 2010).  Furthermore, the NSm fluorescently tagged 
viruses have been useful in the study of virus assembly and morphogenesis 
(Shi et al., 2006).  All the aforementioned viruses are detectable when analysed 
under a fluorescence microscope, however, the viruses fluorescently tagged in 
the Gc protein produce significantly brighter and clearer signals. 
In order to further study the effects of IFN on the replication cycle of BUNV, 
cells which have been treated with IFN could be infected with any of the 
fluorescently tagged viruses and the observed GFP signal, or lack of, used as a 
marker of viral infection and inhibition.  The NSm GFP tagged viruses are a 
useful tool and can be used for such experiments as both the wild-type and the 
NSs deletion viruses have already been rescued.  However the signal from 
these viruses is less clear than rBUNGc-eGFP, but rBUNdelNSs with a Gc GFP 
tag has not been rescued.  Hence I describe here the creation of this 
recombinant virus. 
Rescue of rBUNGceGFPdelNSs virus 
BSR-T7/5 cells were transfected with 1.0 µg pT7riboBUNL(+), 1.0 µg 
pT7riboBUNN and 1.0 µg TVTM-∆7-E.  The pT7riboBUNL(+) plasmid 
expresses the viral polymerase and the pT7riboBUNN plasmid contains the 
mutant S segment which does not encode an NSs protein.  The TVTM-∆7-E 
plasmid encodes the NSm protein and the glycoproteins Gn and the truncated 
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Gc with eGFP fused to its N terminus.  CPE was observed 18 days post 
transfection and the cell supernatant used to plaque purify the virus using BHK-
21 cells.  The infected BHK-21 cells were incubated until green plaques were 
visible by fluorescence microscopy and individual plaques were picked for 
purification.  Amplification was initially in BHK-21 cells and produced many 
green cells, but a low and impractical titre of 1x105 or less.  Thus Vero cells 
were used for amplification and produced a better yield and a workable titre of 
106 pfu/ml. 
Virus growth in Vero cells 
Initially the growth kinetics of the rescued virus rBUNGceGFPdelNSs (GFPdel) 
were investigated by multistep virus yield assay in comparison with 
rBUNdelNSs.  As GFPdel appeared to be less able to grow in BHK-21 cells 
than in Vero cells, many of the subsequent experiments were carried out using 
Vero cells.  Cells were infected with either rBUNdelNSs or GFPdel at an MOI of 
0.01 pfu/cell and at various times virus released into the growth medium was 
collected and titrated by plaque assay.  The rBUNdelNSs virus-infected cells 
released virus that was detected at 12 hours post infection and virus production 
and release increased throughout the course of the experiment (Fig 4.1).  
However, the GFPdel virus was undetectable for the first 24 hours post infection 
but did show an overall increase in titre over 72 hours and was significantly 
attenuated in comparison with rBUNdelNSs (Fig 4.1). 
To confirm that GFPdel was expressing GFP and that it was detectable under 
the fluorescence microscope, Vero cells were infected with GFPdel at an MOI of 
0.01 pfu/cell and images were taken of the in vivo  infection at different times 
over 72 hours (Fig 4.2).  At 12 hours post infection there were few green cells 
which were difficult to find, but at 24 hours post infection  GFP expression had 
increased and there  were many clearly observable green cells.  After 24 hours 
the number of cells expressing GFP increased until 72 hours post infection 
when all the cells were infected and green.  This correlates with the increase in 
titre seen in figure 4.1.  
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GFPdel protein expression 
To analyse expression of viral proteins Vero cells were infected at an MOI of 1 
pfu/cell with rBUNdelNSs or GFPdel and labelled with [35S]-methionine for one 
hour at different times.  Cell lysates were analysed by SDS-PAGE followed by 
autoradiography (Fig 4.3).  Cells infected with rBUNdelNSs showed an increase 
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in expression of L, Gc and N proteins up to 16 hours post infection, but then 
expression was reduced thereafter.  In contrast, infection with GFPdel showed 
significantly reduced expression of L, Gc and N proteins, so that it was difficult 
to discern viral proteins from cellular proteins except for the N protein; which 
peaked expression by 12 hours post infection and reduced afterwards.  Despite 
the lack of NSs there was a small degree of host protein synthesis shut-off in 
rBUNdelNSs infected cells, however shut-off was imperceptible in GFPdel 
infected cells. 
To enable a clearer understanding of the viral protein expression pattern of 
GFPdel the labelled cell lysate was immunoprecipitated with the anti-BUN 
antibody and analysed by SDS-PAGE followed by autoradiography (Fig 4.4).   
Fig 4.4 shows that infection with rBUNdelNSs yields detectable N, Gc and L 
protein 4 hours post infection.  The levels of N and Gc protein expression 
peaked at 12 hours post infection and then remained constant until a slight 
reduction at 24 hours post infection.  The L protein expression peaked at 16 
hours post infection and decreased thereafter.  Viral protein synthesis after 
infection with GFPdel was much clearer via immunoprecipitation.  The N and 
chimeric Gc (which is smaller than wild-type Gc) protein levels peaked at 12 
hours post infection and the L protein level peaked at 16 hours post infection 
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(Fig 4.4).  After the expression of each of these viral proteins had peaked the 
expression level then decreased considerably.  To further show the GFPdel 
virus is following a similar replication cycle as rBUNdelNSs only more slowly 
and thus is attenuated, Western blot analysis was used to detect the viral N 
protein (Fig 4.5).  In rBUNdelNSs infected cells N protein was detected at 8 
hours post infection and the level increased up to 12 hours after which it 
remained constant.  In GFPdel infected cells, N protein was first detectable at 
12 hours and increased in accumulation up to 16 hours and remained constant 
thereafter.  Additionally, Western blot analysis for tubulin was carried out using 
the same lysate as was used for the protein expression, immunoprecipitation 
and Western blot experiments and thus acted as a loading control for all three 
experiments.  
RNA analysis of GFPdel 
The initial reason for the construction and rescue of GFPdel virus was for use 
as a tool for screening cell lines for their anti-BUNV effects.  As any potential 
anti-BUNV effects observed could be attributed to an alteration in transcription, 
the RNA profile of GFPdel was examined, with rBUNdelNSs for comparison.  To 
examine the synthesis of viral genome, anti-genome and mRNA by 
rBUNdelNSs and GFPdel viruses, Vero cells were infected at an MOI of 1 
pfu/cell, lysed for RNA extraction at different times after infection, and the RNA 
was analysed by Northern blot analysis.  The S, M and L segment genomic 
RNAs for rBUNdelNSs were just detectable at 4 hours post infection and the 
intensity of the S segment increased throughout the time course whereas the M 
and L segment intensity increased up to 20 hours and then decreased slightly 
(Fig 4.6).  There was an unexplained extra band between the S and M 
segments that has the size of a double-sized S segment, which has been 
observed previously in some BUNV preparations (R.M.Elliott, personal 
communication).  However, it was not confirmed here as being S segment 
specific as the blots were carried out using all three segment probes together.  
The levels of S, M and L genomic RNA of the GFPdel virus were considerably 
lower than for rBUNdelNSs.  The migration of the M segment corresponded with 
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the replacement of 361 amino acids of Gc with the 238 amino acids of eGFP, a 
net loss of approximately 400 nucleotides.  GFPdel virus replication also 
appeared to be slower than rBUNdelNSs as S segment RNA was barely 
detectable at 4 hours post infection and M and L segment RNAs were not 
detected until 12 hours post infection.  Further blots were analysed using 
probes to detect anti-genomic RNA and mRNA (Fig 4.7) and showed that there 
was a strong signal for the S segment anti-genomic RNA and mRNA at 4 hours 
post infection with rBUNdelNSs, which increased through time points 8 and 12 
and then remained fairly constant.  The same pattern was seen for the M 
segment anti-genome and mRNA although it was not detectable until 8 hours 
post infection, whereas the L segment was not detected.  Due to the small 
differences in size between the L and M segment anti-genomes and their 
respective mRNAs they are not resolved by electrophoresis.  However, there is 
a difference in size between the S segment anti-genome and the significantly 
shorter mRNA (961 nt versus approximately 850 nt respectively), which is 
visible by the broadness of the S segment band in Fig 4.7.  As was seen with 
the genomic RNA, the level of anti-genomic RNA and mRNA from GFPdel 
infected cells was lower than that of rBUNdelNSs infected cells (Fig 4.7) and 
the GFPdel M segment migrated further.  The replication of GFPdel was shown 
to be slower than rBUNdelNSs as S segment anti-genome and mRNA were 
barely detectable at 4 hours post infection, and M and L segment anti-genome 
and mRNA were not detectable until 12 hours post infection.  
Further to above, the rescued GFPdel virus was also intended for studying the 
course of infection over 72 hours.  To check the stability of GFP in the GFPdel 
virus the replication cycle was investigated over 72 hours.  Vero cells were 
infected at an MOI of 0.01 pfu/cell with either rBUNdelNSs or GFPdel and 
labelled with [35S]-methionine for one hour at different times after infection.  To 
enable a clear protein expression profile the cell lysate was immunoprecipitated 
with anti-BUN antibody and then analysed by SDS-PAGE and autoradiography.  
It was clear that protein expression with rBUNdelNSs peaked around 36 hours 
post infection, after which the expression declined and there was much CPE 
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and cell death, which is characteristic of infection with rBUNdelNSs (Fig 4.8).  
GFPdel infected cells expressed L, Gc and N proteins by 12 hours post 
infection and the detected levels peaked at 48 hours and then reduced.  
However, by 48 hours another smaller band was observed which corresponds 
to the size of the truncated Gc protein minus the GFP tag and, less Gc-eGFP 
chimeric protein was synthesised at 72 hours compared to truncated Gc.  CPE 
and cell death were not as marked as cells infected with rBUNdelNSs.  Western 
blot analysis to detect N protein accumulation further showed that the pattern 
was the same for both viruses except that GFPdel accumulated less N protein 
than rBUNdelNSs (Fig 4.9).  The tubulin controls confirm that the same amount 
of protein was loaded into each well for both the labelling experiments and 
Western blot analysis.    
Growth in A549, A549/PIV5/V and A549/BVDV/NPro cells 
The attenuation of GFPdel in BHK-21 and Vero cells resulted in a low titre of 
106 pfu/ml.  Although this titre is useable, it had been found that amplifying 
viruses in A549/PIV5/V cells yielded a higher titre.  This is because 
A549/PIV5/V cells have been transduced to express the PIV5 V protein which 
blocks IFN signalling by targeting STAT1 for degradation (Andrejeva et al., 
2002; Hilton et al., 2006).  Another A549 cell line derivative is the 
A549/BVDV/NPro cells which have been transduced to express the BVDV NPro 
protease which blocks IFN induction by blocking IRF3 transport into the nucleus 
by targeting it for degradation (Hale et al., 2009; Hilton et al., 2006).  
 4 The rescue and characterisation of the GFP-tagged virus rBUNGceGFPdelNSs 
96 
 
A549/BVDV/NPro cells are more efficient at blocking IFN production than 
A549/PIV5/V cells and thus it was thought that they would be the most suitable 
host for amplification of the GFPdel virus.  Multi-step growth cycles of 
rBUNdelNSs and GFPdel were investigated and compared in these three cell 
lines.  The cells were infected at an MOI of 0.01 pfu/cell and the virus released 
into the growth medium was collected at different times after infection and 
titrated by plaque assay.  In A549 cells the rBUNdelNSs titre increased by a 
factor of ten between 12 and 24 hours post infection and then remained 
constant up to 72 hours post infection.  However infection in A549/PIV5/V and 
A549/BVDV/NPro cells yielded higher peak titres of 1.53x107 pfu/ml and 
4.75x106 pfu/ml respectively (Fig 4.10).  In contrast, the GFPdel virus did not 
grow efficiently in A549 cells, and only reached a peak titre of 3.75x103 pfu/ml in 
A549/BVDV/NPro cells.  However, when grown in A549/PIV5/V cells the titre 
increased steadily over 72 hours up to 4x106 pfu/ml (Fig 4.10). 
In parallel with the virus yield assays above, each of the three cell lines were 
infected with either rBUNdelNSs or GFPdel and lysed at different times and 
analysed by Western blotting (Fig 4.11).  Fig 4.11 confirms that both viruses are 
unable to synthesise detectable levels of N protein in A549 cells.  However, 
rBUNdelNSs was able to synthesise N protein in both the A549/PIV5/V and 
A549/BVDV/NPro cell lines, whereas GFPdel was also unable to synthesise 
detectable levels of N protein in A549/BVDV/NPro, although was able to in 
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A549/PIV5/V cells.  Thus, N protein synthesis of both viruses in the three cell 
lines corresponds with the titre of the virus released into the growth medium.  
Based on these results, GFPdel was amplified in A549/PIV5/V cells.  
A549/PIV5/V cells were also infected with GFPdel at an MOI of 0.01 pfu/cell for 
analysis by fluorescence microscopy.  Green cells were visible after 12 hours 
(Fig 4.12) and their number increased up to and peaked at 48 hours.  However, 
at 72 hours there appeared to be less attached cells.   
Discussion 
The aim for this work was to rescue the GFPdel virus and then to characterise it 
to ensure that it would be a useful tool for screening cell lines for their anti-
BUNV properties.  The typical rescue of rBUNV takes approximately four days 
to yield a titre of around 108 pfu/ml, however, the rescue of GFPdel required 18 
days and yielded a low viral titre.  Furthermore, amplification of GFPdel was 
inefficient in both BHK-21 and Vero cells, which was unexpected as these cell 
lines are usually very permissive to bunyavirus infection, replication and 
subsequent amplification of virus.  The GFPdel virus was not expected to 
replicate in A549 cells as they are fully immunologically functional and this virus 
is incapable of synthesising the IFN antagonistic NSs protein.  However, it was 
expected to replicate in both A549 cell line derivatives, A549/PIV5/V and 
A549/BVDV/NPro cells, since these cells express the IFN antagonists the PIV5 
V protein and the BVDV NPro protein respectively.  In the A549/PIV5/V cells 
GFPdel grew to a 100-fold higher titre than when grown in Vero cells and, 
surprisingly, a 1000-fold higher titre than in A549/BVDV/NPro cells.  As all three 
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cell lines have their IFN system inhibited a high viral titre in each was expected.  
This result implies the innate immune response in Vero and A549/BVDV/NPro 
cells is sufficient to inhibit the GFPdel virus, whereas the A549/PIV5/V cells are 
not.  This may be because the BVDV/NPro protein blocks IRF3 and thus the 
synthesis of IFN beta via IRF3-induced gene transcription.  This does however 
still allow the synthesis of IFN beta via NFκB and thus the antiviral response, 
whereas the PIV5/V protein blocks IFN signalling and efficiently blocks the 
antiviral response after the synthesis of IFN and GFPdel virus is able to 
replicate more easily in the A549/PIV5/V cells.  Vero cells are unable to 
synthesise type I IFN but can produce other types of IFN which can mount the 
antiviral response.  Additionally, the NSs protein has a role in regulation of the 
viral polymerase protein such that rBUNdelNSs produces more N protein than 
wt BUNV, which also leads to an earlier onset of apoptosis.  However, the 
double mutation (no NSs and partial deletion of Gc) in GFPdel is further and 
more severely attenuated compared with rBUNdelNSs.  Tracking viral infection 
by immunofluorescence of the expressed GFP tag shows that GFPdel produces 
a viable and sustained infection in both Vero and A549/PIV5/V cells and also 
does not cause the extensive CPE that would be seen in rBUNdelNSs infected 
cells. 
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Over the first 24 hours of infection, GFPdel synthesised lower levels of viral 
proteins but these were easily detectable and followed the same expression 
pattern as that of rBUNdelNSs.  However, the GFPdel genomic M segment 
migrated further than rBUNdelNSs M and there was a difference between the 
genomic RNA expression ratio L:M:S when compared with rBUNdelNSs as the 
GFPdel M segment band was weaker, showing reduced replication of the M 
segment.  Additionally, GFPdel did not cause as much CPE as rBUNdelNSs 
because the virus is even more attenuated and was not synthesising viral 
proteins as rapidly or replicating in and infecting as many cells as rBUNdelNSs.  
Over the time period of 72 hours GFPdel protein expression had a similar 
pattern to rBUNdelNSs except that the peak level of L, Gc and N protein 
expression was at 48 hours for GFPdel but 36 hours for rBUNdelNSs, and the 
overall protein expression and CPE was significantly lower in GFPdel infected 
cells.  Furthermore, after 36 hours the virus began to lose the GFP tag fused to 
the Gc protein (Fig 4.8) and the appearance of a smaller protein band at 48 
hours corresponded with the size of the truncated Gc protein without GFP.  This 
could show a problem with translation or it may be due to misfolding of the Gc-
eGFP glycoprotein and the resulting slow maturation of the chimeric 
glycoprotein occurring post-translationally during protein processing.  Shi et al. 
(2010) showed that rBUNGc-eGFP started to lose the GFP tag after six 
passages but when the GFP in rBUNGc-eGFP was replaced by mCherry, the 
tag sequence was maintained for at least 10 passages.  Therefore it is possible 
that the loss of GFP from GFPdel could be at a nucleotide level which would be 
seen by sequencing the M segment and Northern blotting.  Additionally, the 
A549/PIV5/V cells infected with GFPdel showed a reduction in green cells from 
48 to 72 hours which could be due to the loss or the degradation of the chimeric 
Gc-eGFP glycoprotein or apoptosis.  Although this was not seen in infected 
Vero cells but GFPdel is more attenuated in Vero cells than A549/PIV5/V cells.  
Thus, despite increased attenuation, GFPdel can still be used to follow the 
course of infection over 24 and 72 hours, although the fluorescence of GFP 
may decrease after 36 hours due to either the virus losing the GFP tag or to 
inhibition of the virus or both.  The loss of the GFP tag does make it difficult to 
assess BUNV inhibition by monitoring changes in GFP levels after 36 hours 
post infection.    Therefore this virus is a useful and reliable tool for tracking the 
course of a BUNV infection and thus for screening cell lines for their anti-BUNV 
characteristics over 24 hours but not 72 hours. 
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Summary  
This chapter shows: 
 The rescue of GFPdel. 
 The GFPdel virus is stable over 24 hours but starts to lose the GFP tag 
36 hours after infection. 
 The A549/PIV5/V cell line is the most permissive to GFPdel infection. 
 This GFPdel virus is a useful indicator of infections over 24 hours. 
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5 Screening of ISG inducible cell lines for 
Bunyamwera virus replication 
Introduction 
Chapter One described the induction of IFN and how it results in the 
upregulation of several hundred ISGs and the subsequent synthesis of antiviral 
proteins.  This chapter concentrates on the antiviral proteins expressed from 
ISGs.  The first part of this chapter describes the effects of over-expressing 
particular ISGs on BUNV replication as detected by the highly sensitive plaque 
assay protocol and further by the less sensitive Western blot analysis of N 
protein accumulation.  The second part of the chapter uses imaging techniques 
to study anti-BUNV properties of cells that over-express different ISGs and the 
potential of an image based screening protocol for rapid assessment of BUNV 
inhibition.  The immunofluorescence technique is less sensitive than viral 
plaque formation assay so it can be compared with the plaque assay and 
Western blot data to establish the overall effectiveness of the technique for 
screening.  
Transfection of cells with ISG cDNA expressing plasmids or siRNA to 
knockdown ISG mRNA does not ensure that all of the target cell population 
expresses the transgenic cDNA or has its ISG mRNA targeted, thus the 
experimental data collected from such experiments may not be clear cut.  There 
are over 300 antiviral proteins produced from ISGs, and the individual 
knockdown of one of them may be compensated for by one or many of the 
other ISGs and antiviral proteins synthesised.  Therefore, engineering a cell line 
to over-express an ISG protein when induced averts these problems.  Jiang et 
al. (2008) used the human embryonic kidney (HEK293)-derived cell line FLP-IN 
T REx (Invitrogen) to engineer cells that were able to over-express FLAG 
tagged individual ISG proteins when induced by tetracycline (Tet).  The FLP-IN 
T REX cell line contains stable integrations of a single flippase (FLP) 
recombination target (FRT) site, thus, when Jiang et al. cotransfected these 
cells with a plasmid (pcDNA5/FRT/ISG) that contains a FRT site and encodes 
an ISG along with a plasmid (pOG44) that expresses the recombinase Flp IN, 
the ISG cDNA was integrated into the cellular genome through the FRT site with 
its expression under the control of the TET-on promoter (Fig 5.1).  This method 
was used to create 29 cell lines (kindly donated by Ju-Tao Guo, Drexel 
University College of Medicine, USA); 26 that over-express an individual ISG 
protein, 2 that over-express a mutant ISG protein, and one that over-expresses 
the chloramphenicol acetyl transferase (CAT) protein without a FLAG tag.  
Using these ISG over-expressing cells, the following section investigates the 
effects of various ISGs on BUNV and rBUNdelNSs replication and further tests 
the competency of three GFP-tagged viruses for screening these cell lines for 
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their anti-BUNV characteristics.  Chapter Four described the three GFP-tagged 
viruses rBUNGc-eGFP, rBUNM-NSm-EGFP (BUNGFP) and rBUNM-NSm-
EGFPDelNSs (NSmGFPdel) in detail.  The practicalities of performing the 
experiments presented below proved more difficult than expected as the HEK 
ISG cells adhered loosely to tissue culture plate wells and cover slips thus 
requiring alterations to standard protocols and extra care throughout.  Some of 
the cells were extremely sensitive, in culture, particularly requiring high quality 
cell maintenance.  There are over 300 ISGs and many are barely understood, 
although most used in this study have a known function in innate immunity. 
Growth kinetics and N protein synthesis in HEK ISG cells 
To induce expression of the ISG in each of the HEK293 ISG expressing cell 
lines (hereon after the inducible ISG cell line will have the ISG incorporated into 
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the cell line name e.g. the PKR inducible cell line will be called HEK PKR) the 
cells were incubated with 1 µg/ml of Tet for 48 hours prior to infection.  The cells 
were then infected with BUNV or rBUNdelNSs at an MOI of 0.01 pfu/ml after 
which the virus released into the medium at various time points was titrated by 
plaque assay.  Furthermore, duplicate wells were set up and infected with either 
rBUNGc-eGFP or BUNGFP or NSmGFPdel viruses at an MOI of 1 pfu/ml and 
lysed 24 hours post infection for Western blot analysis for the ISG, N and 
tubulin proteins.  The data collected for each cell line are presented below. 
Negative control 
The first cell line tested was the HEK CAT cells which were used as a negative 
control.  Infection of both the uninduced and the induced cells with either BUNV 
or rBUNdelNSs showed no change in the viral yield (Fig 5.2A and 5.2B) or the 
amount of N protein synthesised (Fig 5.2C).  In this cell line the CAT gene has 
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not been replaced with an ISG thus there is no induced FLAG-tagged protein to 
detect.     
To investigate whether the GFP-tagged viruses would give accurate reflections 
of the growth kinetics of BUNV and rBUNdelNSs the two cell lines HEK 38348 
and HEK PKR cells were selected to be tested with the two NSm GFP-tagged 
viruses BUNGFP and NSmGFPdel.   
FLJ38348 
FLJ38348 is also known as coiled-coil domain containing 75 (CCDC75) protein 
and is 30 kDa in size (Rani et al., 2007).  The function of this protein is unknown 
but it is induced by IFN (Jiang et al., 2008).  FLJ38348 protein contains a short 
conserved region (~40 amino acids) called a G-patch domain which also occurs 
in some putative RNA-binding proteins; therefore its function may involve 
binding to RNA.  The induced HEK 38348 cells infected with BUNV and 
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BUNGFP virus showed no change in viral yield compared with the uninduced 
cells (Fig 5.3A).  When infected with rBUNdelNSs or NSmGFPdel the induced 
cells yielded the same amount of virus as the uninduced cells (Fig 5.3B).  
Although the yield of virus from BUNGFP infected cells was nearly 100-fold 
lower than BUNV infected cells and the cells infected with NSmGFPdel yielded 
over 100-fold lower virus than those infected with rBUNdelNSs.  This was 
predicted as, based on previous work, the GFP-tagged viruses are known to be 
attenuated.  The amount of N protein synthesised by the three tagged viruses 
was the same in uninduced and induced cells (Fig 5.3C). 
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PKR 
PKR, described in Chapter One, is activated by dsRNA which results in its 
autophosphorylation, and phosphorylated PKR phosphorylates eIF2α and this 
in turn blocks cell protein synthesis (Garcia et al., 2006).  Compared with 
uninduced cells, induced HEK PKR cells infected with BUNV showed a ten-fold 
reduction in virus yield in the first 24 hours and this reduction further increased 
through the rest of the 72 hour infection period (Fig 5.4A).  A similar trend was 
observed for the induced cells infected with BUNGFP although the degree of 
inhibition was larger (Fig 5.4A).  After infection with rBUNdelNSs the induced 
HEK PKR cells showed greater restriction on virus yield in the first 36 hours 
post infection but by 72 hours this was reversed and induced PKR appeared to 
enhance the yield of virus (Fig 5.4B).  The level of inhibition on viral yield 
observed in the induced cells infected with NSmGFPdel peaked at 36 hours and 
reduced thereafter (Fig 5.4B).  Western blot analysis showed a significant 
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reduction in the amount of N protein produced in induced cells (Fig 5.4C lanes 
4, 6 and 8) compared with uninduced cells (Fig 5.4C lanes 3, 5 and 7) infected 
with any of the three GFP-tagged viruses.  Additionally the intensity of the N 
protein band for each virus in the uninduced cells was similar (Fig 5.4C lanes 3, 
5 and 7).  Thus the Western blot data correlates with the lower viral yield 
observed in the induced HEK PKR cells. 
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HEK PKRM cells over-express a mutant form of PKR that has the conserved 
lysine residue in the ATP binding pocket replaced with an arginine residue, 
yielding a dominant negative PKR unable to carry out its protein kinase activity 
(Jiang et al., 2008).  When HEK PKRM cells were induced and infected with 
BUNV there was no difference in viral yield compared with uninduced cells (Fig 
5.5A).  Furthermore when induced HEK PKRM cells were infected with 
rBUNdelNSs there was no significant variation in viral yield (Fig 5.5B).  Western 
blot analysis of N protein confirmed no change in the amount of N produced in 
either uninduced or induced cells for all three viruses (Fig 5.5C).  Thus, there 
was no effect on the viral yield in the presence of dominant negative PKR in the 
induced HEK PKRM cells.  
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ISG56 
ISG56 is also known as interferon-induced protein with tetratricopeptide repeats 
1 (IFIT1) and is a 55.3 kDa protein that inhibits the ability of the eIF3e subunit, 
of the eIF3 complex, to stabilise the eIF2-GTP-tRNAiMet complex thereby 
inhibiting translation (Fensterl & Sen, 2011).  Additionally ISG56 contains 
multiple tetratricopeptide motifs which are able to form scaffolds between 
tandem tetratricopeptide repeats and mediate protein-protein interactions (Lamb 
et al., 1995).  When the induced HEK ISG56 cells were infected with BUNV 
there was little change in the viral yield compared with uninduced cells (Fig 
5.6A), but induced cells infected with rBUNdelNSs showed more variation in 
viral yield (Fig 5.6B).  Western blot analysis showed no difference in the 
amount of N protein between infected uninduced or induced cells (data not 
shown). 
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PLSCR1 and PLSCR2 
Scramblase enzymes are involved in the translocation of phospholipids 
between the lipid bilayer of the cell membrane and are activated by an increase 
in cytosolic calcium which results in the redistribution of phospholipids (Sahu et 
al., 2007).  Phospholipid scramblase 1 (PLSCR1) is highly induced by type I 
and II IFNs and also by various growth factors and is thought to play a role in 
the upregulation of the IFN response and subsequently induced antiviral 
proteins.  Knockdown of PLSCR1 in human cells by siRNA rendered the cells 
more susceptible to VSV infection and yielded higher titres (Dong et al., 2004).  
Furthermore PLSCR1 requires palmitoylation in order to be inserted into the 
membrane and when this does not occur, PLSCR1 is relocated to the nucleus 
where it binds to DNA and ultimately leads to enhanced expression of several 
antiviral ISGs (Dong et al., 2004).  Over the course of 72 hours the HEK 
PLSCR1 induced cells infected with BUNV showed no change in the viral yield 
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compared with the uninduced cells (Fig 5.7A).  Similarly, when infected with 
rBUNdelNSs there was little variation in viral yield (Fig 5.7B).  Furthermore, the 
Western blot showed no change in the accumulation of N protein from any of 
the three GFP viruses (Fig 5.7C).  The PLSCR1 related isoform PLSCR2 plays 
a role in the bidirectional transbilayer migration of phospholipids leading to the 
loss of asymmetry of the phospholipids of the plasma membrane. The induced 
HEK PLSCR2 cells infected with BUNV resulted in no significant change in viral 
yield (Fig 5.8A), which was also observed for the induced cells infected with 
rBUNdelNSs (Fig 5.8B). 
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ADAR1 
Members of the adenosine deaminase class of enzymes function to edit RNA 
by deaminating adenosine residues within double-stranded RNA thus 
generating inosine residues (Samuel, 2011).  One of the consequences of this 
enzymatic activity is the introduction of mutations into viral RNA genomes.  The 
136 kDa Adenosine Deaminase Acting on RNA (ADAR) 1 protein is upregulated 
by IFN, is located in the cytoplasm and is responsible for hypermutation of viral 
RNA (Gelinas et al., 2011).  The HEK ADAR1 cells infected with BUNV showed 
no significant reduction in BUNV yield between uninduced and induced cells 
throughout 72 hours (Fig 5.9A).  Infection with rBUNdelNSs also showed no 
change in yield between the cells throughout (Fig 5.9B), and Western blot 
analysis detected no alteration in the amount of N protein produced from any of 
the three GFP-tagged viruses (Fig 5.9C). 
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MTAP44 
MTAP44 is also known as IFN-induced protein 44 (IFI44) and is part of the IFI 
superfamily (Hallen et al., 2007).  MTAP44 is a 50 kDa protein comprising 444 
amino acids, and it aggregates to form microtubular structures.  The induced 
HEK MTAP44 cells infected with BUNV showed a reduced viral yield from 12 
hours through to 72 hours with an 18-fold reduction at 36 hours lowering to a 6-
fold reduction by 72 hours (Fig 5.10A).  However, the induced cells infected 
with rBUNdelNSs virus showed no inhibition in yield until 36 hours post infection 
which showed a 4-fold reduction which further increased to a 12-fold reduction 
by 72 hours (Fig 5.10B).  Western blot analysis detected no change in the 
amount of N protein produced by any of the three GFP-tagged viruses (Fig 
5.10C).  The FLAG-tagged MTAP44 itself was difficult to detect using Western 
blotting techniques but was shown to be inducible with Tet pre-treatment (Fig 
5.10, lane 2).  Therefore the system of MTAP44 induction by Tet was reliable 
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and could be used to test MTAP44 for inhibitory effects on BUNV via virus yield 
assays but the detection of MTAP44 by Western blot was not reliable. 
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BST2 
BST2 also known as tetherin, is a 19.7 kDa type II transmembrane glycoprotein 
that has been shown to restrict the release of virions from cells by forming a 
proteinacious link that tethers the virion to the surface of the cell (Kaletsky et al., 
2009; Neil et al., 2007; Yondola et al., 2011).  The induced HEK BST2 cells 
infected with BUNV showed a five-fold reduction in viral yield by 48 hours 
compared with uninduced cells (Fig 5.11A).  There was also a reduction in viral 
yield from induced HEK BST2 cells infected with rBUNdelNSs virus, compared 
with uninduced cells, observed to be nearly ten-fold by 36 and 48 hours post 
infection (Fig 5.11B).  The Western blot for N protein showed that the amount of 
N was unchanged between uninduced and induced cells for each of the three 
GFP-tagged viruses (Fig 5.11C).  
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Ubiquitination 
STAF50 is also known as TRIM22 and is a 57 kDa protein located in the 
nucleus but can localise to the cytoplasm (Kajaste-Rudnitski et al., 2010).  It 
may function as an E3 ubiquitin ligase and is also able to ubiquitinate proteins in 
a TRIM22-dependent manner.  HIV-1 transcription is restricted by STAF50 
which also targets the Gag protein by disrupting its trafficking to the cell surface 
(Barr et al., 2008).  The induced HEK STAF50 cells infected with BUNV or 
rBUNdelNSs produced a similar yield of virus compared with uninduced cells 
throughout the 72 hours (Fig 5.12A and 5.12B respectively).  The amount of N 
protein produced by the NSs deletion virus (lane 7 and 8) was significantly less 
than the two GFP-tagged BUNV viruses (lanes 3, 4, 5 and 6) although when 
comparing each virus in the uninduced and induced cells there was little 
difference (Fig 5.12C). 
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ISGylation 
ISG15 
ISG15 was described in more detail in Chapter One; it is strongly induced by 
IFN and is one of the first and most abundantly expressed proteins, and a key 
component of ISGylation (Zhang & Zhang, 2011).  During ISGylation ISG15 is 
conjugated onto lysines of target proteins by its C-terminal sequence LRLRGG.  
Like ubiquitination this involves several enzymatic proteins homologous to the 
ubiquitin enzymes E1, E2, and E3.   Figure 5.13A shows the viral yield from 
HEK ISG15 cells infected with BUNV and there was little difference until 36 and 
48 hours post infection when there was a 5- and 6- fold reduction respectively.  
A similar slight reduction in viral yield was also apparent in rBUNdelNSs 
infected HEK ISG15 cells (Fig 5.13B).  Western blot analysis of the uninduced 
and induced cells to detect FLAG-tagged ISG15 using two different anti-FLAG 
antibodies did not detect any protein.  However, Western blot analysis using an 
anti-ISG15 antibody did detect FLAG-tagged ISG15 (Fig 5.13C).  Thus, this 
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suggested that the FLAG-tag on ISG15 was not available for binding, but did 
confirm induction of FLAG-tagged ISG15 by Tet treatment.  
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UBE2L6 
The UBE2L6, also known as ubcH8, protein is a 17.8 kDa protein which is a 
member of the E2 ubiquitin-conjugating enzyme family that is part of the 
ISGylation pathway (Zhao et al., 2004).  UBE2L6 is responsible for conjugation 
of ISG15 to target proteins.  The HEK UBE2L6 cells infected with BUNV (Fig 
5.14A) or rBUNdelNSs (Fig 5.14B) showed little difference in viral yield when 
either uninduced or induced.  This was further corroborated by Western blot 
analysis which showed no change in the amount of N protein from GFP-tagged 
virus infected uninduced and induced cells (Fig 5.14C).  However, there was 
less N protein in the NSs deletion virus infected cells (lanes 7 and 8) compared 
with the GFP-tagged BUN virus infected cells (lanes 3, 4, 5, and 6), suggesting 
some further attenuation. 
 5 Screening of ISG inducible cell lines for Bunyamwera virus replication 
120 
 
FLJ20637 
FLJ20637 is also called HerC6 and is a putative E3 ubiquitin protein ligase that 
directly transfers ubiquitin from a thioester (E2) to the substrate (ubiquitination 
target) (Hochrainer et al., 2005).  FLJ20637 was thought to be involved in 
ISGylation as it shares 49% identity with HerC5 which has ISG15 E3 ligase 
activity (Dastur et al., 2006; Versteeg et al., 2010).  A study using siRNA to 
knockdown FLJ20637 showed little effect on overall ISG15 conjugation but did 
suggest a role in targeting a small set of proteins compared with Herc5 (Dastur 
et al., 2006).  However, recent studies have shown the mouse homologue to 
FLJ20637, mHerc6, to be an ISG15 E3 ligase (Versteeg et al., 2010).  Both the 
uninduced and the induced HEK 20637 cells were infected with either BUNGc-
eGFP or BUNGFP or NSmGFPdel virus and the amount of N protein after 24 
hours was detected by Western blotting (Fig 5.15).  The amount of N protein 
synthesised did not change between uninduced and induced cells (compare 
lanes 3 with 4, and 5 with 6, and 7 with 8), however comparing the amount of N 
protein synthesised by each virus shows a reduction in BUNGc-eGFP infected 
cells compared with the NSmGFP-tagged viruses (compare lanes 3 and 4 with 
lanes 5, 6, 7, and 8).  As with some previous cell lines the FLAG-tagged ISG 
was difficult to detect, thus the bands showed different intensities but are 
thought to represent equal induction. 
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USP18 
USP18, also known as UBP43, is a 43 kDa protein also involved in ISGylation 
(Malakhov et al., 2002).  This protein is a member of the de-ubiquitinating 
proteases and is able to efficiently cleave ISG15 fusions.  Thus USP18 is 
involved in reversing the process of ISGylation (termed de-ISGylation) and is 
vital for maintaining a balance of ISG15 conjugated proteins within a cell.  The 
HEK USP18 induced cells infected with either BUNV (Fig 5.16A) or 
rBUNdelNSs (Fig 5.16B) showed little change in viral yield over 72 hours, 
except for an increase in BUNV yield from induced cells at 72 hours.  
Additionally the amount of N protein produced by GFP-tagged BUNV (Fig 
5.16C, lanes 3, 4, 5 and 6) was greater than that produced by the NSs deletion 
virus infected cells (Fig 5.16C, lanes 7 and 8).  The USP18 band observed was 
difficult to detect but is clear in lanes 2, 4 and 8 (Fig 5.16C) so is thought to 
have been induced across all induced cells. 
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ISG12a 
The ISG12a protein is also known as IFI27 and is 11.3 kDa in size (Rosebeck & 
Leaman, 2008).  ISG12a promotes IFN induced apoptosis by associating with 
or inserting into the mitochondrial membrane and rapidly inducing the release of 
cytochrome c from the mitochondria and the activation of various caspases and 
Bcl-2-associated X (BAX) protein.  Thus, ISG12a enhances IFN-dependent 
perturbation of normal mitochondrial function.  HEK ISG12a-induced cells 
infected with BUNV showed no reduction in viral yield over 72 hours (Fig 5.17A) 
however, infection with rBUNdelNSs showed a significant reduction in viral yield 
until 48 hours where there was a 10-fold increase in viral yield 
compared with uninduced cells (Fig 5.17B).  The Western blot for N protein 
showed no change in the levels of N protein produced from all three GFP-
tagged viruses in infected uninduced and induced cells (Fig 5.17C).  
Furthermore the difficulties with detecting FLAG-tagged ISG12a account for the 
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less intense band in lane 6 (Fig 5.17C) although ISG induction is thought to 
have occurred across all Tet-induced cells.  
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GBP1 
Guanylate binding protein 1 is 67.9 kDa in size and is in the large (p65) GTPase 
superfamily of proteins which comprises GBP1 to GBP5 (Prakash et al., 2000).  
Guanylate binding proteins are defined by their ability to bind guanine 
nucleotides (GMP, GDP and GTP) and they have two binding motifs which 
differentiates them from GTP-binding proteins that have three binding motifs.  
Over-expression of GBP1 has been shown to inhibit HCV in cell culture and, 
further, the NS5B protein of HCV binds GBP1 thereby blocking its GTPase 
activity and consequently its antiviral effect (Itsui et al., 2006; Itsui et al., 2009).  
Thus, similarly with the Mx proteins, GBP1 antiviral activity is mediated through 
its GTPase activity.  The viral yield from induced HEK GBP1 cells infected with 
either BUNV (Fig 5.18A) or rBUNdelNSs (Fig 5.18B) showed little restriction 
when compared with uninduced cells. 
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FLJ20035 
FLJ20035 is also known as DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 (DDX60) 
and is a probable ATP-dependent RNA helicase induced by type I IFNs (Bigger 
et al., 2004).  The HEK FLJ20035 cells infected with BUNV or rBUNdelNSs 
showed no change in viral yield between the uninduced and induced cells over 
72 hours (Fig 5.19A and Fig 5.19B respectively).  The Western blot analysis 
showed no change in the amount of N protein synthesised in uninduced and 
induced cells, but there was less N protein in the NSs deletion virus infected 
cells (Fig 5.19C, lanes 7 and 8) than in the GFP-tagged BUNV infected cells 
(Fig 5.19C, lanes 3, 4, 5 and 6).  The FLAG-tagged 20035 protein was 
particularly difficult to detect which could be due to its location at the C-terminus 
of the DDX60 protein but it was induced following Tet treatment as shown in 
lanes 4 and 8 on the Western blot (Fig 5.19C, upper panel). 
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MAPK8 
Mitogen-activated protein kinases (MAPK) are serine-threonine kinases 
involved with rapid gene expression in response to extra-cellular stimuli such as 
cytokines (Dong et al., 2002).  The c-Jun N-terminal kinases (JNKs) comprise 
MAPK8, MAPK9 and MAPK10 and are activated in response to stress stimuli 
such as UV irradiation, heat shock and cytokines.  MAPK8 is induced by IFN 
and regulates AP-1 transcriptional activity by phosphorylating several of its 
constituents but is also involved in the TNF-α induced apoptosis pathway.  
MAPK8 is capable of either promoting or inhibiting viruses as it has been shown 
to restrict varicella-zoster and vaccinia virus replication but to enhance reovirus 
replication (Clarke et al., 2004; Hu et al., 2008; Rahaus et al., 2004). The HEK 
MAPK8-induced cells were infected with BUNV or rBUNdelNSs and both 
infections showed no significant change in viral yield from uninduced infected 
cells (Fig 5.20). 
 5 Screening of ISG inducible cell lines for Bunyamwera virus replication 
127 
 
Viperin 
Viperin is also known as radical S-adenosyl methionine domain containing 
(RSAD) 2 protein and is 42 kDa in size (Chin & Cresswell, 2001).  This protein 
has been demonstrated to inhibit IAV by disrupting lipid raft formation at the 
plasma membrane which is vital for IAV budding and leads to “daisy chain” 
formation budding (Wang et al., 2007).  HEK Viperin cells induced to express 
viperin and then infected with BUNV showed an inhibition of viral yield 
throughout the 72 hours.  The inhibition increased from 10-fold by 12 hours up 
to 100-fold by 48 hours compared with uninduced cells (Fig 5.21A).  When 
infected with rBUNdelNSs virus the reduction in viral yield increased from 10 
fold by 12 hours to 1000-fold by 72 hours (Fig 5.21B).  Western blot analysis for 
N protein showed a significant reduction in the amount of N produced by 24 
hours post infection (Fig 5.21C). 
 5 Screening of ISG inducible cell lines for Bunyamwera virus replication 
128 
 
The HEK VPM1 cells when induced over-express a viperin mutant (VPM1) that 
has had three cysteine residues in the conserved motif I of viperin replaced with 
three alanine residues thus removing the enzymatic capability of viperin (Jiang 
et al., 2008).  There is no effect on viral replication observed following induction 
of VPM1 in these cells (Fig 22A).  Thus, the inhibitory effects of over-expressed 
wild-type viperin on BUNV were abrogated when induced HEK VPM1 cells were 
infected with BUNV (compare Figure 5.21A and 5.22A).  When HEK VPM1 
cells were infected with rBUNdelNSs virus there was an initial 10-fold increase 
in viral yield in the induced cells but this was reduced to little difference by 24 
hours and thereafter (Fig 5.22B).  This shows that the loss of the enzymatic 
function of viperin impairs its ability to inhibit BUNV replication.  The Western 
blot analysis confirmed the abrogation of viperin activity did not result in a 
change in the amount of N protein by 24 hours post infection (Fig 5.22C).    
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IFITM proteins 
The interferon induced transmembrane (IFITM) proteins are induced by both 
type I and II IFNs and they contain two transmembrane domains and a highly 
conserved cytoplasmic domain with the N- and C- termini in the luminal space.  
They have been shown to inhibit the endocytic entry of IAV haemagglutinin  
(HA)-pseudotyped retroviruses and their subsequent early replication as well as 
restricting DENV and WNV replication at an early stage in their life cycle (Brass 
et al., 2009).  The filoviruses, EBOV and Marburg virus (MARV), and the SARS 
coronavirus were shown to be restricted by IFITM proteins in the late stages of 
the endocytic pathway, however IFITM proteins have shown little or no effect on 
the entry of viruses in the Arenaviridae family (Huang et al., 2011). 
The ISG9-27 protein is also known as IFITM1 and is a 13.9 kDa protein 
comprising 125 amino acids (Alber & Staeheli, 1996; Lewin et al., 1991).  The 1-
8D protein is also known as IFITM2 and is a 14.6 kDa protein comprising 132 
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amino acids and the 1-8U protein is also known as IFITM3 and is a 14.6 kDa 
protein comprising of 133 amino acids (Lewin et al., 1991). 
Figure 5.23A (above) shows the BUNV yield from uninduced and induced HEK 
9-27 cells over 72 hours.  Twenty-four hours post-infection there was a 5-fold 
reduction in BUNV yield in induced cells, which further increased through 36 (7-
fold) and 48 (14-fold) hours but was reduced at 72 (2-fold) hours.  Over the 
same time-frame, rBUNdelNSs was only slightly restricted by 36 and 48 hours 
post infection (Fig 5.23B).  However, Western blot analysis showed no 
reduction in the accumulation of N protein from any of the three GFP viruses 
investigated (Fig 5.23C).  Thus, the reduction in viral yield did not result in a 
detectable reduction in N protein expression. 
The Western blot for the HEK 1-8U cells showed little effect on N protein after 
the cells were induced but a slight reduction in the amount of N protein 
produced from rBUNGc-eGFP infected cells warrants further investigation (Fig 
5.24).  
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The HEK 1-8D cells showed no difference in BUNV or rBUNdelNSs yield 
between uninduced and induced cells (Fig 5.25A and 5.25B).  This was further 
corroborated by the Western blot which showed no change in the amount of N 
protein from each virus (Fig 5.25C). 
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SAMHD1 
SAMHD1 is a putative nuclease that is 72 kDa in size.  It is involved in the 
regulation of the innate immune response as it is upregulated in response to a 
viral infection and seems to act as a negative regulator of the antiviral response 
(Rice et al., 2009).  The accumulation of N protein in both uninduced and 
induced HEK SAMHD1 cells was the same for each of the three GFP-tagged 
viruses (Fig 5.26).   
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OAS proteins 
The OAS proteins have been described previously in Chapter One.  Essentially, 
they function by activating RNase L, which then degrades viral RNA and not 
only directly inhibits the virus but can also further stimulate the IFN response via 
RLR signalling and thus indirectly inhibit viral replication (Malathi et al., 2007; 
Silverman, 2007).  The HEK OAS1V1 cells when induced and infected with 
BUNV showed an overall 5-fold reduction in viral yield, whereas infection with 
rBUNdelNSs virus gave an overall 3-fold reduction compared with uninduced 
cells (Fig 5.27A and 5.27B).  However, the induced HEK OAS1V2 cells showed 
little difference overall in viral yield when infected with either BUNV or 
rBUNdelNSs, compared with uninduced cells (Fig 5.28A and 5.28B).  
Furthermore, 2’, 5’ oligoadenylate synthetase-like (OASL) is similar to OAS1 
and, while it does not have 2’, 5’ OAS activity, it does bind to RNA and DNA.  
Infection of induced HEK OASLV1 cells with the three GFP-tagged viruses 
showed no inhibition of N protein accumulation compared with uninduced cells 
(Fig 5.29). 
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The data collected from virus yield assays and Western blot analysis for each 
cell line in this section are summarised in table 5.1 below. 
Table 5.1: Summary of the effect on viral inhibition by induced HEK ISG 
cell lines. 
HEK293 ISG-
expressing cell 
line 
Inhibition* on 
BUNV yield † 
Inhibition* on 
rBUNdelNSs 
virus yield † 
Inhibition of N 
protein † 
GenBank 
accession 
number 
CAT - - -  
ISG 9-27 - - - 003641 
ISG12a - + - BN000227 
ISG15 - - NDC 005101 
ISG20 NDC NDC NDC 002201 
ISG56 - - - 001548 
1-8D - - - 006435 
1-8U - - - 021034 
ADAR1 - - - 001111 
MTAP44 + + - D28915 
GBP1 - - NDC 002053 
MAPK8 - - NDC 002750 
Viperin + + + AF442151 
VPM1 - - -  
PKR + + + AH008429 
PKRM - - -  
SAMHD1 NDC NDC - 015474 
STAF50 - - - X82200 
BST2 - - - 004335 
FLJ20637 NDC NDC - AK000644 
FLJ38348 - - - AK095667 
FLJ20035 - - - AK000042 
PLSCR1 - - - 021105 
PLSCR2 - - NDC  
UBE2L6 - - - 004223 
USP18 - - - 017414 
OAS1V1 - - NDC 016816 
OAS1V2 - - NDC 002534 
OASLV1 NDC NDC - 003733 
* Inhibition of 10-fold or higher. 
† + indicates the ISG inhibits the virus.  
 NDC denotes no data collected. 
 
Screening by immunofluorescence  
To further assess the utility of the three GFP-tagged viruses for screening cell 
lines for their anti-BUNV properties, immunofluorescence was used.  An 
immunofluorescence protocol that is fast and reliable would enable high 
throughput screening of cells and compounds of interest.   
The immunofluorescence experiments in this section were carried out as 
described in Chapter Two and at an MOI of 1, and infected cells were visualized 
using a confocal microscope.  The cells were fixed 24 hours after infection and 
the FLAG-tagged ISGs and the viral N protein were detected by indirect 
immunofluorescence, whereas the GFP-tagged proteins were observed by their 
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autofluorescence.  To determine the extent of infection, the percentage of 
infected cells was calculated by counting the number of GFP-positive cells out 
of 1000 cells.  Under the confocal microscope rBUNGc-eGFP produces 
punctate bright green dots when the chimeric GcGFP protein is expressed.  
However, expression of the NSmGFP chimeric protein from the two NSm GFP-
tagged viruses is significantly less bright and more evenly distributed. 
HEK 38348: The induced mock cells clearly showed that this protein was 
located in the nucleus and was not detected without Tet induction (Fig 5.30, 
panel 1 and 2).  Both uninduced and induced cells showed 100% infection by all 
three GFP-tagged viruses (Fig 5.30, panels 3-8) and panels 6-8 show that cells 
were simultaneously induced and infected.  The data correlate with the earlier 
 5 Screening of ISG inducible cell lines for Bunyamwera virus replication 
137 
 
virus yield assay and Western blot data showing no effect on BUNV.  
Additionally, BUNV replicates in the cytoplasm and the 38348 protein clearly 
locates in the nucleus. 
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HEK PKR: The mock cells when induced did show a clear signal compared with 
the uninduced cells (Fig 5.31, panel 1 and 2).  Similarly with other cell lines the 
uninduced cells were 100% infected by each of the three GFP-tagged viruses 
(Fig 5.31, panels 3, 4 and 5).  Panel 3 shows many infected cells with 
numerous bright green and punctate dots showing the synthesis of the chimeric 
GcGFP proteins which may have already been assembled into virions (Shi et 
al., 2010).  Panel 4 also shows many green cells due to the synthesis of the 
chimeric NSmGFP protein which will be used by the virus during 
morphogenesis but is not packaged and as the virus is far into the replicative 
cycle this is why there was less N protein.  NSmGFPdel is even more 
attenuated than the other GFP-tagged viruses thus the infected cells in panel 5 
have not progressed as far as in panels 3 and 4 (Fig 5.31).  In comparison, 
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panels 6, 7 and 8 show considerably less chimeric GFP protein than N protein 
as they are not as far into their replicative cycle compared with panels 3 and 4 
(Fig 5.31).   In the induced cells, however, 40% of the cells showed evidence of 
infection for each virus (Fig 5.31, panels 6, 7 and 8), supporting the earlier 
findings of lower viral yield and reduced N protein synthesis (Fig 5.4).  The 
attenuated NSmGFPdel virus was unable to synthesise detectable chimeric 
NSmGFP proteins by 24 hours post infection (Fig 5.31, panel 8).   
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HEK ISG9-27:  Induction of the mock cells resulted in a bright and intense 
signal from the FLAG-tagged ISG9-27 stained with anti-FLAG antibody that was 
not present in the uninduced mock cells (Fig 5.32, panel 1 and 2).  Infection of 
the uninduced cells with each of the GFP-tagged viruses resulted in 100% of 
the cells being infected (Fig 5.32, panels 3, 4 and 5), however in the induced 
cells the number of infected cells was 90% (Fig 5.3, panels 6, 7 and 8) and 
further supports the slight reduction in viral yield observed earlier by viral yield 
assays (Fig 5.23).  The N protein signal was weaker than in other cell lines but 
was equally visible in both uninduced and induced cells.  Panels 6, 7 and 8 (Fig 
5.32) also show the simultaneous induction and infection of the cells and, as the 
ISG9-27 protein is normally located in the plasma membrane, it was not 
observed in the nucleus. 
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HEK 1-8D:  A strong and bright signal from the FLAG-tagged ISG 1-8D stained 
with anti-FLAG antibody was observed in the induced mock cells compared with 
the uninduced cells (Fig 5.33, panel 1 and 2).  Infection with any of the three 
GFP-tagged viruses resulted in 100% of the uninduced cells being infected (Fig 
5.33, panels 3, 4 and 5).  Furthermore, induction of the cells conferred no 
inhibitory effects on the viruses as 100% of the cells were infected which was 
observed by the GFP signal as the N protein signal was weak in comparison, 
particularly in panels 5 and 8 (Fig 5.33), demonstrating the advantage of using 
the GFP-tagged viruses.  This corresponds with the earlier findings from viral 
yield assays and Western blot analysis that showed no inhibitory effect by the 1-
8D protein on BUNV (Fig 5.25).   
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HEK 1-8U:  There was no observed signal in the mock uninduced cells and a 
strong and bright signal from the FLAG-tagged ISG 1-8U stained with anti-
FLAG antibody in the induced mock cells (Fig 5.34, panels 1 and 2).  When 
infected with any of the three GFP-tagged viruses the uninduced cells were 
100% infected (Fig 5.34, panels 3, 4 and 5).  Figure 5.34 shows simultaneous 
ISG induction and infection (panels 6, 7 and 8), and when the cells were 
induced they showed no restriction on any of the three viruses.  All of these 
data directly relate to the Western blot analysis described earlier (Fig 5.24) that 
showed no restriction on virus replication by the 1-8U protein.  
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HEK PLSCR1:  Induction of the mock cells showed a clear signal compared 
with the uninduced cells, although it was not very bright (Fig 5.35, panels 1 and 
2).  When infected with each of the GFP-tagged viruses the uninduced cells 
were completely infected (Fig 5.35, panels 3, 4 and 5) and the induced cells 
also showed 100% infection, as well as the simultaneous induction and infection 
of the cells (Fig 5.35, panels 6, 7 and 8).  Furthermore, the data shown here 
correlate with both the virus yield assays and Western blot analysis described 
earlier (Fig 5.7). 
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Table 5.2 shows the empirical data collected from the immunofluorescence 
experiments in the form of the % of infected cells out of 1000 that were counted. 
Table 5.2: Percentage of infected cells out of 1000 observed using 
immunofluorescence microscopy. 
   Cell line  
 
Virus 
HEK 
38348 HEK PKR HEK 9-27 HEK 1-8D HEK 1-8U 
HEK 
PLSCR1 
- + - + - + - + - + - + 
rBUNGc-
eGFP 100 100 100 40 100 90 100 100 100 100 100 100 
BUNGFP 
 
100 100 100 40 100 90 100 100 100 100 100 100 
NSmGFP
del 
 
100 100 100 40 100 90 100 100 100 100 100 100 
- denotes uninduced cells 
+ denotes induced cells 
 
Discussion 
The screening of these cell lines using immunofluorescence proved to be a 
useful and accurate tool.  Of the six cell lines used, four (38348, 1-8D, 1-8U and 
PLSCR1) showed no visible inhibition as all were 100% infected by 24 hours 
post infection which was further reflected in the absence of change observed in 
Western blot analysis and viral yield assays.  Of the other two cell lines, ISG9-
27 showed a 10% reduction of cells infected, which correlates with a 5-fold 
reduction in viral yield at 24 hours.  However there was no effect on the amount 
of N protein synthesised suggesting that ISG9-27s inhibitory effect is early on in 
the replicative cycle of BUNV.  The last cell line analysed by 
immunofluorescence was HEK PKR which showed a significant reduction of 
60% in infected cells which was further illustrated by the detection of less N 
protein on the Western blot and in a lower viral yield.  However, the reduction 
observed was of infected cells as opposed to all cells infected but viral 
replication reduced by 60%.  This suggests that the over-expression of PKR 
inhibits viral infection before translation of detectable N or chimeric GFP 
proteins, which is consistent with PKRs antiviral mechanism.  It could be that 
the cells were infected but the infection detection methods (staining and 
autofluorescence of translated proteins) used were unable to detect infected 
cells in stages of viral replication prior to translation.  Chen et al. (Chen et al., 
2010) showed that heterocellular IFNβ induction occurs in BUNV infected cells, 
therefore PKR expression may induce other antiviral mechanisms that further 
inhibit the early stages of BUNV replication, which is consistent with the role of 
PKR as a PRR.  Thus this fluorescence technique, that utilised the GFP tagged 
viruses, is useful for screening cell lines for their anti-BUNV properties by 
showing the one cell line (HEK PKR) out of six that was found (by viral yield 
assay and Western blot) to be able to considerably inhibit BUNV replication.  
 5 Screening of ISG inducible cell lines for Bunyamwera virus replication 
145 
 
Further, the visible 10% reduction in infection of HEK ISG9-27 cells correlated 
with a reduction in viral yield.  Importantly the method produces data four days 
before plaque assays and is less time consuming.  Furthermore, with the use of 
fluorescence microscopes and plate readers this time can be cut to real-time 
analysis as the GFP fluorescence can be observed in vivo and the cells 
returned to the incubator for later time observations or further fixed for staining 
and confocal microscopy or lysed for Western blot analysis.  Thus this would 
enable an efficient screening process. 
Suitability of GFP-tagged viruses for screening: Comparisons of the viral yields 
from BUNV, rBUNdelNSs and the three GFP-tagged viruses in HEK 38348 cells 
showed that, though attenuated, the GFP viruses followed a similar growth 
pattern as BUNV and rBUNdelNSs.  Using HEK PKR cells further corroborated 
this finding by showing a similar pattern in viral yield across both uninduced and 
induced cells, thus demonstrating that the detection of GFP from the GFP-
tagged viruses was representative of the viral inhibition that was shown to be 
occurring.  However, there was variability in virus yield observed across many 
of the uninduced HEK ISG cell lines, most likely attributable to virus preparation 
using different cell lines.  Elite virus stocks are, usually, amplified and titred 
using BHK cells.  Therefore the titre may be different when infecting HEK cells, 
thereby explaining the observed fluctuations in viral yield from uninduced cells 
expressing different ISGs.  For these reasons the GFP-tagged viruses are 
suitable for screening as observations by immunofluorescence match those of 
more classical virology.  However, further thought is required to consider the 
location of the GFP tags and the subsequent consequences.  Despite many 
years of fruitful research on orthobunyaviruses, there is still much to learn, and 
all the ramifications of inserting GFP into the NSm protein or of replacing part of 
the N-terminal of the Gc protein with GFP are not yet known.  These 
manipulations may have useful or detrimental effects on each of the stages of 
replication from entry to egress, which is emphasised by the attenuation of the 
tagged viruses, and therefore the viruses should be used for screening in 
conjunction with other assays that can confirm any effects that are or are not 
found. 
One concern with studies using cells engineered to over-express ISG proteins 
is the dependency of some proteins on other ISGs and or cellular factors for 
their antiviral effect.  For example ISG15 is dependent on proteins in the entire 
ISGylation pathway such as UBE1L, UBE2L6, HerC5 and USP18 which are 
responsible for activation, conjugation, ligation and de-ISGylation of ISG15 
respectively, thus each is vital for the pathway.  Therefore over-expression of 
just one of these individual proteins may not be sufficient for the successful 
inhibition of virus.  Versteeg et al. (2010) showed that in their system 
substitution of either ISG15, E1, E2, or E3 with GFP resulted in the loss of 
ISG15-conjugate formation.  However, over-expression of UBE1L may lead to 
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increased activation of ISG15 and the subsequent hyper stimulation of the 
ISGylation pathway.  Likewise over-expression of the rate limiting factor in the 
pathway may increase the efficiency of the whole process.   
De-ISGylation requires deconjugation enzymes and studies have identified five 
classes of de-ubiquitinating proteolytic enzymes, one of which is the ovarian 
tumour (OTU) domain family.  Several mammalian proteins which have an OTU 
domain have been shown to be involved in deconjugation of ubiquitin, such as 
the NF-κB activation inhibitor A20 which down regulates TNF-α signalling via 
TRAF6 de-ubiquitination (Boone et al., 2004; Evans et al., 2004).  The 
nairovirus CCHFV L protein contains an OTU domain and has been shown to 
reduce the level of ISGylated proteins almost as well as UBP43 (USP18), thus 
counteracting the effects of ISG15 (Frias-Staheli et al., 2007).  An OTU domain 
was found in other nairovirus L proteins but not in any other viral L proteins of 
the four remaining genera in the Bunyaviridae (Frias-Staheli et al., 2007), 
although the existence of other OTU-like domains cannot be dismissed. 
In this study the significant level of virus inhibition was taken to be 10-fold or 
greater because many ISGs appear to show low level restriction which 
demonstrates the combined antiviral strategy employed by cells.  This does not 
lower the importance of the role, in combination, that each ISG plays in the 
antiviral response to BUNV infection but merely enables identification of the 
ISGs that have a more involved function in the antiviral response.  Three cell 
lines showed a > 10-fold reduction in viral yield; HEK MTAP44, HEK viperin and 
HEK PKR.  The viperin- and PKR-expressing cells further showed a reduction in 
N protein levels, suggesting a larger role in inhibition of BUNV replication.  
Several cell lines showed a < 10-fold reduction in viral yield but none of these 
cells inhibited the amount of N protein detected.  A negative effect of viperin, 
PKR and ISG20 has been described on HCV replicons (Jiang et al., 2008) 
whereas my preliminary data regarding ISG20 suggest no effect on BUNV but 
data on rBUNdelNSs have not yet been collected.  The inhibition of BUNV and 
rBUNdelNSs by the over-expression of PKR and viperin will be discussed 
further in Chapter Six and Chapter Seven, respectively.   
The induced HEK MTAP44 cell line showed significant restriction (> 10-fold) by 
36 hours post-infection in BUNV and by 48 hours in rBUNdelNSs infected cells.  
Little is known about the function of this protein but it has been shown to 
aggregate with microtubules and thus, this may affect the early viral transport in 
the cell.  A previous study showed MTAP44 to be localised in the cytoplasm 
after IFN induction and that it contains a GTP binding site (Hallen et al., 2007).  
This led them to suggest that MTAP44 binds to intracellular GTP ergo depleting 
the cytoplasmic levels of GTP and ultimately leading to the inhibition of cell 
division/growth.  The depletion of GTP by MTAP44 does not however appear to 
inhibit N protein synthesis. 
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In addition to the PKR, viperin and MTAP44 cell lines, several other lines 
showed some level of restriction (20035, 20637, ISG9-27, ISG12a, ISG15, 
ISG56, OAS1V1, BST2) while the rest (MAPK8, USP18, UBE2L6, 1-8U, 1-8D, 
ADAR1, PLSCR1, PLSCR2, GBP1, STAF50, SAMHD1, 38348, OAS1V2, 
OASLV1) showed no detected restrictive effect at all.   
The reduction in viral yield but not in N protein level observed from induced 
HEK 9-27 cells suggests slight inhibition at an early stage of the BUNV 
replication cycle.  As stated earlier recent studies have shown ISG9-27 to inhibit 
IAV, the two filoviruses EBOV and MARV, and two major flavivirus pathogens 
DENV and WNV, by an as yet unknown mechanism that involves the late 
stages of endocytosis (Brass et al., 2009; Huang et al., 2011).  Thus, this may 
account for the slight restriction in viral yield observed as BUNV entry requires 
acidification of the late endocytic vesicles.  There was even less restriction on 
rBUNdelNSs suggesting the ablation of NSs is advantageous in counteracting 
ISG9-27 mediated viral inhibition.  Furthermore, as the restriction was only seen 
in the viral yield assays and not on the amount of N protein, it suggests that the 
deletion of the N-terminus of the Gc protein may have interfered with the 
antiviral mechanism of ISG9-27 on BUNV.  Of the two other IFITM proteins, 1-
8D and 1-8U, 1-8D appears not to have any restrictive capabilities on BUNV 
and rBUNdelNSs, whereas 1-8U showed slight restriction of rBUNGc-eGFP 
virus, which further corresponds with the distinct antiviral properties of each of 
the IFITM proteins seen elsewhere.   
ISG12a induces apoptosis and therefore the slight restriction of viral replication 
observed in induced BUNV infected cells could be due to the cells becoming 
apoptotic.  This is exacerbated in rBUNdelNSs virus infected cells as the NSs 
protein would normally inhibit apoptosis by interacting with IRF3 (see Chapter 
One).  Consequently, apoptosis was possibly triggered by two independent 
mechanisms in HEK ISG12a-induced and rBUNdelNSs-infected cells: the over-
expression of the pro-apoptotic ISG12a and the absence of the anti-apoptotic 
NSs protein.  Furthermore, the spike of viral yield observed at 48 hours could be 
explained by more cells being infected in the uninduced cells, leading to greater 
cell death and thus, fewer cells would be available for infection.  This can be 
observed by the extensive cell death seen in rBUNdelNSs infected cells 
compared with ISG12a induced cells. 
Four cell lines (ISG15, ISG56, OAS1V1, and BST2) showed low inhibition in the 
viral yield assays, although ISG56 expression only inhibited rBUNdelNSs.  
Together these data imply an overall antiviral effect against BUNV is achieved 
through several independent inhibitory mechanisms acting synergistically.  
Some ISGs, such as PKR, viperin and MTAP44, play a larger role in the 
inhibition of BUNV replication but no single ISG has been found as yet that 
causes the extent of inhibition on the level such observed in other systems, 
such as in the inhibition of HIV replication by BST2. 
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Summary  
This chapter shows: 
 The effects of 26 (plus 2 mutated ISGs) ISG expressing cell lines. 
 That PKR and Viperin show inhibitory effects on BUNV. 
 That MTAP44 has restrictive effects on BUNV. 
 The screening of six ISG expressing cell lines with tagged GFP viruses 
using immunofluorescence. 
 The GFP-tagged viruses can be used for screening cell lines in 
conjunction with other techniques. 
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6 PKR inhibition of Bunyamwera virus 
Introduction 
PKR was discussed in detail in Chapter One.  The previous chapter 
investigated the growth kinetics of BUNV and rBUNdelNSs in HEK PKR cells 
and showed that the over-expression of PKR resulted in a ten-fold reduction in 
viral yield and a significant reduction in the synthesis of N protein from those 
cells. Therefore, the aim of this chapter was to investigate the inhibitory effects 
of PKR on BUNV replication in more detail. 
Protein expression in HEK PKR cells 
To further investigate the effect of over-expressed PKR on BUNV, HEK PKR 
cells were infected at an MOI of 0.01 pfu/cell with BUNV or rBUNdelNSs and 
labelled with [35S]-methionine for one hour at different times over a 72 hour 
period.  The cell lysates were then analysed by SDS-PAGE followed by 
autoradiography (Fig 6.1).  Comparison of the uninduced and induced mock 
cells demonstrated that over-expression of PKR and the subsequent 
translational inhibition results in some non-viral host cell protein shut-off (Fig 
6.1A, Mock).  Both uninduced and induced cells infected with BUNV showed an 
increase in the viral L, Gc and N proteins with the N protein peaking at 24 
hours, and clear host protein synthesis shut-off occurring by 24 hours and 
progressively increasing thereafter.  However, the induced cells showed 
significantly less intense protein bands for the viral proteins L, Gc and N 
confirming the inhibitory effect on protein synthesis by PKR, and shut-off 
appeared stronger and earlier at around 12 hours.  Infection of uninduced cells 
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with rBUNdelNSs yielded a similar viral protein synthesis pattern to BUNV with 
L, Gc and N protein synthesis increasing up to 24 hours post infection, however, 
host protein synthesis shut-off was not clearly visible until 36 and 48 hours post 
infection (Fig 6.1B).  There was no NSs protein expression thus the mechanism 
of shut-off observed in rBUNdelNSs infected cells was likely due to cap 
snatching by the L protein resulting in degradation/instability of decapped 
mRNAs.  rBUNdelNSs infected induced cells showed a huge reduction in 
overall protein synthesis which is attributable to increased PKR expression.  
The viral L, Gc and N proteins were discernible but their intensities were low 
compared with the uninduced cells.  Western blot analysis was carried out to 
monitor the accumulation of viral proteins (Fig 6.2).  In the uninduced cells 
infected with BUNV there was little increase in the amount of N protein 
accumulated after 36 hours (Fig 6.2A) which correlates with the protein 
labelling data that showed N protein synthesis peaked at 24 hours (Fig 6.1A).  
Western blot analysis of induced cells, however, showed that N protein 
synthesis continued until at least 48 hours post infection as the amount of N 
protein continually increased (Fig 6.2), but the total amount of N protein was 
considerably less than in uninduced cells.  When infected with rBUNdelNSs, 
uninduced cells showed a reduction in N protein accumulation after 36 hours 
(Fig 6.2B), most likely attributable to virus-induced apoptosis (Kohl et al., 2003).  
However, induced cells showed a continual increase in viral N protein over 72 
hours confirming that viral protein synthesis continued even after induction of 
PKR and thus that over-expression of PKR did not prevent but merely slowed 
the course of infection.  In agreement with this, the overall level of N protein 
accumulation even at its peak was lower in the induced than the uninduced 
cells, showing that expression of PKR attenuates viral replication and protein 
synthesis.   
 6 PKR inhibition of Bunyamwera virus 
151 
 
RNA analysis in HEK PKR cells 
To investigate the viral RNA profile, HEK PKR cells, both uninduced and 
induced, were infected with either BUNV or rBUNdelNSs at an MOI of 0.01 
pfu/cell. RNA was extracted at different times after infection and analysed by 
Northern blotting.  RNA extracted from uninduced BUNV-infected cells showed 
the predicted pattern of L, M and S genomic RNA segments (Fig 6.3A).  RNA 
from induced cells was significantly reduced for each segment, with a strong S 
segment signal whereas the L and M segments were barely detected.  When 
infected with rBUNdelNSs the uninduced cells showed the predicted pattern for 
each segment whereas in the induced cells viral RNA synthesis was 
significantly lower (Fig 6.3B).  Thus these two sets of data showed that over-
expression of PKR considerably reduced but did not abrogate the synthesis of 
viral genomic RNA. 
It is not possible to resolve the BUNV anti-genomic RNA and mRNA species for 
the L and M segment by Northern blotting.  It is, however, possible to resolve 
the two positive sense RNA species for the S segment because there is a 
difference in size between anti-genomic RNA (961 nt) and mRNA (850 nt) of 
approximately 11.5%.  The uninduced cells infected with either BUNV or 
rBUNdelNSs showed the predicted migrations and strong signals for each viral 
segment (Fig 6.4A and B).  However, viral synthesis of positive sense RNA 
was significantly reduced for both BUNV and rBUNdelNSs. 
The reductions in viral RNA synthesis seen here correlate with the observed 
reduction in viral protein synthesis discussed earlier.  Thus, it is apparent that 
induction of PKR expression in HEK PKR cells attenuated viral replication by 
inhibiting both viral RNA and protein expression. 
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BUNV replication in PKR knockdown cells 
To investigate the role of PKR in the innate immune response to viral infection, I 
used a human A549 cell line engineered to express shRNA against PKR 
(A549shPKR cells (kindly donated by Rick Randall, University of St Andrews, 
UK)). 
Growth kinetics in A549shPKR cells 
To investigate the growth kinetics of wild-type and NSs deletion mutant viruses 
in A549shPKR cells, the cells were either not treated or pre-treated with IFNβ 
for 24 hours and then infected at an MOI of 1 pfu/cell.  Virus released into the 
growth medium was collected at various times and titrated by plaque assay.  In 
both the untreated and treated cells the BUNV titre increased until 24 hours but 
in the treated cells the titre was ~100-fold lower than the untreated cells, at all 
time points (Fig 6.5A).  The data shown here contrast with the data described 
earlier in Figure 3.7, which showed no increase in BUNV titre in cells pre-
treated with IFNβ. 
However, the untreated cells infected with rBUNdelNSs produced 1000-fold 
higher titre than IFNβ treated cells by 24 hours (Fig 6.5B).  Thus, the 
knockdown of PKR restored BUNV, but not rBUNdelNSs, replication in IFNβ 
pre-treated cells. 
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Protein expression in A549shPKR cells 
Earlier data shown in Chapter Three showed that IFN pre-treatment (in A549 
and Vero cells) blocked detectable viral protein synthesis (Fig 3.8, 3.9, 3.12), 
thus in vivo labelling was used here to determine whether the knockdown of 
PKR under the same conditions could alter that finding.  Untreated and IFNβ 
pre-treated A549shPKR cells were infected with either BUNV or rBUNdelNSs at 
an MOI of 1 pfu/cell, labelled with [35S]-methionine for 1 hour at different times 
over a 24 hour period, and then analysed by SDS-PAGE and autoradiography 
(Fig 6.6).  Untreated cells infected with BUNV showed a clear increase in viral 
protein synthesis from 4 to 12 hours post infection, and host cell protein shut-off 
was clearly observed by 24 hours (Fig 6.6A, middle panel).  Conversely, the 
cells treated with IFNβ showed a significant reduction in viral protein synthesis 
with no viral proteins visible throughout the 24 hours (Fig 6.6A, right panel).  
Furthermore, there was no observable virus induced host protein shut-off in the 
same samples.  Infection with rBUNdelNSs resulted in a similar pattern of viral 
protein synthesis; in the untreated cells viral proteins were visible by 8 hours 
and remained constant through 12 hours and then reduced by 24 hours but in 
the treated cells there were no visible viral proteins.  Thus, pre-treatment with 
IFNβ was able to block viral protein synthesis and prevent virus-induced protein 
shut-off by BUNV.    
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To further understand viral protein synthesis under these conditions, the 
labelled cell lysates were immunoprecipitated with anti-BUN antibody and then 
analysed by SDS-PAGE and autoradiography (Fig 6.7A).  BUNV infected 
untreated cells showed viral protein synthesis was underway for Gc and N 
protein by 4 hours and for L protein by 8 hours.  Protein synthesis increased 
and plateaued at 12 hours and reduced again by 24 hours, which is consistent 
with the data described above.  The treated BUNV infected cells showed weak 
N protein expression at 8 and 12 hours (Fig 6.7A).  rBUNdelNSs infected but 
untreated cells produced a similar protein synthesis pattern to BUNV but the L 
and Gc protein levels were less, however protein synthesis in the treated cells 
was undetectable (Fig 6.7B).   
These data correlate with the viral titres described in Figure 6.5 and show that 
there was protein synthesis occurring in Figure 6.6 but at a level undetectable 
by the method described there. 
Western blot analysis to detect N protein showed a significant increase, from 4 
hours through to 24 hours, in the amount of N protein expressed by untreated 
BUNV infected cells (Fig 6.8).  In contrast, the IFN pre-treated cells not only 
showed a large reduction in detectable protein but also that N protein levels 
peaked at 12 hours and were reduced by 24 hours, indicative of protein 
degradation.  Compared with BUNV-infected cells, those infected with 
rBUNdelNSs showed less intense N protein signals which were detectable at 4 
hours, peaked at 12 hours and then reduced by 24 hours (Fig 6.8).  In contrast, 
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there was no detectable N protein from the IFN-treated cells.  The tubulin blots 
confirm not only protein loading controls for the Western analyses but also for 
the in vivo labelling experiments.  Thus, IFN pre-treatment inhibited viral protein 
synthesis by both BUNV and rBUNdelNSs, as determined by monitoring N 
protein production. 
  
 6 PKR inhibition of Bunyamwera virus 
157 
 
RNA analysis in A549shPKR cells 
Activation of PKR leads to a reduction in host cell protein synthesis via inhibition 
of translation.  Therefore, in the absence of PKR, the cellular restriction 
mechanism(s) of IFNβ on BUNV replication may involve transcriptional 
inhibition, either for primary transcription or genome amplification.  To 
investigate this further, untreated and pre-treated A549shPKR cells were 
infected at an MOI of 1 pfu/cell, total RNA extracted at several time points after 
infection, and then analysed by Northern blotting.  Using probes complementary 
to genomic viral RNA, it was clear that pre-treatment with IFNβ significantly 
restricted BUNV and completely restricted rBUNdelNSs (Fig 6.9).  From 
untreated BUNV infected cells, genomic S, M and L segments were detected at 
4 hours and the intensity of each segment increased throughout the 24-hour 
experiment, correlating with data discussed above.  However, when pre-treated 
with IFNβ, there was a large reduction in detectable viral RNA: while there was 
detectable S genomic RNA and faint (clearer on longer exposure) bands for the 
M and L segments, the overall level of RNA was greatly reduced (Fig 6.9A).  
Untreated cells infected with rBUNdelNSs also showed detectable S and M 
genomic RNA at 4 hours, both of which increased through 8 and 12 hours and 
then were reduced by 24 hours.  Whereas the L segment was not detected until 
8 hours and then increased slightly by 12 hours, and was also reduced by 24 
hours post infection.  Unlike BUNV-infected cells however, treatment with IFNβ 
resulted in no detectable viral genomic RNA (Fig 6.9B). 
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Using probes that were complementary to anti-genomic viral RNA, it was clear 
that pre-treatment with IFNβ severely restricted viral RNA synthesis but, as with 
genomic RNA, it was barely detectable from either BUNV or rBUNdelNSs (Fig 
6.10).  BUNV infected untreated cells showed signals for positive sense S, M 
and L segment RNA at 4 hours post infection and the signal from all three 
segments increased throughout the 24 hour experiment (Fig 6.10A).  Due to the 
small difference in size between mRNA and anti-genomic RNA of the M and L 
segments they do not resolve using this system but it is possible to resolve the 
S segment RNA species.  There did not appear to be any BUNV S segment 
mRNA or anti-genomic RNA specific inhibition in the treated cells, compared 
with the untreated cells, although the band separation was not optimal (Fig 
6.10A). 
In untreated cells, rBUNdelNSs S and M segment RNA was detected at 4 hours 
and increased up to 12 hours but was then reduced (Fig 6.10B).  The L 
segment was not detected until 8 hours post-infection and then the level 
increased until 12 hours, after which it was reduced by 24 hours.  However, pre-
treated cells infected with rBUNdelNSs produced significantly less positive 
stranded RNA and S, but not M or L, segment RNA was weakly detected.  
Neither positive sense M or L segment RNA was detected from treated cells 
even after longer exposures.  These data from both viruses correlate with the 
data observed in Figure 6.9.   
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Additionally, naïve A549 cells were infected with either BUNV or rBUNdelNSs 
and immediately treated (synchronous treatment) with IFNβ.  While PKR is 
present in an inactivated state in cells all the time, its expression was 
upregulated following IFN treatment at 12 hours post treatment (Fig 6.11, 
Mock).  In contrast, infection with BUNV did not induce an increase in PKR 
expression and, moreover, BUNV was even able to restrict PKR expression 
after IFN treatment (Fig 6.11, BUN).  Thus there was no increase in PKR levels 
observed in BUNV infected cells.  Infection with rBUNdelNSs induced a slight 
increase in expression of PKR in the absence of IFN which was enhanced by 
the addition of IFNβ (Fig 6.11, rBUNdelNSs).  However, the slight increase in 
expression of PKR from rBUNdelNSs infected cells also in the presence of IFN 
was not as much as was observed from mock infected IFNβ treated cells, 
suggesting that rBUNdelNSs also inhibits IFN-induced PKR. 
Discussion 
PKR is a critical molecule in antiviral immunity, since it acts both as a PRR that 
is able to detect viral dsRNA, and as an ISG that inhibits host cell protein 
synthesis by phosphorylating eIF2α (Garcia et al., 2006).  Therefore, it is not 
surprising that cells with activated PKR are likely in a state of reduced 
translation and protein synthesis and this was clearly demonstrated in the mock 
infected cells in Figure 6.1.  This mechanism can be an extremely potent way of 
blocking viral protein synthesis and for several viruses PKR is blocked in order 
to permit replication.  There are various methods of blocking PKR utilised by 
different viruses, such as direct interaction with PKR, degradation of PKR, 
sequestration of dsRNA and the dephosphorylation of eIF2α (Garcia et al., 
2006; Langland et al., 2006).  The HIV1 TAT protein sequesters dsRNA, 
thereby removing the PAMP recognised by PKR, and TAT also directly interacts 
with PKR to prevent its autophosphorylation (Clerzius et al., 2011).  Therefore, 
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over-expression of PKR in cells should make the cells highly sensitive to dsRNA 
and enhance the effects of the subsequent activation of PKR on host cell 
protein synthesis.   
Streitenfeld et al. (2003) demonstrated that in MEF cells both BUNV and 
rBUNdelNSs activate PKR but this activation does not confer any resistance to 
the viruses in cell culture.  However, using PKR knockout mice they found that 
PKR does show some weak protection in vivo to BUNV infection.  Thus, 
perhaps activation of PKR is ultimately beneficial to BUNV once the infection 
becomes established.  The mechanism of the primary IFN antagonist NSs of 
BUNV is to inhibit host cell protein synthesis at a transcriptional level by 
blocking RNA polymerase II mediated transcription (Chapter One).  It may be 
the case that normal expression of PKR is beneficial to BUNV replication by 
enhancing the effect of host cell protein synthesis shut-off by blocking further 
cellular protein translation.  This PKR-induced translational inhibition, along with 
cap snatching, may allow for increased viral protein translation as NSs blocks 
de novo cellular mRNA synthesis and cap snatching reduces cellular levels of 
mRNA.  At the same time viral mRNA and translation is able to increase 
because the cellular translational machinery has been liberated from cellular 
mRNAs.  In the induced HEK PKR cells, both BUNV and rBUNdelNSs proteins 
were less intense and cellular protein synthesis was clearly lower.  Likewise, 
even though the level of N protein expression was less in the induced cells it 
still increased thereby showing that the virus was restricted but not stopped by 
PKR.  Clearly PKR over-expression attenuates but does not stop viral 
replication for either virus.  Further, even in the absence of NSs, there is some 
viral replication, suggesting that there is more to BUNV inhibition of the IFN 
response than just NSs.  These data also correlated with the RNA analysis that 
showed restriction by PKR of both genomic and anti-genomic viral RNA but not 
abrogation.  Data in Chapter Five (Fig 5.4) showed that both BUNV and 
rBUNdelNSs were restricted by a factor of 10 in plaque assay by the over-
expression of PKR, which also significantly reduced the amount of N protein, 
thus correlating with the data from this chapter also. 
As seen previously in Chapter Three, pre-treatment with IFNβ completely 
inhibited BUNV replication but this was partially reversed here by knocking 
down PKR with shRNA which shows that PKR is not a major factor but just one 
part of the IFN response that inhibits BUNV replication.  However, rBUNdelNSs 
was more restricted than BUNV in protein and RNA synthesis and particularly in 
the virus titre showing that the NSs protein is still vital for overcoming the IFN 
response and enabling successful viral replication in the absence of PKR. 
The phlebovirus RVFV also encodes a NSs protein on the S segment but in an 
ambisense coding strategy.  RVFV is highly pathogenic, predominantly because 
of the action of the NSs protein which, like BUNV, blocks IFN induction at a 
transcriptional level but via a different mechanism to BUNV and the NSs-
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deletion mutants are IFN inducers and thus attenuated.  Habjan et al. (2009) 
and Ikegami et al. (2009) demonstrated that not only does RVFV inhibit PKR 
expression but the virus also targets PKR for proteasomal degradation which is 
unlike any other bunyavirus and not observed here for BUNV.  Thus, other 
bunyaviruses target PKR likely by different mechanisms compared to BUNV.   
Research investigating the mechanisms behind the action of PKR, both as a 
dsRNA sensor and as an antiviral protein, is constantly updating the complex 
pathways and cellular proteins involved in the PKR-dependent antiviral 
response.  The ISG ADAR1 has been shown to actually inhibit PKR activation, 
thereby suppressing the phosphorylation of eIF2α and enhancing the replication 
of VSV (Li et al., 2010).  Also, PKR inhibited HIV replication can be returned to 
normal by the expression of ADAR1 and the inhibition of ADAR1 expression 
results in inhibition of HIV expression (Clerzius et al., 2009).  Thus some viruses 
are able to inhibit the PKR response but also are helped by cellular factors that 
are most likely there to regulate the PKR response.  As yet it is unknown 
whether ADAR1 or other ISGs enhance BUNV replication by inhibiting PKR.  
Further work is needed to elucidate the mechanism by which BUNV is able to 
block PKR in order to facilitate viral replication. 
Summary 
This chapter shows: 
 Over-expression of PKR inhibits viral protein synthesis. 
 Furthermore, over-expression of PKR inhibits overall viral RNA 
synthesis. 
 Knockdown of PKR in A549 cells rescued BUNV replication. 
 However, knockdown of PKR in A549 cells did not rescue rBUNdelNSs 
replication but did enable detection of some protein and RNA synthesis.  
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7 Viperin inhibition of Bunyamwera virus 
Introduction 
Viperin (Virus inhibitory protein, endoplasmic reticulum-associated, IFN-
inducible) was initially identified as cig5 in human primary skin cells infected 
with HCMV (Zhu et al., 1997a) and later the homologues vig1 and mvig were 
identified in rainbow trout leukocytes infected with the rhabdovirus viral 
haemorrhagic septicaemia virus (VHSV) (Boudinot et al., 1999) and murine 
dendritic cells infected with VSV or pseudorabies virus (Boudinot et al., 2000), 
respectively.  Chin and Cresswell (2001) went on to show that viperin was 
highly induced by both type I and II IFNs and had antiviral activity against 
HCMV.  More recently, viperin has been found to be induced by several 
different viruses and shown to have antiviral activity against various viruses 
including IAV, HCV, and HIV (Helbig et al., 2005; Jiang et al., 2010; Rivieccio et 
al., 2006; Severa et al., 2006; Wang et al., 2007).   
Viperin is a 361 amino acid protein with a predicted molecular mass of 42.2 
kDa, containing an amphipathic α-helix at its N terminus followed by a CX3CX2C 
motif in the middle and a C terminal conserved domain (Jiang et al., 2008).  
Hinson (2009a) showed that viperin self-associates and that the 42 amino acid 
amphipathic α-helix is responsible for viperin localisation to the cytosolic face of 
the ER and inhibition of soluble protein secretion.  Further to this Hinson 
(2009b) found that the N terminal amphipathic α-helix was necessary for 
localisation to lipid droplets.  Duschene (2010) confirmed that the CX3CX2C 
motif enables viperin to bind iron-sulphur ([4Fe-4S]) clusters and catalyse the 
reductive cleavage of SAM, thus viperin is also called radical S-adenosyl 
methionine (SAM) domain-containing 2 (RSAD2) .   
Complete understanding of the antiviral mechanism of viperin has yet to be 
elucidated, although insights into the specific action of viperin-mediated 
restriction on some viruses has been shown previously.  Wang et al. (2007) 
demonstrated that viperin interacts with farnesyl diphosphate synthase (FPPS) 
and inhibits the enzymatic function of FPPS in lipid metabolism which results in 
the disruption of lipid raft formation.  Lipid rafts play a vital role in the replication 
cycle of IAV as the envelope of IAV is enriched in lipid rafts and the ensuing 
accumulation of viral envelope proteins stimulates the budding process of IAV 
particles (Scheiffele et al., 1999).  Thus viperin restricts IAV by blocking viral 
release and causing a “daisy chain” budding effect.  Viperin inhibits HCV 
replication by associating with lipid droplets, a vital part of the HCV replication 
cycle, and interfering with HCV in an as yet unidentified manner (Hinson & 
Cresswell, 2009a).  Both SINV and JEV induce viperin expression but SINV 
induced expression is in an IFN-dependent manner whereas JEV directly 
activates the viperin promoter via IRF3 and AP-1 (Chan et al., 2008).  
Additionally, SINV replication was significantly reduced by the over-expression 
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of viperin but JEV was not restricted unless the proteasomal inhibitor MG132 
was also added.  RNAi knockdown of viperin enhanced SINV replication but did 
not affect JEV replication, thus JEV may induce viperin but is able to neutralise 
the antiviral effect of viperin by targeting viperin for degradation.  Therefore 
understanding of the full role that viperin plays in antiviral immunity is 
incomplete and research into the antiviral mechanism of viperin is ongoing. 
As described in Chapter Five a second cell line showed inhibitory effects on 
BUNV in virus yield assays.  The HEK Viperin cell line over-expresses viperin 
when induced with tetracycline and was found to inhibit BUNV and rBUNdelNSs 
yields by 100- and 1000-fold respectively which further correlated with a 
reduction in the amount of N protein synthesis seen by Western blot analysis.  
This Chapter investigates the effects of viperin in more detail.  
Viral protein expression in HEK viperin cells 
Initially, to look at the protein expression of BUNV in HEK viperin cells they 
were infected at an MOI of 0.01 pfu/cell with either BUNV or rBUNdelNSs.  The 
infected cells were labelled with [35S]-methionine for one hour at different times 
and then whole-cell lysates were analysed by SDS-PAGE and autoradiography.  
The N protein signal increased in intensity from 12 to 24 hours and reduced 
thereafter in the uninduced HEK viperin cells infected with BUNV (Fig 7.1A).  
Host cell protein synthesis shut-off was observed by 24 hours, however shut-off 
was drastically reduced in BUNV-infected induced HEK viperin cells and was 
only slightly observed even by 72 hours.  The N protein signal was significantly 
reduced at 12 and 24 hours in comparison with uninduced cells, and a host 
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band comigrated with N (Fig 7.1A), therefore Western blot analysis was needed 
to confirm the identity of N.  Infection of uninduced cells with rBUNdelNSs 
showed N protein expression increasing from 12 to 24 hours and reducing 
thereafter, as well as a reduction in host protein synthesis after 36 hours (Fig 
7.1B).  In the induced cells infected with rBUNdelNSs there was no observed 
viral protein expression. 
Analysis of the protein labelling experiment indicated that BUNV had no 
difficulty replicating in the uninduced cells.  In contrast, in the induced cells, the 
signal for the N protein was considerably reduced and was difficult to discern 
from cellular proteins (Fig 7.1A).  Western blot analysis confirmed that BUNV N 
protein synthesis peaked at 24 hours and the signal for the N protein remained 
around the same level up to 72 hours (Fig 7.2A).  Furthermore, the Western 
blot confirmed that N protein was being synthesised in the induced cells by 12 
hours and the amount of N protein then increased until 36 hours, which 
correlates with the protein labelling experiment.  The amount of N protein 
observed by Western blot from the uninduced cells infected with rBUNdelNSs 
followed a similar pattern to that of BUNV, being detectable by 12 hours, 
increasing through 24 and 36 hours and then decreasing (Fig 7.2B).  A similar 
pattern to BUNV was also observed for the induced cells infected with 
rBUNdelNSs but there was significantly less protein detected overall, with the N 
band intensity peaking at 36 hours and decreasing by 48 hours.  Viperin 
expression following Tet induction was confirmed by Western blotting and was 
slightly elevated after viral infection, suggesting increased stimulation of viperin 
expression (Fig 7.2A and B). 
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RNA analysis: HEK Viperin and VPM1 cells 
Over-expression of viperin clearly affects the levels of viral protein synthesis.  
To determine if the restriction was at the transcriptional level, HEK viperin cells 
were infected with either BUNV or rBUNdelNSs at an MOI of 0.01 pfu/cell and, 
at various times, total cell RNA was extracted and analysed by Northern 
blotting.   
Essentially, the over-expression of viperin significantly reduced the amount of 
genomic RNA detected from both BUNV and rBUNdelNSs infected cells.  The 
uninduced BUNV infected cells showed strong signals for each segment by 24 
hours whereas the induced cells significantly reduced the amount of detectable 
genomic RNA (Fig 7.3A).  The uninduced cells infected with rBUNdelNSs also 
showed strong signals for each genomic RNA segment by 24 hours and a 
significant decrease in the level of genomic RNA detected (Fig 7.3B). 
As with the genomic RNA analysis, the viral mRNA and anti-genomic RNA 
showed strong signals and the predicted migrations for each segment in the 
uninduced cells, and in the induced cells there was a significant decrease in the 
overall amount of RNA detected.  To see the L and M segments the blots had to 
be over-exposed.  This could be due to the lower activity of the L and M probes 
or to less than optimal transfer of those segment RNAs.  The size difference 
between the S segment mRNA and anti-genomic RNA is about 11.5%, making 
it possible to resolve the two S segment RNA species by electrophoresis, but 
not the L and M segment RNAs.  Therefore, the RNA analysis shown here is 
focussed on the S segment.  The uninduced BUNV infected cells showed the 
amount of mRNA increased from 12 hours up to 36 hours and then decreased, 
whereas the amount of genomic RNA increased throughout the course of 
 7 Viperin inhibition of Bunyamwera virus 
166 
 
infection (Fig 7.4A, -Tet lower panel).  However, in the induced cells infected 
with BUNV (Fig 7.4A, +Tet upper panel) the amount of mRNA followed a similar 
pattern as from the uninduced cells but the amount of genomic RNA was 
reduced.  This suggests that there was a block in anti-genomic RNA either 
transcriptionally or post transcriptionally, and could explain the reduction in 
genomic RNA described earlier.  The induced cells infected with rBUNdelNSs 
showed considerably less positive sense RNA than the uninduced cells but anti-
genomic and mRNA could not be separately distinguished (Fig 7.4B). 
To further confirm that over-expression of viperin caused inhibition of anti-
genome transcription, cells that over-express a mutant form of viperin (HEK 
VPM1 cells) in which the enzymatic capability of viperin was removed, were 
infected with BUNV at an MOI of 0.01 pfu/cell.  At different times the total 
cellular RNA was extracted and analysed by Northern blotting (Fig 7.5).  The 
genomic RNA for each segment from the uninduced cells had been detected by 
36 hours and the level increased for each segment throughout the course of 
infection (Fig 7.5A, -Tet).  Exactly the same pattern of detected genomic RNA 
was observed in the induced cells but the signal was slightly less intense (Fig 
7.5A, +Tet).  Positive-stranded S and M segment RNA from the uninduced cells 
was detected at 24 hours and increased up to 36 hours whereas the L segment 
RNA was detected at 36 hours and increased thereafter (Fig 7.5B, -Tet).  Thus, 
loss of the enzymatic function of viperin in these cells abrogated the inhibitory 
effect of viperin on BUNV RNA synthesis. 
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Viperin induction 
Over-expression of viperin clearly restricts BUNV replication but it is unknown 
whether viperin is induced in naïve cells following infection with BUNV.  To 
address this question, naïve A549 cells were infected with BUNV or 
rBUNdelNSs at an MOI of 5 pfu/cell and subjected to synchronous IFNβ 
treatment.  At different time points over a 24 hour period, the cells were 
harvested, lysed and then analysed by Western blotting (Fig 7.6).  As expected, 
the amount of N protein produced by both BUNV and rBUNdelNSs increased 
throughout the experiment in the IFNβ untreated cells (Fig 7.6, BUNV and 
rBUNdelNSs N panel) and for both viruses less N protein was detected when 
exogenous IFNβ was added at the time of infection (as seen earlier in Chapter 
Three).   
The human ISG MxA is only induced by IFN and is therefore a reliable marker 
of successful IFN induction and signalling.  Mock infected cells showed strong 
induction of MxA by the addition of IFNβ (Fig 7.6, Mock MxA panel).  However, 
BUNV infection alone did not induce MxA, although MxA was induced in BUNV-
infected cells treated with exogenous IFNβ but to a lower level than that 
observed in IFNβ-treated mock cells (Fig 7.6, BUNV MxA panel).  Thus, BUNV 
was able to inhibit MxA induction by IFNβ as seen by the considerably reduced 
signal compared with mock IFNβ treated cells.  In contrast, rBUNdelNSs 
induced MxA expression on its own and the level of MxA observed was higher 
following the addition of IFNβ (Fig 7.6, rBUNdelNSs MxA panel).  The level of 
induction by rBUNdelNSs in the absence of IFNβ was slightly more than in 
BUNV infected IFNβ treated cells and, in the presence of IFNβ, was only slightly 
increased, thereby demonstrating the ability of rBUNdelNSs to inhibit MxA 
despite not expressing an NSs protein. 
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Viperin expression in A549 cells was confirmed by the signal observed when 
the cells were treated with IFNβ (Fig 7.6, Mock viperin panel) and, while viperin 
expression peaked by 12 hours, it did remain constant up to 24 hours.  The 
viperin antibody also detected an as yet unknown band just below viperin.  
BUNV did not however induce viperin in the absence of exogenous IFNβ, but in 
the presence of exogenous IFNβ viperin was induced to the same level as 
observed in the mock-infected cells (Fig 7.6, BUNV viperin panel).  Additionally, 
BUNV was not able to inhibit viperin expression induced by exogenous IFNβ 
although it was able to inhibit MxA expression under the same conditions.  
Unlike BUNV, rBUNdelNSs induced viperin in the absence of IFNβ although not 
quite as strongly as observed in mock IFNβ treated cells (Fig 7.6, rBUNdelNSs 
viperin panel).  Exogenous IFNβ treatment of rBUNdelNSs infected cells 
induced viperin expression although the induction was slightly higher than in 
either mock or BUNV-infected IFNβ-treated cells, showing that not only are 
IFNβ and rBUNdelNSs capable of inducing viperin, but they also have a 
combined cumulative effect on viperin expression (Fig 7.6, rBUNdelNSs viperin 
panel).   
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Stirnweiss et al. (2010) showed that induction of viperin can be by two different 
pathways: the first is via induction of IFNβ that then induces ISGF3 which 
mediates the induction of ISGs such as viperin; the second is via the 
transcriptional induction of IRF1 which can directly activate the viperin promoter.  
Western blot analysis showed that IRF1 was weakly upregulated by IFNβ in 
mock infected cells (Fig 7.6, Mock IRF1 panel) and also by BUNV treated with 
IFNβ (Fig 7.6, BUNV IRF1 panel).  However, rBUNdelNSs was a good inducer 
of IRF1 independently of IFNβ addition (Fig 7.6, rBUNdelNSs IRF1 panel).   
STAT1 is expressed constitutively in cells and both pathways mentioned above 
are dependent on the activation (by phosphorylation) of STAT1: the first as 
ISGF3 is a complex comprising STAT1/STAT2/IRF3; and the second as STAT1 
directly activates IRF1.  Consequently, IFNβ treatment stimulates STAT1 
expression (Fig 7.6, Mock STAT1 panel) whereas BUNV infection does not 
induce STAT1 expression unless in the presence of IFNβ and even then 
expression is reduced due to expression of BUNV NSs protein (Fig 7.6, BUNV 
STAT1 panel).  In contrast to BUNV, rBUNdelNSs did induce STAT1 but not 
quite as strongly as IFNβ (Fig 7.6, rBUNdelNSs STAT1 panel).  In the mock 
and BUNV infected cells phosphorylation of STAT1 was weakly detected after 
addition of exogenous IFNβ (Fig 7.6, Mock and BUNV P-STAT1 panel).  
rBUNdelNSs however, was a strong inducer of STAT1 phosphorylation 
independently of IFNβ addition (Fig 7.6, rBUNdelNSs P-STAT1). 
Discussion   
The HEK VPM1 cell line over-expresses a viperin mutant that has had the three 
cysteine residues in the CX3CX2C motif 1 replaced with three alanine residues, 
thus eliminating its viperin-like enzymatic capability.  Chapter Five showed that 
over-expression of VPM1 had no effect on viral yield and further by Western 
blot that N protein synthesis was unaffected.  The inhibitory effect of viperin on 
BUNV was taken further here by Northern blotting which showed viperin to 
inhibit BUNV RNA synthesis.  Additionally, this RNA restriction was not seen in 
the mutant viperin VPM1 cells suggesting the RNA restriction is also dependent 
on the enzymatic action of CX3CX2C motif 1 of viperin. 
Also, in this system host protein synthesis shut-off was drastically impaired in 
BUNV-infected induced viperin cells, even more so than in the uninduced cells 
infected with the NSs deletion virus rBUNdelNSs.  The level of host protein 
synthesis shut-off was similar between induced cells infected with either BUNV 
or rBUNdelNSs, suggesting the antiviral mechanism of viperin involves NSs.  
Perhaps viperin interferes with the transport of NSs thereby allowing the time 
required by the IFN system to respond to BUNV infection.  Multiplicity of 
infection must be considered when discussing shut-off and the low MOI used 
was required to ensure that the experiment was not stopped early due to 
immense cell death induced by rBUNdelNSs. 
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Investigations into the effects of IFN on BUNV infection have found that over-
expression of viperin clearly restricts BUNV replication.  IFNβ and rBUNdelNSs 
induce viperin expression and therefore the remaining question is whether 
viperin is part of the global cellular response to BUNV infection or a more 
specialised attack on one stage of the BUNV replication cycle.  BUNV was 
found to inhibit viperin expression, probably due to the expression of BUNV NSs 
blocking host cell protein synthesis.  However, it may be that, like JEV, BUNV 
induces viperin expression and then targets viperin for proteasomal 
degradation.  As BUNV NSs is extremely efficient at host cell protein shut-off, 
targeting viperin for degradation is unlikely to be required.  However, NSs is 
itself degraded in a proteasome- and ubiquitination-dependent manner 
(Ingeborg van Knippenberg, personal communication), therefore perhaps 
viperin is either targeted by NSs for degradation or is co-degraded with NSs.  
Further work is required to establish if and how BUNV induces viperin and 
whether NSs restricts or induces viperin degradation. 
As Wang et al. (2007) showed that viperin expression restricts IAV budding and 
release, it was hypothesised that viperin may restrict BUNV by interfering with 
the lipid structure around the Golgi, possibly including lipid rafts.  It is unknown 
whether BUNV uses lipid rafts or even how lipid composition affects BUNV 
replication.  Therefore further investigation into the lipid composition and 
structure of BUNV particles from 293 cells and HEK viperin cells would begin to 
address this.  Preliminary data from infected 293 cells suggests the lipid 
composition can be ascertained (data not shown) and thus the method could 
reveal the effect of viperin over-expression on the lipid composition of BUNV 
particles. 
In Chapter Five the HEK PLSCR1 cell line, which over-expresses the 
scramblase enzyme PLSCR1 was shown to have no effect on BUNV yield.  
This scramblase enzyme is involved in the translocation of lipids between the 
lipid bilayer of the cell membrane thus, as BUNV buds from the Golgi and not 
the cell membrane PLSCR1-mediated lipid trafficking does not affect BUNV 
replication.  Additionally, PLSCR2 appeared to enhance the viral yield of 
rBUNdelNSs.  Therefore, lipid trafficking and composition could play an 
important function in the BUNV replication cycle.  
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Summary 
This chapter shows: 
 Over-expression of viperin restricts viral protein synthesis and virus 
induced host protein synthesis shut-off. 
 Viperin inhibits overall RNA synthesis. 
 The restrictive capability of viperin is dependent on its CX3CX2C motif 1. 
 BUNV inhibits viperin expression whereas rBUNdelNSs induces viperin 
expression. 
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8 Final thoughts 
The data presented in this study has furthered the understanding of the effects 
of IFN on the BUNV replication cycle and may provide insight into potential 
treatment for bunyavirus infections.  The viral protein NSs was already known to 
be an IFN antagonist and the engineered rBUNdelNSs has been shown to be a 
strong IFN inducer (Bridgen et al., 2001; Weber et al., 2002).  The primary 
function of the IFN system is to detect and nullify viral infections.  Therefore the 
IFN system relies on being able to detect viral infections quickly and to then 
rapidly signal the host cell’s antiviral defence system and to signal neighbouring 
cells to go into the antiviral state.  Once in the antiviral state, the cells are 
primed for rapid detection of viral infection and to mount the appropriate antiviral 
response. 
The initial aim for this project had two parts: firstly to advance the understanding 
of the effects of IFN on BUNV replication; and secondly, to identify specific ISGs 
that affect the BUNV replication cycle.  Chapter Three showed that priming cells 
first with IFN appears to fully restrict BUNV and that treating the cells with IFNβ 
after infection appears to have little effect on the virus.  It was further shown 
here that synchronous treatment with IFNβ immediately following infection had 
a significant effect on viral replication.  This treatment caused an overall drastic 
reduction in synthesis of N and Gc proteins, probably due to a block in 
translation as there was an increase in positive-stranded viral RNA, but not in 
genomic RNA.  A previous study rescued 57 viable recombinant BUN viruses 
with a mutated N protein and these could be used in IFNβ studies to establish 
the importance of the N protein in the successful IFNβ response to BUNV 
infection (Eifan & Elliott, 2009).  Further to this, viral polymerases have been 
shown to be involved in the antagonism of the IFN response (Iwai et al., 2010; 
Wang & Ryu, 2010; Yu et al., 2010), and the BUNV L protein contributes to host 
cell protein synthesis shut-off by cap snatching.  It should be investigated in 
more detail for other IFN antagonistic properties.  As the polymerase protein is 
present within virions, it is feasible that the polymerase plays an important role 
in the early phase of host cell innate immune antagonism and not only by cap 
snatching.  Finally, an important point to note is that Vero cells are not able to 
produce type I IFNs due to a spontaneous mutation and they also have a 
relatively inefficient IRF3 response but they are able to synthesise type III 
(IFNλs) IFNs (Chew et al., 2009; Emeny & Morgan, 1979).  Vero cells do have 
IFNARs and therefore can respond to type I IFNs, but they have been shown to 
be highly responsive to IFNλs.  Moreover, IFNλ expression and function is very 
similar to type I IFNs in that they activate the JAK/STAT signalling pathway 
which activates ISGF3 and subsequently results in the expression of many 
ISGs.  Recently the hantaviruses SNV, ANDV and Prospect Hill virus (PHV) 
were shown to induce IFNλ in Vero cells, and hantaviruses are not thought to 
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be detected by MDA5 but both HTNV and BUNV are detected by RIG-I (Lee et 
al., 2011). 
The IFN system involves many cellular proteins and pathways that are 
interlinked and enable rapid detection of viral infections.  The PRRs detect 
various viral PAMPs and subsequently signal the induction of the IFNβ 
promoter.  Secreted IFNβ acts in both an autocrine and a paracrine manner, 
triggering the host cell’s antiviral defence mechanisms while the surrounding 
cells enter the antiviral state.  Numerous ISGs are upregulated and can impede 
viral infection although some have been shown to enhance the viral infection.   
The second angle on the initial aim of the study was to determine the role, if 
any, that particular ISGs played in restricting BUNV replication.  Chapters Five, 
Six and Seven addressed this.  Chapter Five tested 26 ISG inducible cell lines 
for restrictive capabilities on BUNV replication and found three showed 
inhibitory effects ten-fold or greater; MTAP44, PKR and viperin.  No further work 
was undertaken on MTAP44 here but both PKR and viperin were further 
investigated (Chapter Six and Seven respectively).   
PKR has been previously shown to be induced by BUNV infection and to have 
only marginal inhibitory effects on BUNV replication (Streitenfeld et al., 2003).  
This study quantified the restriction of PKR, as well as examining the role of 
another ISG, viperin.  Prior to this study viperin was unknown to inhibit 
bunyaviruses.  The role of viperin in controlling the lipid composition of lipid rafts 
and lipid droplets has been investigated regarding IAV and HCV respectively 
and may play an essential role in BUNV replication inhibition as BUNV buds into 
the Golgi (Hinson & Cresswell, 2009a; Wang et al., 2007).  Detailed lipidomic 
studies would reveal the specific lipid composition of bunyavirus virions and 
determine if they utilise lipid microdomains. 
PKR and viperin act synergistically on BUNV: as BUNV infects cells, PRRs 
(such as PKR and RIG-I) detect the virus and trigger the IFN system leading to 
the upregulation of the IFNβ promoter and subsequently the expression of 
antiviral proteins such as PKR and viperin.  An increase in PKR expression 
further enhances viral detection and inhibition of host cell protein synthesis.  
BUNV primary transcription and NSs expression occurs and the NSs protein 
interacts with the Mediator complex and subsequently blocks RNA polymerase 
II mediated host cell transcription.  Thus, while the virus fights to control cellular 
transcription via NSs, the cell fights to control BUNV via the action of viperin 
and PKR (and other innate antiviral mechanisms and ISGs).  However, when 
antiviral proteins are already expressed (either by IFN induction or in a 
transduced cell line) it is very difficult for BUNV to overcome the antiviral state 
as the cells are primed to restrict the expression of viral proteins, such as NSs.  
Furthermore, if viperin targets NSs and is already expressed at the time of 
infection then it may prevent NSs from blocking host cell transcription.  
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However, BUNV was still able to enter the cells and to replicate at low levels, 
suggesting there is a mechanism for overcoming expressed antiviral proteins.  
Perhaps a low level of expression of NSs is enough for the virus to gain the 
advantage over the innate immune response.  Other viruses, such as PIV5, are 
known to be able to dismantle the IFN-induced antiviral state (Carlos et al., 
2005). 
Further useful studies to be done would be to engineer three cell lines: one that 
over-expresses both viperin and PKR; one that expresses shRNA for viperin 
knockdown; and one that expresses shRNA for both viperin and PKR 
knockdown.  These could be used to quantify the effects of both viperin and 
PKR together on BUNV as well as to see whether PKR and viperin shRNA 
knockdown rescues virus replication in IFNβ pre-treated cells, as discussed in 
Chapter Six.  Additionally, these Tet-inducible ISG-expressing cell lines could 
be used to look at the effect of ISG induction post-infection to establish whether 
either viperin or PKR over-expression is able to inhibit BUNV replication once it 
has been established.  This study has presented data showing post-infection 
treatment with IFNβ has limited restrictive effects on BUNV replication (Chapter 
Three) but perhaps the rapid over-expression of known BUNV inhibitors (such 
as PKR and viperin) after infection may result in some BUNV restriction. 
The reverse genetics system established by Bridgen et al. (1996) and later 
improved by Lowen et al. (2005) has enabled the engineering of many 
recombinant viruses with the aim of further understanding the BUNV replication 
cycle.  These engineering studies resulted in the production of several 
fluorescently tagged viruses that were able to carry out successful replication 
cycles although they were somewhat attenuated (Shi et al., 2010; Shi et al., 
2009; Shi et al., 2006).  In this study, three GFP-tagged viruses were used to 
investigate the efficacy of using them to screen the ISG-expressing cell lines for 
their anti-BUNV characteristics.  There are two viruses with their NSm protein 
tagged with GFP; BUNM-NSM-EGFP and BUNM-NSM-EGFPDelNSs.  
However, there is only one Gc-GFP tagged virus and the study of the effects of 
IFN (and subsequent ISGs) on BUNV is more easily carried out in comparison 
with rBUNdelNSs in parallel.  Therefore, an additional objective for this project 
was to engineer rBUNdelNSs to express GFP fused to the Gc protein (as in 
BUNGc-eGFP) and to characterise the virus, which was achieved and 
documented in Chapter Four.  Subsequently, Chapter Five showed the efficacy 
of using three of the recombinant viruses for screening ISG-expressing cell lines 
for their anti-BUNV characteristics.  The data presented from viral yield assays, 
fluorescence and Western blot analyses correlated and distinguished between 
non-inhibitory and inhibitory ISGs and demonstrated the usefulness of the 
fluorescently tagged viruses in screening the cell lines.  Furthermore, with the 
use of inverted fluorescence microscopes, cell lines could be set up in multi-well 
plates and used for imaging of live cells infected with fluorescently tagged 
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viruses in real-time over many time points.  Indeed, a recent study generated 
over 380 ISG and red fluorescent protein expressing cell lines which were used 
to analyse the effects on the replicative cycle of the expressed ISG on several 
different GFP-tagged viruses by fluorescence activated cell sorting (FACS) 
(Schoggins et al., 2011).  The study highlighted several broadly acting ISGs and 
that a common mechanism of ISG mediated inhibition was at the translational 
level.  
There is little or no cytopathogenicity caused by viruses in the Orthobunyavirus 
genus infecting invertebrate cells but many are cytolytic in their respective 
vertebrate hosts.  The most successful viruses are able to infect the target cell 
and replicate without destroying the host organism as this enables further 
propagation of the virus.  Measles virus is highly contagious and is spread via 
aerosol and is therefore able to infect many people within the same room 
(Griffin, 2007).  The mortality rate from measles virus infection in developed 
countries is low so the virus is able to spread easily and rapidly (if the 
population were not vaccinated).  The mortality rate from filovirus infection, such 
as Ebola virus, can be as high as 90% and therefore the population is often 
decimated in rural areas before the virus can spread to highly populated areas 
(Geisbert & Hensley, 2004).  Some of the more pathogenic bunyaviruses that 
infect humans, such as CCHFV and HTNV have mortality rates that can be as 
high as 30% and 15%, respectively (Whitehouse, 2004; Wichmann et al., 2002).  
The mortality rate of RVFV is approximately 1% but has been as high as 29% in 
hospitalised cases (Bouloy & Weber, 2010) and the orthobunyavirus LACV has 
a mortality rate up to 1.9% (Haddow & Odoi, 2009).  The NSs protein of 
bunyaviruses is very efficient at antagonising the IFN response by causing host 
cell protein synthesis shut-off, therefore it may be that BUNV has evolved to be 
less pathogenic in order to enhance the longevity of the virus population.  This 
is evidenced by the relatively low mortality rate from disease outbreaks caused 
by many members of the Bunyaviridae.  Perhaps BUNV is able to persistently 
infect an as yet unidentified mammalian cell line.  HTNV causes asymptomatic 
persistent infections in rodents whilst it can be highly pathogenic in humans 
(Zeier et al., 2005).  Hantaviruses are spread horizontally in rodents often by 
biting, but also, and for human transmission by aerosolised excreta, ergo they 
are not arboviruses.  Perhaps the reason other members of the Bunyaviridae 
are unable to cause persistent infections in humans is that they are transmitted 
by arthropods.  Polymerase (both transcriptase and endonuclease) activity in 
arthropods may be reduced which could result in less damage to the host cell 
thereby allowing for low level viral replication as a persistent infection (Carvalho 
et al., 1986; Rossier et al., 1988).  Furthermore, the production of non-classical 
(sub-genomic) DIs with truncated L proteins or that are temperature sensitive, 
could have limited the polymerase activity.  Renewed interest in DIs has 
emerged from studies showing that it is the DIs themselves that are detected as 
PAMPs and lead to the induction of the IFN response (Killip et al., 2011).  Thus, 
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perhaps successful persistent infections in arthropods are not hindered by DI 
synthesis, but infection of mammalian cells by the same viruses results in 
strong IFNβ activation due to DI synthesis (Elliott, 1996; Scallan & Elliott, 1992).  
IFN is a potent inducer of the antiviral response and is used to treat several viral 
infections such as HCV and hepatitis B virus (HBV) but IFN treatment has 
several adverse effects such as headache, muscle pain, convulsions, dizziness, 
hair thinning and depression.  Therefore new methods of treating viral infections 
are constantly being sought.  Identifying particular ISGs that inhibit BUNV may 
reveal broadly acting ISGs with inhibitory effects on other highly pathogenic 
bunyaviruses, such as HTNV, CCHFV and RVFV.  Alternatively, the inhibitory 
ISGs could be virus specific but acting on a homologous viral replication 
mechanism, such as reverse transcription, thus highlighting areas for research.  
Furthermore, several ISGs are able to exhibit their antiviral effect without 
irreversibly damaging the host cell.  Therefore isolating an ISG that has a 
combination of known viral antagonist (broadly or specifically) and low cellular 
damage would be commercially useful as an antiviral as it has potential to be 
administered without damaging side effects. 
Understanding the host cell innate immune response to BUNV infection and 
how this response targets BUNV makes it possible to envision the engineering 
of viruses that are attenuated whilst at the same time able to elicit a strong 
immune response.  Thus such viruses could be used to treat already infected 
individuals to prime their immune response to the established viral infection and 
ameliorate disease.  This knowledge further facilitates the production of more 
effective vaccines as the viral proteins not targeted internally can be used to 
elicit a strong and rapid humoral immune response.    
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